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Abstract
Cardiovascular diseases (CVD) are responsible for more deaths than any other disease,
continue to threaten the quality of life for many, and is a major burden to the health care
system. The Framingham Heart Study (FHS) identified the major CVD risk factors that
became essential to effective CVD screening strategies and the Framingham Risk Score
(FRS), is used to assess CVD risk. Based on the concepts of the health behavior model
and CVD as a cardiometabolic disorder, multivariate logistic regression analysis was
used to evaluate the association between fasting blood glucose (FBG) levels and a CHD
event, and to determine the value of FBG replacing a diagnosis of diabetes (DM2) in the
FRS. The data set consisted of the 2,677 subjects of the FHS III cohort. In the univariate
analysis, both DM2 and FBG were statistically significant (both p =.000), but the
association was stronger for DM2, b = 2.138, OR = 8.483 (95% CI: 4.229, 17.105) than
for FBG, b = .015, p = .000, OR=1.015 (95% CI: 1.009, 1.022). When adjusted for age,
blood pressure, cholesterol, and smoking status, only DM2 remained statistically
significant, OR = 2.295, p = .041, (95% CI: 1.035, 5.087) in the model. The FBG version
of the FRS did not provide any improvement in performance, as it was marginally
inferior to the DM2 version. Furthermore, the interactions between FBG and the
metabolic risk factors were not statistically significant for this given data set. The results
imply that a diagnosis of diabetes remains the factor of choice for inclusion in the FRS
model for predicting the 10-year risk of CHD and replacing it with FBG provides little to
no practical benefit. These findings support the use of CVD risk factor reduction and the
use of effective screening tools in CVD prevention and promotion heart health.
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Chapter 1: Introduction to the Study
Introduction
Diseases involving the heart and/or blood vessels are known collectively as
cardiovascular diseases (CVDs) and include disorders such as angina pectoris (AP);
myocardial infarction (MI); stroke; heart failure (HF); peripheral artery disease (PAD);
and coronary heart disease (CHD, or coronary artery disease or CAD). Every year over
800,000 persons in the United States, 4 million in Europe, and another 11 million around
the globe die from CVDs (American Heart Association, Center for Disease Control, and
Prevention, & National Institutes of Health, 2015; Ferreira-GonzáLez, 2014). In
particular, CHD, the most common CVD, is responsible for approximately 70% of all
CVD deaths, and it is the leading cause of morbidity and mortality worldwide (Grimes,
2012; Jones & Greene, 2013).
Not only are cardiovascular diseases responsible for more deaths than any other
disease type, they are a major burden to the society. CVDs cause more physical
disabilities, are a major financial drain on the healthcare system, and they also contribute
to many health disparities (World Health Organization, 2016). In the United States alone,
CVDs claim the lives of 2,200 Americans every day, while another 92 million remain
alive to deal with the disease and its many related complications ( Benjamin et al., 2017).
In 2012, those living with cardiovascular disease and its physical, mental and social
impact, generated $316 billion, in direct health care cost and loss of productivity
combined ( Benjamin et al., 2017). Consequently, responding to the epidemic of heart
disease has been the focus of many national and international healthcare organizations.
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Given the severity of the threat they pose, there is a concerted effort at reducing
the incidence and prevalence of CVDs. The American Heart Association uses records of
risk factors from epidemiological and clinical data to monitor the prevalence and
incidence of CVD and track the results of prevention and treatment efforts (Goff et al.,
2014). The 2020 Impact Goal remains committed to reducing CVD deaths by 20% and to
a general improvement in cardiovascular health by 20% by the year 2020 ( Benjamin et
al., 2017). The Healthy People 2020 initiative uses early risk identification and treatment
to “improve cardiovascular health and quality of life through prevention, detection, and
treatment of risk factors” (U.S. Department of Health and Human Services, 2018).
Critical to any effective early identification and prevention strategy is effective risk factor
detection and classification.
Background
Over half a century ago, the Framingham Heart Study (FHS) expanded the
understanding of CVDs by identifying the major risk factors involved (Dawber et al.,
1959; Dawber, Meadors, & Moore, 1951). The FHS research continues to today and now
includes other chronic diseases but CVD remains its primary focus (D’Agostino, Pencina,
Massaro, & Coady, 2013; Kannel & McGee, 1979; Mahmood, Levy, Vasan, & Wang,
2014). The major CVD risk factors uncovered by the FHS include gender, age,
cholesterol level, smoking status, blood pressure, and history of heart disease (Dawber et
al., 1959; Dawber & Lansing, 1966; Kannel, Castelli, Gordon, & Mcnamara, 1971).
Subsequent epidemiological and clinical research have confirmed and further elucidated
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the role of these risk factors in the long-term development of CVD (Centers for Disease
Control and Prevention, 2013)
Most of the established CVD risk factors are modifiable, and it is for this reason
mainly that CVD is classified as a preventable disease. The CDC reported that 80% of all
CVD deaths in 2010 were the direct result of these modifiable factors, and as such those
deaths were considered avoidable (Centers for Disease Control and Prevention, 2013). In
fact, prevention strategies focused on risk factor reduction have resulted in significant
decreases in the prevalence, the incidence, the morbidity, and the mortality of CVD (Goff
et al., 2014; Grundy et al., 2002; Stone et al., 2013). Effective CVD prevention is
dependent on early detection and prediction, for which accurate and reliable risk formulas
are essential ( Eichler, Puhan, Steurer, & Bachmann, 2007; Fuster & Kelly, 2010; Keaven
Anderson, Wilson, Odell, & Kannel, 1991;Wilson et al., 1998).
One of several CVD risk formulas is the framing risk score (FRS) formulated by
the Framingham heart study researchers. The initial version, published in 1998, was
developed using many of the risk factors discovered several decades earlier (Wilson et
al., 1998). The original FRS formula was used to determine the likelihood of an
individual developing CVD over a given period, most commonly, 10-year period (Wilson
et al., 1998). A revised version, released 4 years later, replaced diabetic status with
dyslipidemia and added hypertension medication to represent a history of heart disease
(Grundy et al., 2002). This was based on diabetes now being considered a CVD risk
equivalent, and with the omission, diabetics were now regarded as having a history of
CVD (D’Agostino et al., 2008). In addition, the third and most recent version of the FRS
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is now gender specific, and male and female FRS includes measures of age, total and
HDL cholesterol, systolic blood pressure, and cigarette smoking (Dahlöf, 2010;
O’Donnell & Elosua, 2008).
Presently, almost anyone with relevant medical information can obtain a measure
of their 10-year risk of CVD. The FRS is available in many formats including survey
questionnaire printouts, as tables and charts for readout, or as computerized programs for
healthcare professionals, and even as smart phone applications for lay persons
(D’Agostino et al., 2008; “Framingham Risk Score Calculator for Coronary Heart
Disease,” 2018). The FRS is the most widely used CVD screening tool in the United
States (Steyerberg et al., 2010), and has become the heart of the public health response to
the CVD epidemic (Kones, 2011; Mahmood et al., 2014; Wilson et al., 1998). Since its
introduction in the late 1990s, alternative CVD risk screening approaches have been
developed, but the FRS remains the most popular (Günaydın et al., 2016; Tsao, 2015).
Although the FRS has been an invaluable tool in the task of screening for
individual CVD risk, it has several noteworthy limitations. First, the experts have
confirmed that the FRS’s predictive ability is limited to future coronary heart disease
(CHD) only and does not extend to other coronary events, such as stroke, ischemic attack
or heart failure (D’Agostino et al., 2013; Root, Hu, & Duncan, 2014). Second, the FRS
overestimates CVD risk in some populations and underestimates CVD risk in others,
impeding its usefulness in targeting high risk individuals for prevention treatment (
Günaydın et al., 2016; Kones, 2011; Van Staa et al., 2014 ). Third, the FRS’s inability to
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track changes in risk levels over time, also presented opportunities for formula
optimization (Dahlöf, 2010).
One of the more popular areas of formula optimization for CVD risk models has
been the reevaluation of the role of diabetes as a risk factor. There are several reasons for
this reevaluation but the main two are (a) the changes in the working definition of the
disease diabetes (new glucose threshold and new diagnostics), and (b) the significant
increase in the incidence and prevalence of diabetes over the last 50 years (Mayfield,
1988; Shaw, Zimmet, McCarty, & de Courten, 2000; Wareham, 1998). Reevaluation of
diabetes was also supported by the discrepancy relationship between observational
studies, with respect to CVD and diabetes treatment, and findings in clinical trials, at the
end of the last decade (Qazi & Malik, 2013a). The efforts to abate the increased CVD
mortality and morbidity of diabetics by treating hyperglycemia has proven ineffective
(Duckworth et al., 2009; Kelly, Bazzano, Fonseca, & al., 2009; Miller et al., 2008;
Reaven et al., 2009). This led to the call for more research into the interaction between
diabetes and cardiovascular diseases and the level of CVD risk possessed by those with
diabetes.
The role of the diabetic status as factor in the FRS has undergone several changes
over the years. Diabetic status was included as binary yes/no variable in the first
published FRS formula several decades after the FHS was launched (Wilson et al., 1998).
And, despite subsequent augmentation, namely replacing dichotomous or categorical
variables (e.g. cholesterol and blood pressure) with their continuous counterparts,
diabetes remained dichotomous, only to be eventually omitted from the formula (Grundy
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et al., 2002). However, a diagnosis of diabetes based simply on an arbitrary threshold for
blood glucose ignores the complexity of the association between glucose levels and CVD
risk, a complexity that is confirmed in clinical research (Faeh, Rohrmann, & Braun,
2013; Fawwad, Moin, Siddiqui, Hydrie, & Basit, 2016; Park et al., 2013). But the
eventual exclusion of diabetes from the FRS has resulted in the loss of significant risk
information and may have rendered it less effective in predicting heart disease.
The relationship between blood glucose and the risk of CVD provides important
CVD risk prediction. Previous research show that blood glucose levels both above and
below the diabetes threshold are associated with the probability of CVD development
(Dahlöf, 2010; Kadowaki et al., 2008; Park et al., 2013; Perreault et al., 2014; Valentino
et al., 2015). It is now accepted that hyperglycemia, hypoglycemia, and glycemic
variability are all implicated in the macrovascular dysfunction common in diseases of the
heart and circulatory system ( Benjamin et al., 2017; Saisho, 2014; The Emerging Risk
Factors Collaboration, 2010; Zhang et al., 2014). Moreover, recent research claims that
glucose level may be a better predictor of CVD development than is cholesterol level and
supports its inclusion in CVD risk formulas (Braun, Bopp, & Faeh, 2013; Clark, Perkins,
Carson, Boyd, & Jefferson, 2015; Lammertyn et al., 2011).
Unlike a decade ago when the clinical evidence was contradictory, several studies
now show that the control of blood glucose levels does improve symptoms of CVD (Chi,
Snaith, & Gunton, 2017; Coch & Green, 2016; Kelly et al., 2009; Xu & Rajaratnam,
2017). Carter et al (2016) recently found that among the primary risk indicators
(hypertension, cholesterolemia, and hyperglycemia) hyperglycemia is the most effective
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cardiometabolic marker and has the strongest association to high CVD risk in African
Americans. Prediction models that exclude glucose levels, even at the prediabetes state,
ignore important CVD risk prediction and stratification information (Huang, Cai, Mai, Li,
& Hu, 2016). More accurate risk prediction information could ultimately lead to more
effective early prevention strategies. And it is this theory that was the basis of the
statistical analysis in my research project.
Problem Statement
Despite decades of clinical and epidemiological research, estimating the risk of
CVD in the general population remains challenging. The FRS, the most commonly used
prediction tool, has many known limitations with regard to precision and accuracy
(Brindle et al., 2005; Eichler, Puhan, Steurer, & Bachmann, 2007). Even with its
widespread use, the FRS is far from infallible, frequently generating overestimations or
inconsistent results, with significant classification errors, which has been reported as high
as 37% on one occasion (D’Agostino et al., 2008; Kones, 2011). A more effective and
accurate risk assessment tool is critical to an improved public health response to the
burden of CVDs (Goff et al., 2014; Kones, 2011).
Recognition of CVD as a cardio-metabolic disease can lead to important
improvements in the risk prediction effort. Some of the most key CVD risk factors (BMI,
high cholesterol, and high blood pressure), along with insulin resistance and
hyperglycemia, are all symptoms of metabolic syndrome (MetS), which is itself a most
effective predictor CVD risk (Clark et al., 2015; D’Agostino et al., 2008; Goff et al.,
2014). Treating CVD as a cardiometabolic disorder, and using metabolism indicators
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such as blood glucose levels as a risk factor, may provide valuable risk prediction
information (Cockram et al., 2001; D. Lloyd-Jones et al., 2010). In this research I aimed
to demonstrate the utility of blood glucose levels in improving the discriminatory power
and classification ability of the FRS predicting the most injurious of CVDs, CHD.
Purpose
This study investigated the effect of blood glucose (BG) levels on the
performance of the FRS formula. The approach involved generating an alternative
version of the FRS formula, in which the binary variable diabetic status was replaced
with continuous variable, BG levels values and evaluating the prediction performance of
the FRS version. The coefficients or odds ratio (OR) of the two risk factors (BG and
diabetic status), as well as the overall performance of respective multiple logistic
regression (MLR) models was assessed for both. The role of the comorbid, metabolic risk
factors (BMI, cholesterol, blood pressure), was also examined for any interaction with
and then their effect on the predictive role of blood glucose level on the model’s
performance. The objective was to produce a more accurate, and therefore reliable
algorithm for predicting CHD event probability among asymptomatic individuals (see
D’Agostino et al., 2013; Van Staa et al., 2014). The formulas were based on the 10-year
CHD risk algorithm the FRS generated from the original Framingham heart study data
set.

9
Research Questions
I sought to answer the following three research questions:
RQ1: Is the relative risk for glucose level higher than that for diabetic status in the
CHD 10-year risk prediction?
H01: There is no difference between the relative risk for glucose level and that for
diabetic status in the CHD 10-year risk prediction.
Ha1: The relative risk for glucose level is higher than that for diabetic status in the CHD
10-year risk prediction.
RQ2: Is the measure of accuracy for glucose level higher than that for diabetic
status in the CHD 10-year risk prediction formula?
H02: There is no difference between the measure of accuracy for glucose level and
diabetic status in the CHD 10-year risk prediction formula.
HA2: The measure of accuracy for glucose level is higher than that for diabetic status in
the CHD 10-year risk prediction formula.
RQ3: Is the measure of accuracy for glucose level independent of ‘BMI’,
cholesterol level or blood pressure level in the CHD 10-year risk prediction formula?
H03: The measure of accuracy for glucose level is independent of ‘BMI’, cholesterol
level or blood pressure level in the CHD 10-year risk prediction formula.
HA3: The measure of accuracy for glucose level is dependent on BMI, cholesterol level or
blood pressure level in the CHD 10-year risk prediction formula.
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Theoretical Framework
Health Behavior Model
The concepts on which this study is based are the health behavior model (HBM)
and the cardiometabolic model of heart disease. The former is borrowed from the social
sciences and is very commonly used in health care research and in developing public
health strategies (Esparaza-del Villar et al., 2017). There are three main supposition on
which the HBM is based: perceived vulnerability, perceived severity, and perceived
efficacy (Janz & Becker, 1984). According this model, an individual’s health behavior is
motivated by their belief and that belief is based on the information and level of health
education to which they have been exposed or are in their awareness. HBM suggests that
proper knowledge of the association between risk factors and the related diseases is
critical to heart healthy behavior (Khorsandi, Fekrizadeh, & Roozbahani, 2017). The
identification of the CVD risk factor, dysglycemia, and the level of risk they present is
the goal of this study.
Cardiometabolic Model of CVD
In the cardiometabolic model, there is a close relationship between the elements
involved in metabolic disorders and those involved in heart disease (Brunzell, Davidson,
& Fuberg, 2009). It is already accepted that a diagnosis of diabetes incurs a two-four-fold
increase risk of heart disease, depending on gender (Booth, Kapral, Fung, & Tu, 2006;
Conroy et al., 2003; Fox, 2010; Sarwar et al., 2010). I focused on one of the overlapping
risk factors, namely dysglycemia, and its inclusion in the CVD risk prediction formula as
a predictive factor in predicting the outcome of a CHD event. Dysglycemia t damages the
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blood vessels of the heart and this is usually the initiation of or exacerbation of other
factors that lead to CHD (Jackson et al., 2016; Kozakova et al., 2017; Saisho, 2014). This
analysis attempts to take a closer look at this relationship between glucose level and CHD
by measuring its strength the relationship and testing its utility in the CHD prediction
formula.
Nature of the Study
This research is a quantitative study using statistical analysis of an existing data
set to evaluate the answers to the research questions. The data set is from the third cohort
of the FHS clinic data, collected from over 4,000 of the descendants of the first cohort
that began in 1964 (Framingham Heart Study Longitudinal Data Documentation, 2004).
More details will be included in Chapter 3. The variables of interest are fasting blood
glucose (FBG) and diabetes diagnosis (DM2) and they were compared for their predictive
ability and their interaction other metabolic comorbidities (cholesterol, blood pressure,
BMI), for their effect on the relation to the outcome of a CHD event (Rudestam &
Newton, 2014). The methodology involves both univariate and MLR analyses of the FHS
data set as secondary data. The Framingham risk score (FRS) is the formula that
describes the relationship between the variables, developed by the FHS researchers based
on the many risk factor they discovered, and is a multivariable logarithm of the
probability of developing coronary heart disease. The same latest version of the 10-year
FRS was used in this research to evaluate and compare the predictive value of FBG
versus DM2.
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Assumptions, Limitations and Delimitations
Assumptions
The FHS is a seminal epidemiological study in the fields of public health and of
medicine and has provided invaluable insight into the factors involved in the
development of cardiovascular diseases (O’Donnell & Elosua, 2008). The subsequently
derived FRS has proven instrumental in predicting cardiac events for many at risk but
asymptomatic members of the population (O’Donnell & Elosua, 2008). I assumed that
the data FHS collected was accurate and included objective responses from the
participants, competence on the part of the health care workers’ in conducting surveys
and in performing examinations, and accurate recording and documenting of the relevant
information.
Despite the limitations and the challenges to the internal and external validity of
the original Framingham cohort, the study successfully identified several major CVD risk
factors. The researchers were careful to point the steps needed for internal and external
validation that other researchers should put in place (O’Donnell & Elosua, 2008; Pencina
et al., 2009). These factors do provide general applicability to similar demographics, even
if calibration is required in cases of the nonuniform distribution of variable among certain
groups or for groups with risk factor prevalence that are different from the FHS
(Hermansson & Kahan, 2018; Tsao, 2015)(Moons et al., 2012). The foundation laid by
the FHS continues to be the benchmark for CVD research, but the limitations of the tools
and the persistence of the disease necessitates an ongoing effort at improving on CVD
risk formulas’ performance.
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Limitations
Despite the great successes of the FHS, the usefulness of the FRS, and the many
effective succeeding projects, there are shortcomings that must be addressed (Schlendorf,
Nasir, & Blumenthal, 2009). First, the outcome of the original cohort focused solely on
CHD and therefore the data does not extrapolate well in the prediction of other coronaryrelated events (Mahmood et al., 2014). Second, given that several groups were
underrepresented in the original cohort, use of the FRS is less than ideal for certain
groups like for young people or for ethnicities other that are not whites of European
descendent (Hemann, Bimson, & Taylor, 2007). Thirdly, the original delineation of no
prior CVD events and the challenges to internal validity (the response rate, recall bias,
mortality/attrition, etc.) resulted in a sample that was healthier than the general
population (Mahmood et al., 2014).
Notably, the initial FHS was conducted when diabetes was less prevalent, and the
diabetes protocol used was different from the present. The previous criterion for a
diagnosis of diabetes was a random blood glucose level of 200 mg/dL or more, but the
current criterion is a fasting blood glucose of 125 mg/dL or more (Framingham Heart
Study Longitudinal Data Documentation, n.d.). As a result of the difference in diabetes
diagnosing, the FRS’s discriminatory powers within current populations, where diabetes
is now more prevalent, is compromised. Other adverse features of the original cohort
include the absence of factors like metabolic risk factors such as C-reactive protein
(CRP) levels and coronary artery calcium (CAC) (Kones, 2011). These issues, combined
with restriction of risk estimation to only a 10-year period, as opposed to a 5-year or 30-
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year period, all leave opportunity for optimization of the FRS formula (Schlendorf et al.,
2009). This optimization can take many different directions, but this study focuses on the
role of fasting blood glucose levels (FBGs) in CVD risk estimation.
Delimitations
The FHS researchers considered the long-term epidemiological study design most
suitable for studying the lifestyle and environmental factors involved in the development
of cardiovascular disease (O'Donnell & Elosua, 2008). The participants were restricted,
due to the logistics of the early stages of the study, to adults living in the town of
Framingham, Massachusetts (Dawber & Lansing, 1966; Mahmood et al., 2014) The
middle-class white, mostly of European descent, residents of this town were believed
(erroneously) to be geographically, socioeconomically, and environmentally
representative of the rest of the country (Mahmood et al., 2014). The variables measured
and recorded, including age, gender, serum cholesterol, diastolic and systolic blood
pressure, glucose, and diabetes, were predetermined by the study leaders as potential risk
factors relevant to the outcome (Dawber et al., 1951).
The original cohort sampling spanned 5 years from October 1948 to 1953 and
potential candidates were between the ages of 20 and 70 years (Dawber & Lansing,
1966). From that group, two-thirds of the all the families in the town were selected at
random, and all eligible members in those families were invited to participate.
Subsequently, there were only two edibility criteria- being 30 to 59 years old and having
had no history of cardiovascular disease (Dawber & Kannel, 1966). Of the 6,507 invited
to participate, some 5,209 were interested in participating, resulting in a 68.7% response
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rate (Tsao, 2015). The researchers believed that this was an adequate sample size for
generating reliable results, but there were still other challenges to the internal and
external validity of the results (Mahmood et al., 2014). The internal and external validity
of the data collected will be discussed further in chapter three.
Significance of the Study
The uncertainty surrounding the pathophysiology of CVD, and its oftensubclinical symptomology, serve to complicate most detection and prevention strategies
(K. M. Anderson, Wilson, Odell, & Kannel, 1991; Kones, 2011). Comorbidity between
the risk factors and the varying prevalence rates among the different populations both
challenge any effort at risk assessment (D’Agostino et al., 2013; Haregu et al., 2016;
Scheerbaum et al., 2017). The limitations of the current screening tools —inadequate
scope, insufficient sensitivity, and sometimes, imprecise results— continue to underscore
the need for risk estimation augmentation (Kones & Rumana, 2014; D. Lloyd-Jones et
al., 2010). This research is a part of the need for augmentation research that advances the
effectiveness of risk prediction formula.
The increased prevalence of metabolic diseases, which do strongly predispose to
heart disease, makes both metabolic and diabetic factors essential CVD risk factors.
Glucose is a most fundamental maker for cardio-metabolic given its significant
relationship to both developing diabetes and developing CVDs (Haregu et al., 2016;
Huang et al., 2016; Park et al., 2013; Valentino et al., 2015). As such, glucose should be
an important predictor of cardiovascular health as well. This dissertation research will
provide additional information on the effect that blood glucose levels predictive potential

16
and its potential for improving the performance of the FRS-CHD risk assessment
formula.
Positive Social Change
This research focuses on glucose as a major risk factors associated with
cardiovascular disease and aims to further elucidate its role in CVD risk prediction. The
findings will impact the way cardiovascular disease is screened for in the field and the
way it is treated in the both the outpatient and hospital setting (Hosseini, 2015).
Secondly, it will help guide the physicians’ decisions about where and how to direct often
limited resources in CVD prevention and treatment efforts, especially for those at high
risk (Hosseini, 2015). Finally, the information generated may influence health education
and literacy efforts among the low and moderate-risk population, providing greater
incentive for behavioral change adoption (see Rosenstock, 1974).
I was motivated to complete this study by the burden that exists for more effective
screening tools and for a greater efficiency and wider applicability of the CVD screening
protocols (see Kones, 2011; Lloyd-Jones et al., 2010; Roger et al., 2012). The results
could be used to support treatment regimen and the education of the public about the
effectiveness of the positive lifestyle and behavioral changes effective in protecting
against this deadly disease (see Goong et al., 2016). This research may provide much
needed insight about cardiometabolic pathophysiology that informs future
epidemiological and clinical research (see Dahlöf, 2010; Kones, 2011). The objective is
to move the field closer towards the goal of reduced CVD mortality and morbidity and a
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greater quality of life and heart health for those at risk, as well as the afflicted by CVD
and those who care for them.
Summary
CVD is currently the deadliest of all diseases and it is a major burden on the
healthcare system. The FHS uncovered the many CVD risk factors and shifted the
emphasis from treatment to prevention. The FRS is a multivariate logistic regression
formula used to predict the probability of developing CHD and has been used effectively
in reducing the incidence and prevalence of the CHD. Despite its effectiveness and
widespread use, the FRS has some notable limitations that necessitate optimization. By
nature, CVD is believed to be a cardiometabolic disease, as many metabolic markers are
strongly associated with the disease outcome. I hypothesized that replacement of the
dichotomous variable of diabetic status with that of the continuous variable glucose levels
in FRS should provide an improve stratification and classification power to the formula.
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Chapter 2: Literature Review
Introduction and Literature Review Strategy
The purpose of this literature review is to detail the burden of CVD, both past and
present, and to establish the need for ongoing CVD research, specifically in area CVD
risk assessment. Although, there has been a decline in the incidence and prevalence of
CVD over the last 7 decades, it remains the leading cause of death in most nations
(Emelia J. Benjamin et al., 2017). This decline is largely the result of the identification of
the major risk factors followed by concerted and successful efforts in reducing the
prevalence of these risk factors, mainly that of cigarette smoking . However, the increase
in obesity and other metabolic disorders pose new threats to cardiovascular health . Other
studies have looked at the role of various risk factors in risk assessment models, but none
have focused the role of glucose level in the most common risk assessment formula, the
FRS.
This second chapter of the dissertation will begin with the delineation of the
pathophysical model and the conceptual framework on which this research is based. This
will be followed by a discussion of the history and epidemiology of heart disease and
how it went from being a rare disease to an epidemic. Next will be an account of the
research into heart disease and how the FHS got its start and how it became a seminal
study, not just in heart disease but in public health in general is then presented. The first
half of chapter will close out with a description of how the CVD risk factors were
discovered and how their discovery influenced the CVD screening and prevention
therapy in use today.
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The second half of this chapter will focus on the multivariate risk model that came
out of the FHS FRS. Each of the risk factors included in the FRS and their role in CVD
screening is described in detail. The next section will focus on the disorders of
carbohydrate metabolism and how they are related to the development of heart disease.
Glucose level, as the main metabolic marker, will be a highlighted with information
about how it is measured, how it affects the metabolic system, and its role in screening
for CHD. The discussion will also report on the current state of glucose lowering therapy
in CHD prevention therapy. The chapter will end with a discussion on the main risk
assessment tools, their formula performance evaluation and their optimization over the
years.
The literature search for this chapter was conducted using several electronic
databases that cover research in the areas of medicine and health. These included
PubMed, Medline, CINAHL, ProQuest, Springer, Google Scholar, and Elsevier. The
keywords used for searching these databases include cardiovascular disease, CVD,
coronary heart disease, CHD, CVD risk factor, diabetes, blood glucose, blood sugar,
pre-diabetes, metabolic syndrome, CVD risk assessment, and CVD risk tools. The
Boolean operators (AND, OR, NOT) were used to ensure the relevance of the returned
journal articles. For articles not available online, I made requests to the Walden
University Library staff and was either provided with the article or directed to an
alternative available source. For current epidemiological data on heart disease and related
risk factors, I used the websites of scientific and governmental intuitions such as the
CDC, WHO, AHA, NIH and NCLBI.
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Given the nature and importance of the topic of heart disease, there was an
abundance of available sources. However, a critical review allowed for restriction to
articles that had relevance to the objective of the research. Articles chosen focused on the
most common and the most dangerous of the CVDs, CHD and its risk factors, the tools
for CHD assessment, and the role of blood glucose as a risk factors and in risk
assessment tools. Efforts were made to obtain the primary research article or the original
report of the findings, and to restrict use of only research conducted by or associated with
reputable institutions. On obtaining access to the articles, the abstract was perused to
determine the relevance of the article and if it appeared relevant then the full text was
reviewed. Additional articles were found in the references of the articles returned from
the original search. All articles deemed important were then saved to a Mendeley account
where they were tagged and filed for later reference and citation in the document.
Theoretical Framework
Health Behavior Model
The theoretical framework used for this research is the health behavior model
(HBM), which was developed using theories from social and behavioral sciences
(Esparaza-del Villar et al., 2017; Janz & Becker, 1984). HBM was first used in the 1950s
by the U. S. Public Health Service in their efforts to curb the spread of tuberculosis (TB)
(Esparaza-del Villar et al., 2017; Hosseini, 2015; Rosenstock, 1974). It remains one of
the most popular conceptual frameworks for understanding changes in or explaining and
predicting acceptance of new health behaviors (Janz & Becker, 1984). It has been
successfully applied to several public health issues such as TB, breast self-exams,
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osteoporosis prevention, Hepatitis A & B vaccination, and Pap smear testing (Esparazadel Villar et al., 2017).
The HBM is based on three main components: (a) perceptions of susceptibility or
vulnerability to the condition or disease; (b) perceptions of the severity of the disease and
its consequences; and (c) perceptions of the effectiveness of action to avert or ameliorate
the disease condition (Janz & Becker, 1984). The other tenets of the model include the
perceived barriers to selected actions or action, cues-to or triggers-to these particular
actions, and self-efficacy or confidence to carry out the chosen actions (Hosseini, 2015).
The energy or force driving the new behavior comes from the perceptions of severity and
susceptibility, while the choice of behavioral path is influenced by subjective barriers and
any feelings or lack thereof, of self-efficacy (Janz & Becker, 1984). Essentially, a person
health behavior is driven by their own perceived susceptibility and whether acting will
relieve their susceptibility.
The general tenet of the HBM is that people are only motivated to make changes
in their behavior, as it relates to health, in response to some perceived personal threat or
impending illness (Esparaza-del Villar et al., 2017; Janz & Becker, 1984). Knowledge of
the threat, and the belief that it will be averted by certain actions, is the impetus for the
behavioral changes. Conversely, ignorance of the association between the disease and its
risk factors or the impact of related behavioral changes causes skepticism about the
actions being promoted (Khorsandi et al., 2017). According to HBM, subjects who are
provided with appropriate disease risk information will act to mitigate that risk.
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In the HBM model, health behavior is closely related to health belief, making
knowledge the most important factor in motivation towards change (Rosenstock, 1974;
Janz & Becker, 1984). The HBM guides much of the research and the communication of
relevant information about the susceptibility to CVD, the severity of its consequences,
and the effectiveness of risk factor averting behavior. Behavioral changes and lifestyle
modifications have been shown to reduce the risk of developing CVD as well as
minimize the severity of the symptoms (Esparaza-del Villar et al., 2017; Goong et al.,
2016; Khorsandi et al., 2017). The research objective for my study is to strengthen the
link between glucose level and heart disease will increase attention to this risk factor and
promote the adoption of related health behaviors.
Cardiovascular Framework
The conceptual model that undergirds this study is the relationships between the
established risk factor and the prediction of CVD risk (see Mozaffarian, Benjamin, Go, et
al., 2015). The covariates and commodifiers that have an impact on the outcome are
included in the model (see Figure 1) as well as the complex interactions among these
health determinants and how they are mediated through the specific metabolic risk factors
(see Brunzell, Davidson, & Fuberg, 2009; Nguyen et al., 2012; Wilson & Meigs, 2008)..
Understanding what biochemical factors predates CVD can provide insight into the
etiology of the disease development. Insight into the nature of these factors, their
symptoms, and their role can be used to improve effort at predicting the likelihood of the
disease.
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Figure 1. Cardiometabolic model of CVD development.
Heart disease is a disease of the vascular system, detected as the arteries develop
atherosclerosis and become clogged with fatty substances or plaques made up of lowdensity lipoproteins (LDL) and other material . However, it is now accepted knowledge
that the atherosclerosis is preceded by damage to the walls of the blood vessels, and the
cause of this damage may be the root cause of the disease (Cockram et al., 2001; Jackson
et al., 2016; Kozakova et al., 2017; Saisho, 2014). Increases in blood sugar concentration
have been shown to be associated with significant damage to the blood vessel walls
(Jackson et al., 2016; Tostes & et al., 2009; Zhang et al., 2014) and may therefore be a
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major contributor to atherosclerosis and the subsequent heart disease. This process
explains the connection between diabetes, and more specifically, hyperglycemia and
cardiovascular disease and is basis for cardiometabolic disease theory of CVD.
Based on the medical model of cardiometabolic disease development combined
with the principles of the HBM, I investigated the association between the glucose level
and the development of CVD with the objective of informing and promoting heart
healthy behavior. I focused on the role of blood glucose as a CVD risk factor and how it
affects the performance of a risk assessment algorithm, the FRS. These findings provided
evidence in support of an emphasis on dysglycemia as a marker for metabolic disorder
and a predisposition to CVD. Ultimately, the purpose of the study is to advocate for the
inclusion of glucose level in risk detection formula tools and to encourage glucose
reduction strategies through behavior that foster cardiovascular health.
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History and Epidemiology of CVD
Discovery and Rapid Rise of CVD
A little less than 100 years ago a new era of public health emerged (citation), and
it presented novel challenges to the field. The patterns of old diseases were replaced by
unfamiliar ones and a different set of problems confronted public health practitioners
(U.S. Department of Health and Human Services, 2005). No longer were infectious and
communicable diseases the major global threat they had been for centuries; the greater
danger now lay in noncommunicable diseases (Rosen , 1958). Optimism over the success
of vaccination, improved sanitation, and antibiotics eradication of diseases like small pox
and tuberculosis was replaced by the confusion over a new epidemic of chronic noncontagious health issues (Nieto, 1999a).
It all began with shifts in the causes of morbidity and mortality brought on by the
emergence of new noncommunicable disease. The cause of the increase of these diseases
was unhealthy behaviors and practices . These newly-discovered diseases would
eventually become known as lifestyle diseases due to their most common trait being a
susceptibility to lifestyle changes and behavior modifications (Moore, Chaudhary, &
Akinyemiju, 2017). One of those diseases, heart disease, quickly became seen as the
deadliest (Nieto, 1999; Ockene, Daley, & Tran, 2014). But this shift in the cause of
morbidity and mortality occurred gradually.
Physicians became aware of heart disease somewhere between the middle of the
19th century and the end of World War I (citation). Between 1900 and 1930, CVD moved
from fourth to first on the list of causes of death in the United States (Dalen, Alpert,
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Goldberg, & Weinstein, 2014). Today, CVD accounts for one out of every three deaths in
the United States and in Europe Benjamin et al., 2017; Go et al., 2014; (Kannel &
Boston, 1990; Mozaffarian et al., 2015 ).
The first anecdotal case of heart disease was mentioned in a 1859 report at the
Swedish Medical Society meeting, when the pathological features of myocardial
infarction (MI) were described (Jones & Greene, 2013). By 1923, angina pectoris, still
considered very rare with roughly one case per month, was being documented as
resulting from the later stages of infectious diseases like rheumatoid fever and syphilis
(Jones & Greene, 2013). But by the 1920s, cases specifically identified as CVD were
now ubiquitous and the mortality rate for these diseases rose so sharply that the death rate
was doubling approximately every 5 years (Grimes, 2012).
During the 1930s and the 1940s, more cases of CVD, specifically chronic heart
disease (CHD), were being readily recognized and classified Grimes, 2012; O’Donnell &
Elosua, 2008; (Stehbens, 1995). At around the middle of the 20th century, CVD deaths
numbered twice those of TB and it was fast becoming a major public health concern
(Grimes, 2012). By the last quarter of the century it was so prevalent and deadly that
650,000 CHD deaths were reported in 1978 alone (Levy, 1981,). It was this dramatic
change in the main causes of death, led by CVD, that caught the attention of public health
professionals and epidemiological research efforts on CVD were subsequently launched
(O’Donnell & Elosua, 2008).
Top on the list of research objectives was identifying the causes of heart disease.
Some believed that the cause and the widespread nature of the CVD was due to things
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like the increase in smoking, more sedentary lifestyles, and increased consumption of
processed food, especially sugar (Rosen, 1958). Most notably, smoking alone saw an
eight-fold increase simultaneous to the rapid increase in CVD deaths . The incidence of
smoking in the American population jumped from 5% in 1930 to 42% in 1965 and was
believed by many to be the main reason for the of CVD rise (Dalen et al., 2014). Others
believed the eradication of other deadly diseases and changes in the diagnosis and
reporting practice for CVD resulted in an apparent increase (Nieto, 1999). Later research
would confirm the role of smoking (cigarette and tobacco) as a major risk factor in the
development of cardiovascular and in other lifestyle diseases . Smoking cessation would
mark the beginning of heart disease prevention and the curb of the rising CVD rates .
The Declining Rates of CVD
The rapid increase in the prevalence of cardiovascular diseases during the 1940s
and 1950s began slowing down in the 1960s (Dalen et al., 2014; Dawber & Lansing,
1966). By the late 1964 the disease incidence peaked and then slowly declined in the
latter half of the decade (Dalen et al., 2014; Dawber & Lansing, 1966). The CVD death
rates in the US continued to decline, resulting in a 50% decrease over the next 30 years
(Jones & Greene, 2013). As the CVD rates declined, there was much speculation about
the reason for the decline. The combined effect of personal and communal behavioral
changes, the increase in health literacy, the improved medical therapies, and supportive
public policy were all credited (Dalen et al., 2014). Some believed that it was the
successful combination of primary (risk factor reduction) and secondary (medical
intervention) prevention efforts (Fuster & Kelly, 2010; Nieto, 1999b; Pedersen, 2002).
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Others attributed it to the reduced prevalence of atherosclerosis that coincided with a
drop in cigarette smoking (from 42% to 18% between 1965 and 2012) following the 1964
Surgeon General’s report on the dangers of smoking (Dalen et al., 2014).
The CVD rate decline in the US and Europe was hailed as a victory for public
health. In 2011 some experts predicted, based on age-standardized extrapolations, that the
disease would come to an end in another 5 years (Grimes, 2012)(Grimes, 2012). But that
did not happen, as the declining CVD rates slowed considerably and eventually reversed,
with CVD rates rising in most developing countries (Bragg et al., 2014; Mensah et al.,
2015; Reddy & Satija, 2010). Surprisingly, the continued downward trend in cigarette
smoking was not matched by any further decreases in incidence of CVD (Jones &
Greene, 2013). The experts, baffled by the trend reversal, redoubled their efforts on
continued surveillance and risk factor modeling for the cardiovascular disease complex
(Grimes, 2012).
Origins of the Framingham Heart Study
In the early days of the disease, circa 1930s, the rapid rise in CVD mortality and
morbidity made the disease a top priority in the public health discourse. The consensus
among both health and political leaders was that the situation critically demanded action
(Tsao, 2015). That period in history was marked by very little understanding of the cause
of the disease and even less knowledge of how to respond to the crisis. During this period
of confusion, almost every other death was in some way related to CVD (Mahmood et al.,
2014). It was evident to those in the know that a CVD epidemic was in full force and it
was seemingly getting worse.
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During that time, it seemed no one was protected from the threat of heart disease.
Not only were average individuals being affected, but even the most powerful members
of the community were at risk as the disease was also impacting the top echelons of
society. In 1944, a diagnosis of CVD was confirmed in the nation’s leader, Franklin D.
Roosevelt, who along with his disability, had been living with the major indicators for
years (Rosen G, 1958). President Roosevelt endured many symptoms of CVD during the
later years of his life, eventually succumbing to a premature death in 1945 when his
blood pressure rose dangerously to 300/190 and he suffered a fatal stroke at the age of 63
(Mahmood et al., 2014).
While still in power however, it was President Roosevelt’s administration who
established the National Institutes of Health (NIH) as a federal agency in 1940; an act
contemporaneous with the growing threat to the nation’s heart health (Mahmood et al.,
2014). In 1948, Roosevelt’s successor Harry S. Truman established the National Heart
Act (NHA), which funded the establishment of the National Heart, Lung & Blood
Institute (NHLBI) that same year (Mahmood et al., 2014). The hope was that the NHLBI,
in response to the dramatic increase in CVD mortality, would somehow be able to
unravel the complex etiology of CVD and devise a solution to the epidemic (Lansing,
1961; Jones & Greene, 2013; Mahmood et al., 2014). The benefits of FDR’s foresight in
establishing these agencies are still be reaped today.
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Figure 2. The history of FHS. Graphical representation of the history of FHS. Reprinted
from “The Framingham Heart Study and the epidemiology of cardiovascular disease: a
historical perspective.” by S. S. Mahmood, D. Levy, R. S. Vasan, & T. J. Wang, 2014,
The Lancet, 383(9921), p 999-1008.
Not long after its formation in 1948, the federally funded NHLBI joined with
academic researchers, first from Harvard University and then later from Boston
University, to launch the Framingham Heart Study (Tsao & Vasan, 2015a). Improving
insight into the etiology, finding ways to effectively treat, and curb the spread of the
disease were the objectives (Mahmood et al., 2014; Tsao, 2015). The long natural history
of the disease necessitated a prospective, observation-type, cohort study. The data
collection included, but was not limited to, information on: consent, family history,
medical history, current symptoms, medication, personal and dietary habits, weight,
biometrics, cardiac exam, x-ray, ECG, blood (Hb, cholesterol, uric acid, glucose,
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syphilis), and urinalysis (Dawber et al., 1951). For each case, collected data were
eventually compared to the original clinical findings of the attributes associated with the
development of CVD, with attention paid to the most common CVD subtype- CHD (Tsao
& Vasan, 2015a).
FHS Through the Years
The FHS began in 1948 with 5,209 participants. The off springs’ of the 1st of the
2nd generation (children and grandchildren of the original cohort participants) made up
the 2nd and 3rd FHS cohort (Mahmood et al., 2014; Tsao & Vasan, 2015). These groups
provided additional understandings, including which individuals were susceptible, the
effects of shared environments, and most importantly, familial and multigenerational trait
aggregations (Mahmood et al., 2014; Long & Fox, 2016). The smaller OMNI1 and
OMNI2 groups, started in 1994 and 2003 respectively, focused on increasing the racial
and ethnic diversity of the participant pool beyond the mostly white (of European
descent) participants that made up the first three (Long & Fox, 2016; Tsao & Vasan,
2015a)
The first published report from the biennial FHS examinations described the
extent of the CVD disease, as well as the associated personal and environmental traits
(Dawber, George, & Mann, 1957). The second FHS report, based on data from 6 years of
observation (3 biennial examinations), looked at the role of nationality, education,
smoking and drinking habits (Dawber et al., 1959). By the 3rd cohort, more tests like the
12-lead ECG, cardiovascular imaging procedures, and biomarkers were added to the
assessment (Woodruff, 2012). The main influential factors discovered first were the
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metabolic factors: elevated blood pressure, obesity, and cholesterol level (Tsao & Vasan,
2015). The second follow-up on the original group, implicated the additional factors of
age and gender (Tsao & Vasan, 2015; Long & Fox, 2016). In the late 1950s, more data
analysis determined that cigarette smoking had a major effect on the CVD mortality rate
(Nieto, 1999b), and that it synergistically amplified other factors, as smokers tended to
also have higher cholesterol levels (Tsao, 2015).
The FHS revolutionized the field of epidemiology and birthed the term “risk
factors” (Tsao, 2015). The earliest findings of the FHS study indicated that CVD was
multifactorial (Dawber, George, & Mann, 1957; Dawber et al., 1959). It also caused the
shift in emphasis from secondary prevention and treatment to that of screening and of
primary prevention efforts (Ockene et al., 2014). The FHS results served as the
foundation for primary prevention projects and became an integral part of the CVD
practice guidelines and treatment strategies (D’Agostino et al., 2013). The FHS
originated the multivariate risk factor approach and its tool eventually became known as
the Framingham Risk Score (FRS) risk formula (Mahmood et al., 2014; Tsao, 2015).
The FHS has served as a template for many longitudinal cohort studies and its
protocol has become a widely accepted standard in the field of epidemiology (Kim, 2016;
Tsao & Vasan, 2015a). The FHS project has grown steadily over the last five decades
from the original 5,200+ to over 13,000 participants today in the core cohorts and several
auxiliary projects. The expansion has included ‘risk marker’ measurements such as
homocysteine, fibrinogen, lipoprotein lipase, and c-reactive protein and investigation of
social and psychological factors, most notably stress (Tsao & Vasan, 2015a). But despite
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all the novel projects thus far, the most effective CVD health promotion has been those
that focus on identification and reduction of the traditional major risk factors.
The Creation of the Framingham Risk Score
Primary Prevention and CVD Risk Reduction
Over the years, evidence has confirmed that primary prevention focused on risk
factor reduction lowered the frequency of coronary arteriosclerosis and decreased the
CHD death rate (Dalen et al., 2014; Ray et al., 2014). Primary prevention, unlike
secondary prevention, is administered prior to the onset of the disease with the goal of
preventing of the disease from occurring. Secondary prevention, on the other hand, can
involve drug administration, surgery to reverse an already existing condition, or any
treatment administered after a confirmed diagnosis to minimize complications,
reoccurrence, or death (Stone et al., 2013). The most common and most effective primary
prevention effort focused on smoking cessation, but primary prevention can also include
healthy eating and exercise programs (Grundy et al., 2002; Roger et al., 2012). The
importance of primary prevention and early intervention is underscored by the report that
over 1/3 of the victims of myocardial infarctions die within 24 hours or they develop
debilitating chronic heart failure, angina or have a cardiac arrest (Grundy et al., 2002).
Primary prevention involves screening and early detection of the antecedent risk factors
and applying specific therapies that have been shown to significantly reduce the risk of
developing heart disease and CVD (Jones & Greene, 2013). Primary prevention starts
with searching for and detecting the presence of the certain traits in individuals at risk,
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and for this CVD risk models are most effective tools (Tomasik, Krzysztoń, DubasJakóbczyk, Kijowska, & Windak, 2015).
Disease Modeling and the Framingham Risk Score
The science of CVD risk modeling began in the 1950s with the introduction of the
term ‘risk factors’ in the first FHS report and has progressed to the several dozen models
in use today. The original risk estimation was based on a basic combination of risk
factors into discriminant analysis tables, without any account for the severity or relative
role of each risk factor. This rudimentary tool focused mainly on the four major traits:
hypertension, high cholesterol and diabetes (D’Agostino et al., 2013; Mahmood et al.,
2014). Risk assessment models subsequently progressed to the use of cross-classification
combinations, but they were difficult to understand and even more challenging for the
physicians to use (Mahmood et al., 2014). By 1976, the first Framingham Risk formula
being used were based on seven factors (age, total cholesterol, weight, ECG abnormality,
hemoglobin, cigarettes smoked, and systolic blood pressure) with crude relative risk
values for blood pressure and cholesterol (Truett, 1976 in Mahmood, 2014). By 1998, in
the second iteration of the FRS, a more sophisticated multivariable logistic regression
formula had been devised to calculate an individual's risk score (Mahmood, 2014). The
critical importance of these tools in dealing with CVD morbidity and mortality and the
millions of dollars in healthcare cost potentially saved, resulted rapid distribution of the
different versions of this formula. Many versions are still in use and frequently updated
in the continually evolving the science of CVD risk estimation (Ray et al., 2014).
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CVD is a multifaceted disease and as such requires a complex risk assessment
formula that incorporates several risk factors. Using the FRS, an individual’s calculated
risk score (as a percentage) can be in either four categories: low, moderate or
intermediate, moderately high, and high, depending on the established threshold values.
The ATP III (Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) guidelines classify people into categories that depend on both
their 10-risk score and the presence of certain risk factors. The four are: high risk (FRS
over 20% and CHD or a CHD equivalent or 2 or more risk factors); moderately high risk
(FRS between 10% and 20% and 2 or more risk factors); moderate risk (FRS below 10%
and 2 or more risk factors), and low risk (0 or 1 risk factors) (Pedersen, 2002). Over the
years, the FRS has proven to be an important tool in CVD research, especially the ones
with disease incidence and risk factor similar to that of Framingham, MA, 60 years ago
(Eichler et al., 2007; Fawwad et al., 2016; Feresu, Zhang, Puumala, Ullrich, & Anderson,
2008; Rodondi et al., 2012; Yeung, Yuan, Hui, & Feresu, 2016; Yosaputra, Kholinne, &
Susanto Taufik, 2010).
Unfortunately, in instances where the disease pattern changes (e.g., increase in
diabetes prevalence) or the risk frequencies are different (e.g., low-income, minority,
etc.) the FRS may fail to identify those who need preventative therapy (P Brindle et al.,
2005). Refining the FRS has taken many forms mainly the revaluation of current
variables or the addition of novel risk factors and biological markers, many of which
require expensive equipment. The changing (arbitrarily chosen) thresholds, , risk factor
removal or inclusion, choosing new time periods for testing, and the cost versus benefit
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ratio of any of those changes are important considerations (D’Agostino et al., 2013).
Finally, simply using the disease incidence and prevalence data for a given population to
recalibrate and improve the formula’s performance is the most common ways of
remodeling CVD risk formula to improve its accuracy and precision (D’Agostino,
Grundy, Sullivan, & Wilson, 2001a).
The Most Common Outcome for the FRS: CHD
Cardiovascular disease can be divided into three main classes: congenital heart
disease (i.e., genetic factors or birth defects); disease caused by microorganism (e.g.,
rheumatoid heart disease); and heart disease resulting from atherosclerotic or
hypertensive disorders. Of the many forms of atherosclerotic heart disease, coronary
heart disease (CHD) is the most common and is the leading cause of sudden cardiac
arrest (Dalen et al., 2014). Coronary heart disease (CHD) is the term used to describe the
narrowing of the arteries that supply blood to the heart and is leading cause of CVD
morbidity and mortality, as 6.2 million are hospitalized and 400,000 die from CHD every
year (Kones, 2011). The prevalence of CHD, also referred to as coronary artery disease
(CAD), equals the sum of the prevalence of all other CVDs and accounts for 64% of all
CVD related deaths (Dalen et al., 2014). It is because of numbers like these that point to
the greater threat of CHD, that most CVD risk formulas focus of CHD prediction.
CHD is caused by the narrowing of the arteries when plaque accumulates on the
vessel walls. Plaque, made up mostly of cholesterol, builds up on the walls of the arteries
and reduces the supply of blood to the muscles of the heart (Kannel, Castelli, et al.,
1971). As blood flow decreases, the muscle tissues are deprived of sufficient oxygen and
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begin to die. The death of cardiac tissue is experienced as chest pain and shortness of
breath, the symptoms of angina pectoris (Bennet, Di Angelantonio, et al., 2008).
Ultimately, if the blood flow is completely occluded by fatty deposits or clotted blood,
nutrients and oxygen supply ceases, the muscle tissue dies, and a heart attack occurs.
Unfortunately, some 735,000 Americans experience a heart attack every year
(Mozaffarian, Benjamin, Go, et al., 2015).
The FHS group of researchers provided the very important insight that CHD
disease is always preceded by a condition of atherosclerosis (Dawber & Lansing, 1966;.
The belief then became that CHD was caused by a buildup of plaque in the arteries of the
circulatory system, a process usually starting in the second and third decade of life and
progressively worsening with time (Ockene et al., 2014). Later research revealed, when
this atherosclerosis is exacerbated, the vessels walls become inflamed and the plaque
ruptures; the debris forms a clot that completely occludes blood flow, resulting in a heart
attack or a stroke (Cockram et al., 2001; Hosseini, 2015; Ockene et al., 2014). This had
been the main etiological concept of heart disease for many decades
However, due to the invention of high-tech imaging tools, a better understanding
into the development of CHD was been gained. It is now known that the disease does not
begin with atherosclerosis, but is accurately is preceded by damage to the endothelial
walls of the coronary arteries (Grundy et al., 2002; Pedersen, 2002; Zhang et al., 2014).
The plaque deposits at the injury site are attempts by the body to repair the damage to the
endothelium and is it made up of cellular waste, calcium, fibrinous clotting material, and
the lipid cholesterol at the core (Pedersen, 2002). When this plaque builds up on the walls
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of the body’s arteries, it is referred to as atherosclerosis and plaque accumulation
specifically in the arteries of the heart, is diagnosed as coronary artery disease (CAD) or
CHD (Hutcheson & Rocic, 2012). So, heart disease is more a disease of blood vessel
damage than it is of atherosclerosis. But what causes the damage to the walls and what
risk factors account for this threat?
Components of FRS: The CHD Risk Factors
The risk factors that are involved in the development of CHD fall into four main
categories: genetic, physiological, behavioral, and environmental (Kones, 2011). The
non-modifiable factors are genetic or physiological and include age, gender, and family
history of CHD. The other factors are behavioral or environmental and therefore
modifiable, and they include: smoking status, cholesterol levels, blood pressure, diabetes,
and obesity (Hobbs & Hobbs, 2004). The major predictive risk factors such as high
cholesterol, diabetes, and high blood pressure are linked to diet and level of physical
activity and smoking directly to the individual’s choices, making them all behavioral.
The more recently discovered, less established, factors include biological markers
such as C-reactive protein (CRP), lipoprotein A (lpA), low density lipoprotein (LDL),
fibrinogen, and triglyceride (TG) levels (D. Lloyd-Jones et al., 2010) (Bennet, Di
Angelantonio, et al., 2008). Also included in this category are imaging factors like
coronary artery calcification (CAC), carotid intima media thickness (CIMT), and
coronary angiography- all measured by MRI or CT scans (D. Lloyd-Jones et al., 2010)
(Ray et al., 2014). The sophisticated technology required for these markers makes testing
for them expensive and inconvenient. Additionally, research indicates that these markers
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offer very little improvement in the performance of the predictive models based on
established risk factors (Tsao & Vasan, 2015a).
In the US, screening for primary prevention purposes uses the latest version of the
multivariable FRS to estimate the risk of CHD. The FRS combines measures of the more
classical risk factors (i.e., age, gender, total cholesterol, tobacco use, HDL-C, TC,
systolic blood pressure, and treatment status or CHD history) into an equation that
calculates the risk score. Of the modifiable risk factors, high cholesterol is considered the
strongest predictive factor, (after smoking), followed by diabetes, and high blood
pressure. These modifiable risk factors are the focus of primary prevention efforts that
include smoking cessation, and the lowering of blood pressure and cholesterol levels and
reducing measures of obesity. This research aims to show that blood glucose level
stabilization may also be critical to CVD prevention.
Cigarette Smoking
Smoking cigarette or tobacco is a major CVD risk factor, which was overlooked
in the first report, but later confirmed as having the strongest association to CVD in the
second FHS report (Dawber et al., 1959). Clinical research showed that the effect of
smoking habits are associated with reduced heart rate, decrease oxygen capacity of the
lung, increase blood clotting and chronic damage to the endothelium of the blood vessels
(Ockene et al., 2014). Nicotine, the accompanying toxins, and the free-radicals generated
from smoking all cause direct damage to the tissues, including those of the cardiovascular
system, resulting in reduced cardiac function and an increased propensity to the
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formation blood clots (Ockene et al., 2014). These structural and functional damage to
the blood vessels are what lead to atherosclerosis and eventually cardiovascular disease.
After much debate between the government, the policy makers, and the tobacco
industry, the Surgeon General officially reported, in 1964, that smoking was dangerous
for the smoker’s health (Dalen et al., 2014). The report stated that smoking causes lung
cancer and was linked to heart disease, but the impact of this information on subsequent
CVD surveillance measures was not immediate. Slowly, over many decades, the
prevalence of smoking dropped from 42% in 1965 down to 18% by 2012 (Dalen et al.,
2014). This decline was eventually reflected in the decline in CVD prevalence, and by an
even larger decline in the incidence of heart disease in the population (Tsao & Vasan,
2015a). Now cigarette smoking, though the strongest risk factor, is no longer the most
prevalent as other risk factor have become more common.
Unlike hypertension and hypercholesterolemia, cigarette smoking was found to be
independent of other risk factors (Lansing, 1961). Of the many reversible risk factors,
smoking has the biggest impact as it confers a 6-fold increase in men, and a 3-fold
increase in women in the risk for MI, compared to non-smokers (Amsterdam, 2011). As
with other risk factors, the duration and the intensity of smoking impact the degree of the
risk, as former smokers who are now non-smokers have worse risk profile than those who
never smoked, and the more packs per day the more severe the risk (Fuster & Kelly,
2010). A habit of cigarette smoking is still associated with the risk of Myocardial
Infarction and sudden death due to CVD and smokers are 2-4 times as likely to have a
stroke (Roger et al., 2012) (Mendis, 2010).
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Over the last four decades, CVD mortality has decreased by one third and the
related symptoms have decreased by one half, due in large part to the reduced prevalence
of smoking (Dalen et al., 2014). When a person stops smoking the damaging substances
are eliminated and the many hazardous effects minimized and the risk is gradually
reversed (Jones & Greene, 2013). Consequently, widespread smoking cessation leads to a
considerable reduction in heart attacks and cardiac death rates. Reduced prevalence of
smoking when accompanied by dietary changes was found to amplify the benefits of
smoking cessation (Huxley, Woodward, Huxley, & Woodward, 2011).
Hypercholesterolemia
Although smoking and hypertension were among the first factors found to have a
high correlation to CVD, cholesterol was the first predictive factor uncovered in
analyzing the data (Dawber & Lansing, 1966). Cholesterol values describes the
concentration of fat molecules or lipoprotein dissolved in the blood. In the early days,
when the cross-classification tables were used for risk assessment, total serum cholesterol
had three levels- low, moderate, and high, corresponding to <225 mg/dL, 225-274mg/dL,
and > 275 mg/dL respectively (Truett, Cornfield, & Kannel, 1967). More recent risk
assessments use slightly different values: normal cholesterol levels are <200 mg/dL,
borderline is 200-239 mg/dL, and high is >240 mg/dL (Wilson et al., 1998). According to
the latest ATP III report 39.7% of Americans have a total cholesterol >200 mg/dL with
11.9% >240 mg/dL (Emelia J. Benjamin et al., 2017). In modern risk calculations, the
cholesterol level value, instead of the categories, are entered into the formula for risk
score computation. Hypercholesterolemia is associated with an elevated CVD death risk
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as the RR ranges from 2.83 t0 4.46 depending on the cholesterol level and is even higher
if diabetes is also present (Bertoluci & Rocha, 2017; Dahlöf, 2010)
During the 2nd generation of the FHS in 1971, the FHS lab was technologically
advanced enough to separate the blood lipids in to high density lipoproteins (HDL), low
density lipoproteins (LDL) and lipoprotein A (LpA) (Tsao & Vasan, 2015a). This
allowed for the determination that LDL blood lipids are the pre-disposing risk factor
contributing to plaque buildup in the coronary arteries. The discovery that LDL (and not
HDL) was the blood lipid most predictive of the development of CVD, resulted in the
substitution of the ratio of “total cholesterol to HDL” (Tot Chol/HDL) measure instead of
the “total cholesterol” in risk calculations (Tsao & Vasan, 2015a). When assessing LDL
separately, the optimal level is <100 mg/dL, moderate is 100-129 mg/dL, borderline high
is 130-159 mg/dL, high is 160-189 mg/dL, and very high is >190 mg/dL (Hosseini,
2015). High or very high levels of unhealthy LDL are found in 33% of Americans
(Pedersen, 2002).
More recent research led to the understanding that not only was the HDL
component of total cholesterol not implicated in the development of atherosclerosis, but it
was in fact beneficial to CVD health. HDL has been shown to protect of the endothelial
surface of the cell wall, to reduce LDL oxidation, and to help maintain the cells
sensitivity to insulin of the cells (Kones, 2011; Ray et al., 2014) HDL lowers CVD risk
and is recommended to be ideally > 60 mg/dL, while <40 mg/dL is considered low and
unhealthy (Hosseini, 2015). Epidemiological research has indicated that some 18.7% of
Americans have low levels of the healthy cholesterol HDL (E J Benjamin et al., 2017).
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The difference in the roles of HDL and LDL may explain why total cholesterol as
a risk factor only accounted for 50% or the CVD prevalence in previous data analysis.
Some individuals had the ‘high’ cholesterol, but had no CVD and others had CVD yet
were free of traditional hypocholesterolemia (Nieto, 1999b). High HDL concentration is
now known to be associated with a lower incidence of CVD and is regarded as a negative
risk factor (Pedersen, 2002). To account for this discovery, researchers decided to use the
Total Cholesterol to high density lipoprotein (Tot Chol/HDL) ratio in the Framingham
Risk Score. Eventually, the HDL/TC ratio was replaced by two distinct variables, total
cholesterol (TC) and the high-density lipid cholesterol (HDL) (Wilson et al., 1998).
The drop in the incidence of smoking caused hypercholesterolemia to the become
the most important CVD risk factor, but the prominence of cholesterol as a risk factor has
been challenged by recent research. According to Grimes (2012) the administration of
statin drugs did not cause the drop in the CVD death rate as the decline started before
statins were introduced 1994, and clinical trials showed benefits in only 2% of the
sample, with aspirin and streptokinase therapy benefiting only 5%. Similarly, in clinical
trials, aspirin, streptokinase, ezetimibe, and other cholesterol/plaque reducing
pharmaceuticals lowered cholesterol levels, but had very little (< 5%) or no clinical
benefit (Grimes, 2012). Additionally, the association between lowering of high
cholesterol and the reduction in CHD deaths was only experienced for young men, but
not for the older men or women of any age group (Grimes, 2012).
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Hypertension
There is a powerful association between hypertension and heart disease, and it
was one of the earlier traits identified by the FHS. High blood pressure (HBP) is
diagnosed as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure of ≥90
mm Hg (Goff et al., 2014). HBP is regarded as a leading independent risk factor for CVD
and is believed to result from the efforts of the heart to move blood through blood vessels
that have been narrowed by plaque buildup (Xu, 1991). As the condition of
atherosclerosis progresses and the narrowing of the arteries worsens, the vessel diameters
decrease, the heart is required to work harder and blood pressure goes up in response
(Hollander, 1976). This continual over exertion of the cardiac muscles sets up the
conditions for heart failure (stressed enlarged heart muscles), which can progress to heart
attack or stroke if the blood supply is eventually obstructed. (Renna, 2013).
Hypertension or HBP has a prevalence of 34% in adults, affecting over 90 million
in the US, and 972 million globally (E J Benjamin et al., 2017). Rates in subpopulations
can vary- African Americans have HBP rates of almost 46%, while children have 11%
HBP rates. Of those with a first heart attack, 69% were hypertensive and 77% of stroke
patients and 74% of those with congestive heart failure had blood pressures over 140/90
mm Hg (Mozaffarian, Benjamin, Go, et al., 2015). While hypercholesterolemia may be
regarded as the leading risk factor for CHD, hypertension is significantly correlated with
the other subtypes of CVD and is the leading risk factor for MI, HF, AF, PAD, stroke and
kidney failure (Ockene et al., 2014).
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The finding that an elevated systolic blood pressure (Sys BP) was more predictive
than elevated diastolic blood pressure (Dia BP) of a CHD event was a most important
FHS discovery (Dawber & Lansing, 1966). As a result, systolic and diastolic BP was
replaced by only ‘Sys BP’ as a risk factor in the FRS formula (Kannel, 1971). The FHS
researchers determined that the association between Sys BP and the risk of developing
CVD was continuous and graded no matter the level of BP or the age of the subject
(Kannel, Vasan, & Levy, 2003). Elevated Sys BP (> 140 mg Hg) is directly related to
both obesity and hypercholesteremia and the severity of the risk is dependent on the
presence of other CVD risk factors (Tsao & Vasan, 2015a). One study found that for
blood pressure measures that are above normal, every reduction in the BP by 10 mmHg
reduced the risk of CHD or stroke mortality by 15% (Bertoluci & Rocha, 2017).
Type 2 diabetes (T2DM).
Type 2 diabetes mellitus (T2DM) is a condition of impaired carbohydrate
metabolism. T2DM caused by an inability of cells to respond to insulin, results in
elevated levels of glucose concentrations in the blood. Insulin is a pancreatic hormone
that facilitates the entry of glucose into cells to be used for energy production. When the
supply of glucose is excessive, the high glucose concentration triggers an overproduction
of insulin from the pancreas, in an attempt to shuttle the surplus glucose from the blood
into the cells (Faerch, Bergman, & Perreault, 2012; Roberts, Hevener, & Barnard, 2014).
But this excess of glucose is harmful to the cells and they respond by removing their
insulin receptors from their cell membrane to minimize glucose influx (Roberts et al.,
2014; Zhang et al., 2014) The removal of the insulin receptors renders the cells less able
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to respond to insulin and they are become effectively ‘insulin resistant’ (Roberts et al.,
2014). At the same time the pancreas, which has been pumping out extra insulin to deal
with the rising glucose concentrations, becomes overworked and eventually shuts down
(Sah, Singh, Choudhary, & Kumar, 2016). With less insulin being produced and cells in a
state ‘insulin resistance’, dissolved glucose accumulates in the blood and abnormally high
blood glucose levels or hyperglycemia persists.
Epidemiological and clinical studies now indicate that one of the consequences of
prolonged hyperglycemia is CVD. High concentrations of glucose are damaging to the
cells and tissues of the body (Faerch et al., 2012; Laakso, 2015; Tostes & et al., 2009)
Excessive glucose causes glucose molecules to attach to the protein structures of cells,
the severity and duration of which can be measured by the hemoglobin A1 C (HbA1C)
test (Huang et al., 2016). High concentrations of glucose also cause the cells of the
epithelium of the blood vessels to lose their integrity and become damaged (Laakso,
2015). It is this damage to coronary blood vessels that initiates cardiovascular disease.
Advances in imaging technology have revealed that CVD is preceded by damage
to the arteries that carry blood to the organs and tissues of the body. One of the ways the
body tries to deal with this damage is by generating a blood clotting mechanism with
patches of fatty deposits at the site of injury (D. Lloyd-Jones et al., 2010). Unfortunately,
this ‘patch work’ becomes excessive with ongoing damage (persistent insulin resistance
and resulting hyperglycemia) and it leads to a build-up of plaque on the walls of the
arteries (Clark et al., 2015; Kishore, Kim, & Crandall, 2012) The plaque buildup may
reduce blood flow, comprise the supply of oxygen and nutrients to the tissue, occlude
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blood flow at the site, or break off and travel to other smaller spaces and occlude blood
flow there (Hutcheson & Rocic, 2012; Long & Fox, 2016). If this happens in the heart,
angina and heart attacks results; if the clot travels to the brain and obstructs blood there,
the person suffers an ischemic stroke. Hyperglycemia, and the accompanying
hyperinsulinemia, is believed underly the exacerbation of the many pathologies and
morbidities of CVD (Hobbs & Hobbs, 2004).
CHD Risk Assessment Tool
CHD Risk Tool Performance
Accurate prediction of threat and effective disease prevention and treatment
strategies depends on well-designed risk estimation models. The widespread use of tools
like the FRS and others is a testament to this. A risk formula combines the major risk
factors into an equation that returns an estimation of the risk as the probability of a
disease event happening. The CVD risk formulas typically calculate the probability of
developing CVD events within a given period, usually “10-years” but sometimes “20years”, “30-year” or even “life-time”. Ideally, the use of baseline relative risk and the
levels of exposure of the risk factors used in these tools should be specific to the
population under investigation, otherwise additional calibration adjustment is required
(Eichler et al., 2007).
A more trustworthy stratification can be achieved by changing the disease range
and using alternative thresholds for the categorization of different levels of predicted risk.
Incorporating additional variables or replacing old ones with newer, more strongly
correlated ones, can improve accuracy and stratification power. To ensure the continued
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applicability and utility of prediction tools, the ability to adequately discriminate (to
differentiate between those with CVD outcome from those without) and to sufficiently
calibrate (agreement between the prediction and the observation) are essential. In most
cases, regression statistics are used to generate the model and the corresponding AUC or
c-statistic are used evaluated the model’s performance (Elosua, 2014).
The FRS Tool and its Performance Limitations
The Framingham Risk Score tool has endured the test of time and is credited with
popularizing the concept of risk prediction (Bitton & Gaziano, 2010). Because of these
tools like the FRS physicians no longer must rely on their experience and judgment in
assessing the CVD risk of their patients. Instead they can use the risk prediction function
to more adequately screen and sort patients, more responsibly allocate resources and
more effectively manage the treatment modalities (Günaydın et al., 2016). For a great
many people, the FRS is still the most effective way for predicting the likelihood of
developing CHD as well as screen for the presence and severity of the disease
(D’Agostino et al., 2013).
However, as beneficial as the FRS is, it has its some limitations and these
limitations serve as the main driving force behind of risk score optimization efforts.
Earlier research on the risk factors led to changes such as the removal of HDL from
cholesterol measures and the use of only diastolic blood pressure values. Other changes
such as generating gender specific versions of the formula or the labelling of diabetes as a
CHD equivalent were all done to improve the FRS prediction performance. But as the use
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of the tool became more widespread there were reports of more fundamental issues with
the tool’s performance.
The main limitations of the FRS relate to the less than ideal discrimination and
classification power. A comprehensive study conducted by the FHS team evaluated the
performance of the FRS amongst six ethnically different groups across the US.
Evaluating the classification and calibration ability of the FRS to predict the relative risk
associated with CHD revealed that the tool had an AUC score between 60-70%
(D’Agostino et al., 2001a). By their own standard any risk assessment tool with an AUC
score below 70% is considered suboptimal and should be amended (D’Agostino et al.,
2013). And although, the FRS has been updated since that 2001 report, the issues with
under or overestimation and inadequate classification persist (Çevik, Özcan, & Satman,
2015; Günaydın et al., 2016; Van Staa et al., 2014).
The white middle-class cohort from which the original formula was designed
limited its generalizability to more ethnically diverse populations. Studies conducted by
the NHLBI have determined that the FRS, even after recalibration, tended to
underestimate the risk in populations that have very low incidences of CVD, such as
Japanese, East-Indians and Native-Americans (D’Agostino et al., 2008; N. Garg et al.,
2017; Kones, 2011; Reddy & Satija, 2010). Additional studies reported on the
misclassification and overestimation in high-risk groups or those in the lower
socioeconomic class in the US and among European populations in general (Eichler et
al., 2007; Günaydın et al., 2016; Pike et al., 2016). These findings were concerning and
have reduced the confidence of US and European physicians in using risk equations.
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Other Tools Developed in Response to the FRS Limitations
The next section describes the three most common (after the FRS) CVD risk
estimation models being used in the field of CVD screening and prediction. These tools
were developed from the FRS and came about in response to its limitations. Despite the
recalibration and other adjustments made to the FRS, the inaccuracy was problematic,
and researchers wanted risk formulas that was more representative of how the disease
manifested for their patients. The desire for tools that specifically represented the CHD
risk in their respective countries and communities resulted in the development of the
QRISK, the SCORE, and the ASSIGN.
QRISK: the QResearch database CVD risk score. QRISK was in response to
the challenge of using the FRS in Europe, namely European ethnic diversity and
differences in CVD prevalence. The UK-NICE (National Institute for Health and Clinical
Excellence) developed a revised version of the FRS, called FRS-NICE. The FRS-NICE
added the risk factors BMI, family history of CVD, treatment for hypertension, and social
deprivation to the FRS and raised the threshold for the high-risk category (Collins &
Altman, 2012). Applying the FRS-NICE reduced by half the number of patients being
recommended for primary prevention and thereby reduced the expense and many-sideeffects associated with statin, the cholesterol-lowering drug, usage (Collins & Altman,
2012).
The SCORE (Systematic Coronary Risk Evaluation). SCORE, the second
most common European risk assessment tool, began in 1994 as a collaboration between
the European Society of Hypertension and the European Society of Cardiology using data
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from 12 European cohorts and their 205,178 patients (Tomasik et al., 2015). The six risk
factors used were: total cholesterol, TC:HDL ratio, age, gender, smoking status, and
systolic BP with a 10-year CVD outcome prediction. The larger cohort, the easy-to-read
charts, the inclusion of endpoints other than mortality, and the use of the respective CVD
rates for each region did improve the risk estimation and prediction. This simplified
prevention method assignment and patients were more appropriately categorized for
application of education, lifestyle changes, or medication (Conroy et al., 2003).
ASSIGN (Assessing cardiovascular risk, using SIGN). ASSIGN is the CVD
screening tool developed by the Scottish Heart Extended Cohort (SHHEC) from survey
data, collected from 1944 to 1995 from clinic patients between 25 and 74 without a
history of CVD (Woodward, Brindle, & Tunstall-Pedoe, 2007). Like the QRISK, the
outcome was based on mortality and morbidity measures as well as both CHD and CAD
as this was the most common CVD and the leading cause of death among the Scotts. The
ASSIGN successfully improved upon the sensitivity and specificity of the FRS and
alleviated the disadvantages suffered by high-risk minorities who were previously
insufficiently allocated for preventive care (Tunstall-Pedoe, 2011).
Comparing the Common CVD Risk Formulas. Choosing between models is an
important task for many personnel and organizations involved in CVD screening. There
are several studies comparing the performance of the more common models of risk
estimation. One such study compared the performance of the FRS (US based), the
ASSIGN (Scottish), and the QRISK2 (England and Wales) on the same data set. There
was congruency among all three models, except for the high-risk classification, although
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challenged by the different thresholds (Van Staa et al., 2014). The social-deprivation term
in ASSIGN did not work for non-UK populations but the region-specific data and CVD
history information made the QRISK most accurate overall (Van Staa et al., 2014).
Recently Gunyadin (2016) compared the performance of the SCORE relative to
FRS to determine which was better at predicting CVD. They used the SYNTAX test, an
angiograph measurement of the number of lesions inside the coronary arteries, for a nonformula estimation of CVD risk. According to the results, the SCORE provided better
discrimination among men and diabetic patients, but not among the obese or those with a
family history of CVD. Although, both models predicted a similar level of CHD severity
risk (based on the AUC evaluation), the only factors found to be statistically significant
in the SCORE model were ‘blood pressure’ and ‘total cholesterol’ (Günaydın et al.,
2016).
Performance Evaluation of CHD Risk Tools
It is important that prediction models that have been developed, redesigned, or
extended continue to be adequately reevaluated as these tools are used for making
important decisions, both diagnostically and prognostically. In the field of medicine,
where decisions are usually binary in nature and require an estimation of absolute risk,
logistic regression models have proven effective (Sperandei, 2014). Determining whether
these formulas' predictions can be extended to the other sample population is vitally
important. The calibration ability or the difference between the predicted outcome and
the actual outcome reflects most how well the model describes the data. Making changes
to the formula to improve on its calibration power is central to formula optimization.
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For CVD risk prediction, the models are formulas that combine the major risk
factors generates prediction probability as an attributable risk value. There are many
methods for evaluating the performance of these prediction formula and by convention,
quantifying the performance with known-outcome data sets works best. For logistic
regression formulas, where the outcome is dichotomous, the model’s performance is
evaluated based on four main metrics: (i) the coefficient of the independent variable
(which reflects the strength of the association), (ii) the confidence interval of the
independent variable (which gives an indication of the importance of the variable to the
prediction relationship), (iii) the accuracy of probability of the dependent variable, and
(iv) the goodness of fit of the formula in both its discriminating and its calibrating
abilities (P Brindle et al., 2005; D’Agostino et al., 2001a; Giancristofaro & Salmaso,
2003).
For models whose performance evaluation determined that they need to be
optimized, there are several ways of doing so. Models can be optimized by adding new
markers that extend to the formula but adding this new variable must provide a higher
degree of accuracy (Root et al., 2014). Models can also be optimized by altering the
variables already in use so that there is an increase in the additional risk information
provided (Rodondi et al., 2012). Ideally this altering of the variable should have a
generate an increase in the predictive power. In either case, the new formula is evaluated
against the performance of the old one based on the same principles used in the original
model development.
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Improving the performance of multivariable risk assessments is vital to patients’
classification and treatment guidelines and users should be confident of the tools
applicability and generalizability. This study will compare the predictive performance of
the FRS model that uses ‘diabetic status’ as a marker against the one that uses ‘glucose
levels’. First the relative risk and the confidence intervals of each marker will be
computed and compared, then the attributable risk as a probability for each the two
formulas. The predicted probability will be compared with the observed probability of the
data compared as discriminating ability in the AUC to determine which is the better fit of
the data. Finally, the co-variates will be added to the analysis and the effect on the AUC
of the ‘glucose level’ formula will be assessed.
Glucose and the Crisis of Metabolic Disorders
Spectrum of Metabolic Disorders
Diabetes describes persistent elevated blood glucose levels produced by impaired
carbohydrate metabolism. Diabetes is, however, one of many states that are part of a
continuum of metabolic abnormalities and body weight issues; beginning with mild
insulin resistance, moving to being overweight, then to full-blown insulin resistance and
obesity, followed by pre-diabetes, and finally ending with diabetes (Long & Fox, 2016).
Collectively these disorders, referred to as ‘diabesity’ by Dr. Hyman, are known as
metabolic disorders or impaired glucose tolerance problems, most of which go
undiagnosed and therefore ignored (Hyman, 2012). The rapid rise of metabolic disorders
has been projected to affect some 1.7 billion people worldwide by the year 2020 (Matfin,
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2010). More recent research indicates that in 2012 one in every two Americans (52%)
was already either pre-diabetic or diabetic (Menke, Casagrande, Geiss, & Cowie, 2015).
Cardiovascular diseases are part of a larger group of cardiometabolic diseases that
share clinical markers, that can co-occur, and are interlinked in their development
(Assmann, Schulte, & Seedorf, 2008; Bertoluci & Rocha, 2017; Long & Fox, 2016;
Srikanthan, Feyh, Visweshwar, Shapiro, & Sodhi, 2016; Wilson & Meigs, 2008). The
high probability of co-morbidity necessitates an integrated approach to risk assessment
that combines ‘cardio’ factors and ‘metabolic’ factors of diseases such as CVD. One
cross-sectional study of 5,190 Kenyans looked at the most common cardio-metabolic
markers and concluded that central-obesity (i.e., abdominal obesity), hypertension,
hypercholesterolemia, hypertriglyceridemia, and hyperglycemia were all inter-linked
(Haregu et al., 2016). Assmann et al., (2008) argued that including metabolic markers
significantly improved the accuracy of CVD risk assessment tools. A decade ago, the
FHS researchers concluded that metabolic risk factors, not diabetes only, should be part
of the screening and prevention strategies for CVD (Wilson & Meigs, 2008).
Overweight, Obesity, and BMI
Metabolic disorders usually begin with some form of insulin resistance and if
unchecked progresses through to several stages of metabolic disorders eventually end in
diabetes. The hormone insulin is responsible for the movement of glucose into the cells
as described above. It is also involved in the production of fat- both in the liver and the
fat cells around the body (Sah et al., 2016). Insulin production by the pancreas and
increased insulin resistance of the body's cells promotes the conversion of the excess
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glucose in the blood into fat cells where it can be stored (Roberts et al., 2014; Srikanthan
et al., 2016). The accumulation of fat tissue around the vital organs begins the overweight
status that eventually leads(Roberts et al., 2014) to central or abdominal obesity.
Overweight is usually the first recognizable sign of hyperglycemia, insulin resistance and
metabolic dysfunction (Hyman, 2012; Roberts et al., 2014; Srikanthan et al., 2016).
Overweight status is determined by the height to weight ratio or body mass index
(BMI) and is calculated by dividing the subject's weight by the square of their height
(Kg/m2) (Çevik et al., 2015). A BMI over 25 but less than 29.9 is considered overweight
and affects approximately 35% of the American population (Go et al., 2014). Sometimes
the BMI measures are misleading, and waist to hip ratio is used to be a more accurate
estimation of an individual’s obesity level (Reddy & Satija, 2010). However calculated
though, more than half (53%) of Americans have visceral or abdominal obesity, and 3
billion around the globe are dealing with excess body fat (Kones, 2011).
If overweight condition is not adequately managed the next state, in the metabolic
disorder continuum- obesity, happens. Obesity, measured by a BMI of 30 or above, is
considered the leading cause of preventable death and afflicts 35% of the Americans
(Nichols, 2012). Obesity is a serious medical condition that causes hypertension and
atherosclerosis making it a major CVD risk factor, but it also predisposes individuals to
respiratory problems, sleep disorders, and even cancer (Long & Fox, 2016). Increased
BMI is correlated with hypertension, T2DM, congestive heart failure, and the onset of
atrial defibrillation, and obesity was found to be double the risk of CVD in the original
FHS research (Wilson & Meigs, 2008). Obesity also increases the risk of Angina Pectoris
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and sudden death by cardiac arrest (Long & Fox, 2016). Obesity serves an independent
risk marker for glucose intolerance and a corresponding increased risk of CVD (Long &
Fox, 2016). The rate of obesity and overweight status has been increasing - between 1950
and 2000 the proportion of Americans who are overweight rose from 15 to 30%, while
obesity rose from 3.9 to 14% (Long & Fox, 2016). Today, as many as 70% of American
adults are either overweight or obese (Kones, 2011) and over 80% of overweight patients
have at least one of four major CVD risk factors- hypertension, elevated triglycerides,
low HDL, or impaired glucose tolerance (Nichols et al., 2012).
Pre-Diabetes
The order of progression through the metabolic continuum is not pre-set, obesity
can be preceded by or followed by conditions of pre-diabetes. Pre-diabetes, or
intermediate hyperglycemia refers to the condition where the blood glucose is higher than
normal but not high enough to be diagnosed as diabetic (Huang et al., 2016). Pre-diabetes
is diagnosed with a fasting blood glucose level from 100 to 125 mg/dL (5.6 to 6.4
mmol/L) and is accompanied by an established insulin resistance (Farooq Al-Azzawi,
2015; Tabák, Herder, Rathmann, Brunner, & Kivimäki, 2012). Prediabetes is strongly
associated with other CVD risk factors such as obesity (especially central or visceral
obesity), high levels of LDL cholesterol, high triglycerides, and high blood pressure
(Tabák et al., 2012). Pre-diabetes was found to confer a 12.7 to 22.3 fold higher risk of
developing diabetes, depending on the duration, which is strongly associated with an
increased incidence of CVD (Tsao & Vasan, 2015; Long & Fox, 2016)(Fox, 2010).
Diabetes has been estimated in 13% of the population, but an additional 38% are
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determined to be pre-diabetic (Menke et al., 2015). Currently, there are over 84 million
people living with pre-diabetes and over 90% of them are undiagnosed (Center for
Disease Control & Prevention, 2017).
Metabolic Syndrome
Another condition that is clustered with obesity and pre-diabetes is that of
metabolic syndrome (MetS). MetS is defined as a combination of three or more of the
seven risk factors that include prediabetes, diabetes, central obesity, high blood pressure,
high triglycerides, high levels of LDL, and low levels of HDL (Grundy et al., 2008). A
co-existence of these inter-related parameters produces a synergistic effect that
significantly increases the likelihood of CVD (Farooq Al-Azzawi, 2015). MetS was
found to confer a 7-fold higher risk of T2DM and to double the risk for CVD mortality,
all-cause mortality, myocardial infarction and stroke (Hutcheson & Rocic, 2012). Despite
the dominance of factors such as HDL and BP, when MetS is included in the prediction
formula, the probability of CHD increases from 37.4% to 54.7% (Bertoluci & Rocha,
2017). MetS, found in 35% of the adult US population or 50% for those over 60 years,
has a rapidly rising prevalence, driven mainly by the increase in insulin resistance and
obesity (Aguilar, 2015).
Type II Diabetes
At the end of the metabolic disorder spectrum is T2DM, a state of persistent
hyperglycemia. Unlike Type I Diabetes, in which hyperglycemia is caused by an
autoimmune-based insulin insufficiency, T2DM is caused by a acquired insulin resistance
(American Diabetes Association, 2009; Mayfield, 1988). In the latest classification
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T2DM is diagnosed by a fasting blood glucose (FBG) level above 125 mg/dL or
6.9 mmol/L (Center for Disease Control & Prevention, 2017). In 2009, there were over
110 million Americans, and another 130 million worldwide, living with T2DM and it was
predicted to rise to 180 million by the year 2030 (Fuster & Kelly, 2010). The incidence of
T2DM increased so rapidly, that the projection was changed to 239 million people
affected worldwide by 2030 (Shaw, Sicree, & Zimmet, 2010). The latest report from the
International Diabetes Federation (IDF), states that there are 425 million diabetics on the
planet (half of which are undiagnosed) and it is predicted to increase to 552 million by
2030 and 629 million by 2045 (International Diabetes Federation, 2017).
T2DM, though very common, is a serious illness and is a major cause of chronic
disease, disability, and death. T2DM is associated with heart disease and stroke, and is
the leading cause of kidney failure, lower limb amputation and new cases of blindness
(Dauriz et al., 2015; Sarwar et al., 2010) Despite the decline in CVD related deaths,
diabetics included, there are still a large number who survive and continue suffer the
many complications of the combination of both diseases. T2DM can double, triple or
quadruple (depending on age and gender) the risk of CVD mortality as well as increase
the risk of chronic heart disease and ischemic stroke (Bertoluci & Rocha, 2017). T2DM
and pre-diabetes are associated with many issues arising from damage of the
microvascular vessels which including, retinopathy, neuropathy, and nephropathy, but
CVD remains is the primary cause of death in diabetics (Tabák et al., 2012).(Bertoluci &
Rocha, 2017).
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Diabetic Status in the FRS 10-year Risk Assessment
Early scrutiny of the FHS data identified diabetes is one of the strongest CVD risk
factors, but it would take several rounds of revisions before it would be included as a risk
factor in the FRS assessment formula. In the early 1930s and 1940s, before the FHS,
evidence was already accumulating to implicate T2DM as a risk factor for CVD, but it
was the FHS analysis that provided empirical confirmation of this relationship (Kannel &
McGee, 1979a). Several round of analysis confirmed diabetes an independent risk factor
for CVD, one that conferred a higher risk of CVD mortality and morbidity, with a
substantial impact on all-cause mortality (Avitabile, Banka, & Fonseca, 2012). Later
researcher would find that three out of every four diabetics died from heart disease and
therefore diabetic status should be an important major risk factor in any FRS risk
assessment function (Qazi & Malik, 2013a). But the strength of other risk factor such as
cholesterol and hypertension overshadowed diabetes and it would be included 50 years
after the FHS study began (Bennet, Angelantonio, et al., 2008; Kannel, Gordon, &
Schwartz, 1971; National Heart & Boston University, 2017; Tsao, 2015).
Assessing the risk of developing CVD in asymptomatic groups began
approximately two decades after the data collection for the first FHS cohort started.
Careful investigation of the data revealed several associated risk factors but only the ones
with a relatively strong correlation to CVD were used for CVD risk assessment (Dawber
et al., 1957; Lansing, 1961). Initially, the risk factors were used in cross-classification
tables to generate a risk level, but as the number of risk factors grew, the tables were
replaced with risk equations that generated a score (Truett et al., 1967)(Keaven M
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Anderson et al., 1991). These equation functions were first published in 1967 and
produced an estimate the risk possessed by each individual subject (Friedman, Hyg,
Kannel, Dawber, & McNamara, 1967). The risk factors used then were age, gender, total
cholesterol, left ventricular hypertrophy (LVH), smoking status, and systolic blood
pressure (SBP). Clinicians used the functions to evaluate each patient and assign those
with moderate and high risk to relative preventative treatment.
During the 1970s and the 80s several updates to the FRS model were published
and the risk equation functions were eventually replaced by a risk factor combination to
generate a risk profile. This novel risk profile differed in several ways: it distinguished
between general CVD and its most common type, CHD; there were now 5-year risk and
10-year risk versions; and it included only variables that had a strong association with a
CHD event (Gordon & Kannel, 1982; Kannel & McGee, 1979; Kannel, Castelli, Gordon,
& Mcnamara, 1971). The risk factors were now relegated to those that were
independently correlated to CHD and whose values were easy to obtain during an office
visit. By the end of the 1980s, variables like ‘BMI’ values was added but later replaced
with ‘glucose tolerance test’ (GTT) values; ‘family history’ had been added but removed
because of the difficulty to accurately determine in most cases; and ‘LVH’ requiring
expensive, inconvenient test was also removed (D’Agostino et al., 2001a; Qazi & Malik,
2013a). The new stream-lined formula now included the six variables: age; gender; total
cholesterol; smoking status; and GTT.
After several rounds of revisions, the end of the 20th century birthed the latest
coronary disease prediction logistic regression algorithm. The modern version of the
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Framing Risk Score would mark the first appearance of ‘diabetes’ (as a dichotomous
‘yes/no’) as a variable, having replaced ‘GTT’ levels (Wilson, 1998). The new FRS
assessed the 10-year risk and would go on to have a major impact on the national
guidelines for treatment for hypercholesterolemia and hypertension. Ironically, this 10-yr
FRS version was noted for substituting continuous measures of blood pressure and
cholesterol levels with their risk categories based on the fifth Joint National Committee
on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V) (Cleeman,
2001).
Sometime later, this official 10-year version of the FRS, using the hard CHD
(coronary deaths, MI and stroke) as the endpoint, was adopted by the third Adult
Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP)
(Grundy et al., 2002). The classification using the 10-year risk estimates of the FRS
proved to be more convenient and more accurate, and soon became the basis for the
cholesterol, blood pressure and dietary rules used by physicians throughout the nation
(D’Agostino, 2013; Mahmood, 2013). To this basic formula, the American College of
Cardiology/American Heart Association (ACC/AHA) added cRP and a history of CVD
to generate the Reynolds risk model, and ‘race’ for the Atherosclerotic Cardiovascular
Disease (ASCVD) calculator for working with those who have a history of
atherosclerosis or high LDL (Stone et al., 2013). Despite the existence of other formulas,
it is the 10-year FRS that is regarded as the official formula in the US and the standard
used by clinicians and researchers for all their CHD risk assessment needs (Ford, Giles,
& Mokdad, 2004).
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A diagnosis of diabetes became a most important variable in the official 10-year
FRS. This formula, developed from the first cohort data set, was intended for a relatively
shorter (than life-time risk) horizon and to have the greatest applicability to the age (3074 years) group for whom assessment and prevention therapy would be most beneficial.
Diabetes testing was already a routine medical assessment, and knowing that positive
diagnosis imparted a high CHD risk made it critical to the accuracy of the CHD risk
estimation (Cockram et al., 2001). The ‘diabetic status’ version of the 10-year-FRS
became a valuable tool to clinicians for classifying new patients and for guiding
subsequent treatment plans (Coch & Green, 2016; Damkondwar, Rajiv, Suganeswari,
Kulothungan, & Sharma, 2011; Qazi & Malik, 2013b; Wilson & Meigs, 2008). As one of
the major modifiable risk factors, ‘diabetic status’ helped in correctly assigning patients
for either moderate intervention such as education about diet and activity levels, lifestyle
change; or for stronger intervention like glucose lowering or statin drug prescription
(Alatawi, Kavookjian, Ekong, & Alrayees, 2016; Brindle et al., 2005).
It should be noted that the criteria used for a diagnosis of diabetes during the
initial FHS data collection and analysis was different from that used today. For the first
cohort, diabetes was diagnosed in one of three ways: (i) by history of hypoglycemic
(insulin) use; (ii) a casual blood glucose (CBG) level above 150 mg/dL recorded on two
visits; or (iii) a fasting blood glucose (FBG) level over 140 mg/dL (Wilson et al., 1998).
By the second cohort, GTT were now part of the examination, and abnormal GTT levels
was now the fourth way of diagnosing diabetes. But eventually only the fasting blood
glucose test (FBG) was used and a FBG level over 125 mg/dL indicated the presence of
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diabetes (Shaw et al., 2000; Wareham, 1998). Even though FBG levels were now more
routinely obtained, the use of the dichotomous ‘diabetic status’ in the standard 10-year
FRS, based on an arbitrary threshold, ensured the loss of valuable risk information
(Bertoluci & Rocha, 2017). Additionally, the risk facing those dealing with ‘prediabetes’
would go unrecognized and the risk assessment compromised. Also, further classification
among those diagnosed with diabetes is important for choosing the appropriate secondary
treatment and for monitoring the progression (or regression) of the disease in response to
any of the treatment administered (Kishore et al., 2012).
Like the other major risk factors, cholesterol and blood pressure, diabetic status
had a different relative risk for CVD across the genders. FHS data analysis reported that
T2DM was a significant trait of CVD susceptibility for men and the strongest risk factor
for women (Qazi & Malik, 2013b). Additionally, the FHS determined that T2DM was
associated with a 2 or 4 (male or female respectively) times greater risk of developing
CVD and it was correlated with an increased risk of dying from CVD-related
complications (Fox, 2010). We now know that diabetics die mainly from CVDs such as
MI, CHF, PAD, and stroke, with the increased risk being greater in women than in men
(Cockram et al., 2001; Huang et al., 2016; Long & Fox, 2016; Tsao & Vasan, 2015a).
These gender differences were the impetus for separating the 10-year FRS profile into
distinct gender formulas that improved the sensitivity of the assessment.
By the turn of the new century, T2DM was not only recognized as a major risk
factor, but it was believed to be conferring the worst prognosis to CVD patients, with
both CVD and T2DM having very high impact on the risk of death (Booth et al., 2006;

65
Cockram et al., 2001; Raggi, Shaw, Berman, & Callister, 2004). This information led the
FHS researchers to declare T2DM a CVD risk equivalent and to remove diabetes as a risk
factor from it’s the official 10-year FRS (Bonow, 2002; NHLBI & NIH, 2002). Instead,
all diabetic patients were now labelled as having already suffered a CHD event and
automatically placed in the high-risk category. Subsequently, there were the new
formulas for ‘global-CHD’ and ‘general-CVD’ risk assessment and they include ‘diabetic
status’ as a variable (D’Agostino et al., 2008). However, as with previous versions of the
use of ‘diabetic status’ as a binary limited the accuracy of the FRS.
Alternative models of the FRS, calculating 20-year, 30-years for long-term and 2year and 5-year risk for short-term, were subsequently designed, but the 10-year model
remained the most commonly used. The 2-year FRS formula is used for patients who had
already experienced a coronary event (D’Agostino et al., 2000). The 5-year FRS formula,
being more finely tuned with less generalizability, is usually reserved for the elderly
(over 75 years) or infirmed as they require a more sensitive test (Laurier, Chau, Cazelles,
& Segond, 1994; Rodondi et al., 2012; Westendorp et al., 2009). The risk models with
longer prediction times (20-year, 30-year, and life-time risk) are used for younger
patients and for those from demographics with a lower incidence of CHD, as the 10-yr
tool can underestimate the risk for these groups (Levy, Walmsley, & Levenstein,
1996)(Mccormack, Levine, & Rangno, 1997). The variations of 30-year risk and life-time
risk usually add the variables ‘BMI’ or ‘use of hypertensive medication’ to the basic 10year FRS (Pencina et al., 2009). But the 10-year risk model is most adequate for general
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screening for CHD and is therefore most common (PM Brindle et al., 2005; Cleeman,
2001; Ford et al., 2004; Jahangiry, Farhangi, & Rezaei, 2017; Westendorp et al., 2009).
Diabetes Over the Years
At that time there was little understanding of how diabetes was caused, and even
less attention was placed on how it developed. In addition to the difference in T2DM
diagnosis protocol and the new FRS inclusion criteria, there have been more volatile
changes in diabetes prevalence over the years.

Figure 3. Diabetes over the years. Reprinted from Long-term Trends in Diabetes: CDC’s
Division of Diabetes Translation, 2017.United States Diabetes Surveillance System
https://www.cdc.gov/diabetes/statistics/slides/long_term_trends.pdf
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The disease was significantly less common 60 years ago than it is now, assuming
that the prevalence of diabetes at the early stages of the FHS in 1948 was very lower than
the 0.93% in 1958 (Centers for Disease Control and Prevention, 2017). By the
publication of the first FRS, diabetes was only at 3.39% (1998) and at 6.29% by the
second (2008), less than half the 13.5% prevalence it is today (Centers for Disease
Control and Prevention, 2017). The higher prevalence, the different diagnostic protocols,
and the rapidly increasing incidence rate are reasons for the complicated role of T2DM in
the FRS.
During the last quarter of the 20th century the incidence of diabetes doubled
among individuals between the ages of 40 to 55 and this was mostly those who were
obese (Long & Fox, 2016). However, even though the incidence rate of CVD among
patients with diabetes has fallen by as much as 50% over that same period, the incidence
of CVD among diabetics is still twice what it is among non-diabetics (Long & Fox,
2016). These numbers represent an increase in the attributable risk (AR), the difference in
incidence of CVD for those dealing to diabetes and those who are not, while the relative
risk (RR) which is a measure of the strength of the association remained the same. This
increase in AR is an indication of complication and makes early detection and
stratification even more critical (Fox, 2010). Early detection of T2DM, blood glucose
control, and early aggressive action are all critical to managing subclinical CVD, and it is
for this reason for comprehensively assessing the full range (i.e., hypoglycemia, prediabetes/metabolic syndrome and diabetes) of dysglycemia (Coutinho, Gerstein, Wang, &
Yusuf, 1999; Fawwad et al., 2016; Perreault et al., 2014).
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Need for Stratifying a Diagnosis of Diabetes in Risk Assessment
Stratification is necessary for clinicians to identify patients who are at highest risk
and will therefore be more receptive to, and benefit most from, aggressive treatment.
Stratification enables the clinicians to more accurately sort patients into additional risk
categories such as: no-risk, low-risk, intermediate-risk, moderately high-risk and highrisk. It is also essential for the accuracy of the CVD risk prediction effort, especially
since atherosclerosis and other CVD risks can remain asymptomatic for years
(D’Agostino et al., 2013). This facilitates optimal use of time and resources such as
intensive aggressive treatment including further testing, drug therapy, or surgery for those
at high risk with moderate monitoring or treatments with a lifestyle emphasis for
intermediate risk patients and no treatment for those in the low risk group.
Researchers in the CVD risk prediction field have determined that the risk among
diabetics is far from homogeneous. In fact, many organizations involved in the diagnosis
and treatment of heart disease and/or T2DM such as the ACC, the AHA, the ADA, and
the ESC have rejected the notation that T2DM and CVD are risk equivalent (Bertoluci &
Rocha, 2017)(Bertoluci & Rocha, 2017). In one study found that there were some
diabetics who had CAC (coronary artery calcium) scores of zero, essentially the same
risk level as that of a non-diabetic, especially among younger individuals (Raggi et al.,
2004). Additionally, the AHA has officially recommended further stratification for
diabetics based on age, particularly for those between 40 and 75 years, and on level of
LDL in the blood (Ray et al., 2014). The ESC also recommends stratification for
diabetics based on duration of diabetic condition, especially for those who have had the
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disease more than 10 years, and on the presence or absence of renal dysfunction and the
presence of other risk factors (Piepoli et al., 2016). Similarly, the ADA also recommends
stratification for diabetics based on age, previous CVD status, and the presence of other
risk factors; facilitating varying therapy recommendations such as intense statin therapy,
moderate statin therapy, or simply lifestyle modification for some of those at risk (Coch
& Green, 2016).
Age, as the strongest non-modifiable risk factor, is important to CVD risk
stratification because of the synergistic effect it has on other risk factors. The older the
individual, the greater the accumulation of risk factors and the increased duration and
thus detrimental effect of the disease on the system (K. M. Anderson et al., 1991). A
group of Canadian researchers has recommended important ‘transition’ ages that
clinicians to pay attention to in CVD risk assessment. These age ranges are suspected to
be when the risk of CVD can go from low/no to moderate or from low/moderate to high,
and range between 33 to 48 for women and 45 to 52 for men (Booth et al., 2006). It is
during these ages that newly developed risk factors can appear and serve as a warning or
as new or additional focus for risk reduction therapy.
As indicated by the difference in the transition age, gender is another important
non-modifiable risk factor. The earliest data indicated that men are at a greater risk of
developing CVD than women (4X for men vs. 2X for women risk of CVD), however
men have better CVD survival rates (D. Lloyd-Jones et al., 2010). Intriguingly, with a
diagnosis of T2DM, those differences are reduced, with both genders having similar
increased risk of developing CVD and dying from CVD related consequences (Booth et
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al., 2006)(Amsterdam, 2011). This is believed to be the result of the higher risk profile of
hyperlipidemia and hypertension in women, combined with the reduced probability of
diagnosis and treatment of heart disease (D. Lloyd-Jones et al., 2010). Being female and
having heart disease and diabetes has more severe outcomes for women heart disease is
recognized less frequently.
Another variable that provides an opportunity for stratification of the risk of
developing heart disease is ‘family history of CHD’. The effect of having a family history
of CHD is proportional to the number of biological relatives affected, and this is reflected
in the hazard ratio for one blood relative being 1.5 but HR is 1.79 for two relatives with
CHD (Ray et al., 2014). This increased risk is also dependent on the age of onset for each
family member and the nature of the relationship (parents, sibling, or cousins, etc. (D.
Lloyd-Jones et al., 2010; Tsao & Vasan, 2015a). However, although ‘family history’ is a
better predictor than other biological risk factors, it did not improve the accuracy of the
FRS and its use is only suggested in the case of older patients- males over 55 and females
over 65 (Bertoluci & Rocha, 2017).
Using diabetes as a binary variable in the FRS results in a loss of valuable
information. The risk level of among diabetics are not the same as there is a significant
amount of heterogeneity and using the diagnosis as a risk equivalent reduces the accuracy
power of the formula. Even among those who are non-diabetic there is also range of risk
levels, as hypoglycemia can confer a higher CVD risk than does a normal glucose level.
The use of glucose levels as a risk factor provides additional classification and
discriminatory power thereby increasing the performance power of the FRS tool.
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Glucose Level as CVD Risk Factor
Measuring Glucose Levels
Glucose level is an important CVD risk factor but there are many different
methods for determining the quantity of glucose in the blood. The most common method
is the fasting blood glucose (FBG) test, where a blood sample is collected, first thing in
the morning after abstaining from food for at least 8 hours. The FBG concentration is
reported either in milligrams (mg) per 100 mL (mg/100mL or mg/dL since 100ml = 1 dL)
or in millimoles per liter (mmol/L). A FBG above 125 mg/dL (> 5.5 mmol/L) is
diagnosed as diabetic, between 100-124 mg/dL (5-5.4 mmol/L) is considered prediabetic, 70-100 mg/dL (3.9-4.9 mmol/L) is normal, and below 70 mg/dL (<3.8 mmol/L)
is hypoglycemic (American Diabetes Association, 2015).
Blood glucose levels can also be measured under non-fasting conditions by either
of three ways: the casual blood glucose (CBG) or random blood glucose test; the postprandial blood glucose (PPBG) test; or the oral glucose tolerance test (OGTT). The CBG
is a test of the concentration of a blood sample taken any time of the day, before or after a
meal, and values above 200 mg/dL (11 mmol/L) are diagnosed as diabetic (Kadowaki et
al., 2008). However, the CBG test is not as reliable as the FBG since glucose levels are
subject to normal fluctuations depending on the quantity of carbohydrates consumed in
the last meal and the time since the meal was eaten. The CBG test is most useful for
circumstances where the FBG is unavailable or obtaining it would be inconvenient.
The post-prandial blood glucose (PPBG) test or the oral glucose tolerance test
(OGTT) test are both complicated procedures that involve blood samples taken at over

72
two-hour periods. For both tests, a sample of pre-prandial blood is taken, then the patient
is made to eat a test meal in case of the PPBG or ingest a solution of 75 g of glucose
dissolved in 8 oz water in the case of the OGTT. For the PPBG, a second blood sample is
taken after two hours and the difference in the pre-prandial and post-prandial
concentrations of glucose is determined. For the OGTT, additional blood samples are
drawn every 30 minutes for the next two hours and plot of concentration over time is
obtained (American Diabetes Association, 2009). Ultimately, the blood sugar level at the
end of the two-hours should be <140mg/dl (<7.8 mmol/L) for a normal blood glucose
response (Saisho, 2014). Values between 140–200 mg/dL (7.8–11.1 mmol/L) indicate
impaired glucose tolerance (IGT) or prediabetes, while anything above 200 mg/dL (or
>11.1 mmol/L) is diagnosed as diabetic (American Diabetes Association, 2015). These
tests were commonly used to check for gestational diabetes in pregnant women, but their
utility has recently been questioned.
Lastly, the average glucose concentration during fasting and non-fasting periods
can be measured using the test of glycated hemoglobin, (the HbA1C) test. This newer
biochemical test measures the percentage of particular protein molecules (hemoglobin in
the red blood cells) that have been glycated (i.e., have glucose molecules attached to
them) (Nolan, Damm, & Prentki, 2011). The higher the prevailing glucose concentration,
the more glucose molecules bind to proteins, which negatively affects their structure and
function (Tabák et al., 2012). The results from HbA1C tests reflect the average level of
glucose in the blood over the previous 2-3 months and levels below 42 mmol/mol or
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6.0% are considered normal; 42–47 mmol/mol (6.0–6.4%) is pre-diabetic; and anything
above 48 mmol/mol (6.5%) is diabetic (American Diabetes Association, 2015).
Glucose Levels in Risk Assessment Model
The Full Range of Glucose Level is Associated with CVD Risk
The association between high glucose levels (i.e., hyperglycemia) and its
exacerbation of the many complications of heart disease is well established. However,
glucose levels just below and even far below the diabetic threshold also have an
association with heart disease. Bertoluci and Rocha (2017), reported that hypoglycemia
(FBG of 70-100 mg/dL) or low glucose levels (FBG of 101-125) have a hazard ratio of
2.64 for CVD and for 6.34 for CVD mortality, respectively. This is believed to be an
effect of the high levels of insulin in the blood stream simultaneous to insulin resistance,
that triggers the hypoglycemia and exacerbates the CVD symptoms (Faerch et al., 2012;
Laakso, 2015; Park et al., 2013). This underscores the complex relationship between the
predisposition to CVD and the full range of glucose levels from hypo- to normal to
hyper-glycemia.
There are several studies that demonstrate the relationship between CVD and the
full range of glucose levels. One such study is a cross-sectional analysis the data from a
CVD prevention program that evaluated the CVD risk for 3,739 non-diabetics (Valentino
et al., 2015). FBG values below 125 mg/dL (non-diabetic) were found to be a marker for
CVD risk factor clustering and more specifically glucose levels below 100 mg/dL were
found to be associated with low HDL, high triglycerides, hypertension, abdominal
obesity, and the CVD inflammatory biological markers (Valentino et al., 2015). One

74
interesting aspect of this study was that in cases with similar, healthy cholesterol levels, it
was the difference in glucose levels that identified the potential CVD risk. Findings like
these that emphasize the need to include glucose levels in risk assessment as well as in
risk factor reduction therapy for CVD health promotion.
Another study with middle-aged African Americans in Florida, looked at the role
of modifiable and non-modifiable factors in CVD prediction (Carter, Ralston, YoungClark, & Ilich, 2016). Information on diabetic indicators (blood glucose and insulin),
apolipoproteins, adipokines, and lipid profile were collected. Using both the AHA and
FRS assessment tools they analyzed the data and compared the results for the two
genders. The results confirmed the higher CVD risk for men, and the negative association
between the biological markers (except for HDL) and CVD outcomes. Additionally, the
authors noted that glucose level was the strongest indicator, with the widest applicability
across the groups, for CVD risk prediction (Carter et al., 2016).
An Icelandic meta-analysis of several Western prospective studies also indicated
that glucose levels might be the strongest risk factor associated with vascular outcomes,
CHD, and stroke (Sarwar et al., 2010). The analysis showed that the inclusion of glucose
level, measured as HbA1C values, improved risk assessment as well as intervention and
prevention strategies better than the more simplistic diabetic threshold concept. They also
noted that the HbA1C test provides information on long-term glucose levels and does not
require any fasting or post-prandial conditions, but that it is more expensive than standard
glucose testing and is therefore not routinely measured.
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A long-term follow-up study in Japan found that even random blood glucose or
causal blood glucose (CBG) can be used to predict CVD mortality. Interestingly,
borderline-high (140-200 mg/dL) and high CBG (above 200 mg/dL), the HR values were
2.43 to 2.62 respectively (Kadowaki et al., 2008). For normal range of CBG (126 – 140
mg/dL) the hazard ratio, although predictability lower, was still statistically significant.
The data also showed that the relationship was not affected by time since the last meal,
proving that CBG levels can also be used to predict CVD mortality and is a suitable
substitute in settings where FBG is not available.
A very large cross-sectional study, involving 500,000 Chinese participants,
looked at the association of diabetes and blood glucose levels on the risk of CVD
development (Bragg et al., 2014). Participants age, height, weight, hip and waist
circumference, and levels of blood pressure and non-fasting blood glucose were recorded.
The results agreed with previous reports that diabetes doubled the risk of ischemia and
stroke, but it also showed that among non-diabetics, there was a positive association
between blood glucose levels and heart disease. For levels below the diabetic threshold,
every 1 mmol/L increase in blood glucose correlated with a prevalence increase of 4% for
ischemic heart disease and a 5% increase of ischemic heart attack (Bragg et al., 2014).
Glucose level vs Cholesterol level in Risk Assessment
In a South African study, Lammertyn et al. (2011) looked at the many aspects of
cardiovascular dysfunction among Black Africans. One of the objectives was to compare
the roles of glucose and cholesterol in predicting cardiovascular function. The
measurements included: age, BMI, waist-to-hip ratio, electrocardiograms; systolic and
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diastolic blood pressure, total HDL and LDL cholesterol, smoking, and the use of antihypertensive medication. Each of the 200 adults were subjected to an imaging test that
recorded the carotid intima media thickness (CIMT). An increased CIMT reflects
“impaired compensatory remodeling of the arterial wall and atheroma progression”
following damage and is prevalent in diabetics, predisposing them to stroke and
myocardial infarctions (Lammertyn et al., 2011). The analysis showed a negative
correlation between CIMT and HDL:TC, a positive correlation between glucose and
hypertension, but FBG proved to be the better candidate for CVD prediction.
A study conducted by Faeh et al. (2013) verified that replacing cholesterol levels
with the long-term measure of hyperglycemia, produced a more accurate risk prediction
model. Using the NHANNES III data set and the ESC SCORE formula, they compared
four different models (HDL:TC ratio, cholesterol, and glucose) and found that the
glucose values provided better prediction of CVD mortality compared with the other two
variables, even when below the diabetes threshold values (Faeh et al., 2013). The
researchers added that when the FRS and other models use only diabetes (yes/no) that it
insufficiently maps the potential impact of blood glucose on CVD.
A swiss study that followed 6,095 adults for 32 years, compared the ability of
glucose levels to that of cholesterol levels to predict fatal CVD event (Braun et al., 2013).
Measures of age, gender, blood pressure, smoking, and FBG or total cholesterol were
used in the ESC-SCORE model. The models were cross-validated with another data set
and the area under the receiver-operating characteristic curve (AUC) and integrated
discrimination improvement (IDI) values were used to compare accuracy. The
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researchers found that not only did both low and high glucose levels generate a more
accurate prediction than did cholesterol, but in a joint model (i.e., both cholesterol and
glucose) only the coefficient for glucose was statistically significant (Braun, 2013).
Another study among African Americans looked at the role of fasting blood
glucose and the different components of serum cholesterol in predicting the reactivity to
stress associated with CHD development. Patients were exposed to a prescribed stressful
situation and measurements were taken prior to, during, and while recovering from the
stressful period. The analysis revealed a negative association between HDL and high
blood pressure, and that FBG was better than cholesterol in predicting cardiovascular
stress (Clark et al., 2015). The authors stated that excess insulin was associated with high
glucose concentration and was the mediator of the stress response (Clark et al., 2015).
Glucose Lowering in CVD Treatment
Anti-diabetic drugs failed to show efficacy in cardiovascular treatment because
they were producing insulin, which deleterious to the vascular system. Several clinical
studies that sought to reduce CVD risk by aggressive glucose lowering failed or worsehad to be aborted due to increased morbidity and mortality in the treatment group
(Ginsberg, 2011; Nordestgaard et al., 2013; Reaven et al., 2009; The ACCORD Study
Group, 2011; Zoungas et al., 2009). What these trials had in common was the use of
either insulin supplementation or drugs that stimulated the pancreas to produce more
insulin. Not only did that approach fail to lower the HbA1C, but the CVD outcomes were
poor. Recent research have indicated that while insulin may lower the glucose level, the
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hormone itself has many deleterious effects on the vascular system (Faerch et al., 2012;
Laakso, 2015; Sah et al., 2016).
As further proof that glucose lowering was not the source of the problem, trials
that used non-insulin elevating intervention to lower glucose levels obtain greater success
in reducing the participants CVD risk (Kishore et al., 2012; Xu & Rajaratnam, 2017). In
fact, the use of metformin, a drug that lowers glucose while at the same time increasing
insulin sensitivity was shown to confer significant CVD benefits to diabetics (Roumie et
al., 2012; Skov et al., 2014). These studies confirm that the focus on glucose level is not
misplaced and that association with CVD events is an important one. The strength of the
glucose level association with risk of CVD emphasizes the need for its inclusion not just
in CVD treatment but in CVD screening and risk assessment as well.
Summary
The incidence of cardiovascular disease began rising after WWII and rapidly
became an epidemic in the middle of the last century. Despite a slight decline in the
rising rate by the end of the century, it remains the deadliest of all the chronic diseases
and the number cause of death in most developed and developing countries. The
Framingham Heart Study (FHS), initiated by the US Government in response to the
epidemic of heart disease, was a several decades long prospective study of over 5,000
adults living in Framingham, MA. The FHS successfully identified several of the major
risk factors and encouraged the idea of disease prevention by reducing the incidence and
severity of these risk factors in at risk individuals.
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The FHS also developed and risk assessment model, the ubiquitous Framingham
Risk Score (FRS), based on the risk factors of CHD and used to predict the probability of
developing the disease over a given time period. The FRS, though useful and effective is
limited in its accuracy and as such has undergone several rounds of optimization. The
inclusion of diabetic status as a risk factor in the FRS formula has been challenged over
the years and is now considered a CHD equivalent. However, using this risk factor
dichotomously results in a loss of very important risk information and limits the
performance of the FRS formula. Moreover, because CHD is a cardiometabolic disease,
the continuous variable ‘glucose levels’ inclusion in the FRS model increases the
accuracies and thereby improves its performance.
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Chapter 3: Research Methodology
Introduction
Overview
This chapter includes an outline of the methods I used to answer the three
research questions formulated in the first chapter of the dissertation. Each of the
questions is examined in detail and the research design used to generate an answer is
explained. The chapter begins with a description of the comprehensive research design,
followed by details on the secondary data set chosen, including how the subjects were
selected, how sample data were originally obtained, and how the data were ultimately
handled in preparation of the statistical analysis. Also included in this chapter are the
definitions of the outcome variable and all the explanatory variables featured in the
analyses, along with their operationalization for inclusion in the model. The chapter ends
with a presentation of the three research questions, each followed by the specifics of the
statistical test used and determination of the statistical significance for each.
Study Objective
The purpose of this study was to investigate the effect that the inclusion of FBG
levels, as a risk factor variable, has on the accuracy of the FRS formula in predicting 10year CHD event. The second chapter detailed the history of the FRS formula as
documented in the literature and the many studies that focused on performance
optimization for this formula. One aspect of the FRS performance optimization that has
been overlooked is the inclusion of glucose as a continuous variable, and it is this gap
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that I sought to fill. MLR analysis was used to generate formula pairs (for FBG level and
DM2 status) and the performance in representing the data compared.
Before the multivariate formulas was generated for performance comparison, the
relative risk (as odds ratio or OR) of each of the two factors (FBG and DM2), for the
CHD event outcome, was determined using univariate analysis, along with their
respective confidence intervals. Following the univariate OR comparison, the
multivariate formulas, containing the various cofactors (AGE, SEX, HDL, SMOKING,
BMI and either FBG or DM2) was generated and the ORs of each compared the
appropriate goodness-of-fit tests were used to compare the performance. Finally, the
interaction between the each of the covariates Sys BP, BMI, and HDL and FBG was also
assessed. The effect of the potential moderators (SBP, BMI, and HDL) was evaluated by
the creation of three interaction variables (HDLxFBG, SBPxFBG, and BMIxFBG), that
were included in the MLR formula. An evaluation of OR and significance of the
interaction terms and the performance of the overall performance model was evaluated.
Research Questions
RQ1: Is the relative risk of glucose level higher than that of diabetic status for the
development of CHD in the FHS data set?
H01: There is no difference between the relative risk of glucose level and that of
diabetic status for the development of CHD in the FHS data set.
Ha1: The relative risk of glucose level is higher than that of diabetic status for the
development CHD in the FHS data set.
RQ2: Is the measure of accuracy higher for the glucose level formula than that for
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diabetic status formula in the FRS-CHD 10-year risk prediction model?
H02: There is no difference between the measure of accuracy for glucose level
and diabetic status versions of the FRS-CHD 10-year risk prediction formula.
Ha2: The measure of accuracy for glucose level formula is higher than that for
diabetic status version of the FRS-CHD 10-year risk prediction formula.
RQ3: Is the measure of accuracy for the glucose level formula independent of age,
BMI, cholesterol level, or blood pressure level in the CHD 10-year CHD prediction
model?
H03: The measure of accuracy for glucose level is independent of age, BMI,
cholesterol level, or blood pressure level in the 10-year CHD prediction.
Ha3: The measure of accuracy for glucose level is dependent on age, BMI,
cholesterol level, or blood pressure level in the CHD 10-year CHD prediction.
Research Study Design
Choosing the FHS Data Set
The data set used in this study was the third generation of FHS, a longitudinal
study originating several decades ago to collect information in understanding the factors
that predispose individuals to heart disease. The FHS was a prospective cohort study,
where the exposure or risk factors levels are measured before the disease develops
(D’Agostino et al., 2013). All the subjects were followed over a decade and information
on their risk factors and their disease outcome (whether they developed heart disease or
not) were recorded . This type of study, though more expensive and time consuming,

83
allows for greater accuracy concerning the risk of exposure and it is ideal for
investigating causal relationship (Kannel & Boston, 1990).
The data set is made up of participants from the third generation of the FHS
cohort (FHS-GenIII), combined with the OMNI2 and the new offspring spouses (NOS).
The FHS III data accounts for 4,578 adults, who are the grandchildren of the FHS I,
along with an additional 101 of their non-FHS parents who had not been included in any
of the previous FHS cohorts (Splanksy, 2007). The OMNI2 are the children of the
original OMNI cohort, introduced to include a more racially and ethnically diverse
sample set, but they numbered only 405 (Tsao & Vasan, 2015a). The NOS (New OffSpring) cohort, also added to increase genetic diversity, was made up of the spouses of
the OMNI2 and consisted of only 101 subjects (Govindaraju et al., 2008). The sample
size of the raw data was 4,578 that was reduced to about 60% (2,670) after the filtering
process detailed in data handling section of Chapter 4 of this dissertation.
In the original FHS cohort, several risk factors were measured and recorded for
each of the subjects and analysis of the data uncover the risk factors that were linked to
CVD. This led to the development of risk prediction strategies and to the prominence of
primary prevention effort in response to the rise of CHD and other CVDs (Wilson et al.,
1998). The FHS data have been used extensively over 5 decades to provide additional
insight into the association between a variety of risk factors and the probability of
developing CVD . Despite its limitations, the large, randomly selected data set is still
relevant to predictive studies today. The logistic regression model generated from the
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FHS, the FRS remains the most widely used CVD prediction formula ( Garg et al., 2017),
making it ideal for studying the role of major risk factors such as FBG.
Experimental Validity
External Validation. External validity is a measure of the generalizability of the
research findings beyond the current data set (Stoltzfus, 2011). The risk formula
developed by the FHS team faced issues of validity from the beginning. The first
concerns were who were the truly at-risk individuals, on which aspect of CVD should the
prediction focus, and how would this outcome be defined. The decision was made to
focus on the prediction of CHD, the most common CVD and with the highest clinical
relevance specific to death and disability (Mahmood et al., 2014). For original FRS
formula generation, the development of the first hard CHD (originally called
atherosclerotic heart disease or ASHD), defined as coronary death or myocardial
infraction, were the events was chosen as the outcome of interest (D’Agostino et al.,
2013). With the endpoint decided, the issue was now who was considered at risk and who
should be included in the study and how they would be selected. For the sake of
simplicity, the first cohort was made up of individuals who were at the time free of any
CVD and had not had a previous CVD event (D’Agostino et al., 2013).
The remaining issues of validity included what risk factors should be measured
and what should be the cut-off for follow-up time. The decision about the time was
easier, and a period of 10-year was decided as adequate for CHD risk prediction, but to
ensure all events were captured, 12 years of data was collected on each subject
(D’Agostino et al., 2008). Uncertainty about what factors to include and what to exclude,
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the researchers decided that data on all factors making up a regular clinical exam (gender,
age, height, and weight) along with suspected predisposing factors (BP, HDL, smoking
status, and diabetes) would be collected (Dawber et al., 1957). The debate over which
risk factors should be included continues to be part of the optimization research, but
focus has always been on keeping the formula simple and convenient yet effective as
possible. As a result, more definitive factors that were difficult to assess, were excluded.
An additionally important decision was to the selection of the mathematical
model that would serve as the best risk estimation function for the data set. The ideal
model should not only adequately estimate the risk for the period in question, but it
should also provide some measure of the relative risk for each of the risk factor. The first
model was based on the discriminant analysis, but was replaced by the more robust and
more flexible logistic regression model as soon as its existence was known to the FRS
team (D’Agostino et al., 2013). Over the years, other analyses like the Cox proportional
hazard regression and accelerated failure models were considered (see D’Agostino et al.,
2013). However, the absolute risk at t=10 years provided by the simpler logistic
regression analysis became the preferred measure on which to make important treatment
decisions.
Once I selected the model it became essential that its suitability and performance
be evaluated. At the top of the list of requirements were powers of discrimination and
calibration, the former reflecting the ability to separate between cases and noncases, and
the later measuring the accuracy of estimating an absolute risk probability (see Dawber et
al., 1957). The C-statistics or AUC (area under the curve) was the measurement of choice
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as it describes the sensitivity and the specificity of a function and indicates the ability of
the function to rank an individual’s risk (see Bertoluci & Rocha, 2017). For calibration
evaluation, the FHS researchers first used a specifically designed chi-squared test
combined with Kaplan Meier (K-M) estimates to quantify the difference between the
predicted probability and those reflected in the data (D’Agostino et al., 2013). The K-M
test was suitable for the time-to-event risk estimation models used in the beginning but it
was replaced by the Hosmer-Lemeshow test which more accurately evaluates the
goodness-of-fit for logistic regression models (Giancristofaro & Salmaso, 2003).
Internal validation. Internal validation refers to the replicability of the test
findings and reflects the veracity of the inferred results and a minimization of systematic
error (Eichler et al., 2007; Kones, 2011). Internal validation should ideally be done on a
different data set to avoid overfitting, but suitable alternatives include bootstrapping,
cross validation, or simply split-sample validation (Giancristofaro & Salmaso, 2003). The
10-fold split was the first validation technique for the FRS formula, where the sample
was split into deciles and nine models (developed on different sample sets) were
developed and each tested on the unused 10th sample (Steyerberg et al., 2010). The Cstatistics and calibration plot comparisons are performed for each of the nine models to
select the one that best described the data. Fortunately, the calibration models were not
significantly different from each other or the one generated on the entire data set, making
this method futile (Steyerberg et al., 2010).
Despite the congruency in the internal validation procedure, the researchers
(citation) knew that the best way to validate a multivariate risk model is with a
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completely independent data set. However in a 1999 study, the NLBI had determined that
the FRS performed relatively well on the data from other prospective studies and should
be used with confidence in other populations across the United States (Kannel et al.,
1999). It had also been verified as suitable for other populations across Europe, Asia, and
regions of the Mediterranean, subsequent to adequate recalibration, but that would later
be challenged by European experts in the field of cardiology (D’Agostino et al., 2001a).
Given the racial bias of the original cohort, the FRS’s performance on other populations
of has always been questioned. Researchers discovered that after a recalibration process
the FRS was able to distinguish the high-risk individuals from those at low risk in nonFramingham populations in predicting hard CHD (O’Donnell & Elosua, 2008). This
recalibration, which included adjusting the intercepts for the formula and replacing the
disease incidence with that of the current population, was found to worked well with nonFramingham populations (D’Agostino et al., 2008). This method is the basis of many
recalibration methods used by those who use the FRS in communities outside the United
States.
Secondary Data Set
FHS Data Set: Cohort III, OMNI & NOS
The data used in this study was obtained from the FHS group, and made up of the
third generation of the original cohort that started in 1948 (Lansing, 1961). I requested
permission from the institutional review board (IRB) to contact the FHS researchers and
obtain a copy of the relevant data file. The FHS is a longitudinal, retrospective cohort and
is thus suitable for study risk factor/outcome associations. The FHS has been the credited
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with discovering all the major, now established, and minor risk factors of cardiovascular
disease (Mahmood et al., 2014). This data set was used to develop the renowned formula
used effectively to predict the likelihood of developing cardiovascular disease over a 10year period (Eichler et al., 2007). FHS data has been the basis for 1,000s of published
research articles on the subject related to heart disease and other related illnesses.
The long natural history of the CVD necessitated a prospective, observation-type,
epidemiological cohort study. In the first cohort, the need was to explore the relationship
between the disease and the predisposing factors, while at the same time collect important
data on the disease’s prevalence, incidence and prognosis (Dawber et al., 1951).
Influenced by the enthusiastic physicians of the area and the previous success of the 6year TB study there, participants were recruited through a random sampling of the
residents from the now infamous town of Framingham, MA (Dawber & Lansing, 1966;
Mahmood et al., 2014). To ensure that all the possible subject’s data were accounted for,
an extended follow-up period of data collection was adopted (D’Agostino et al., 2008).
The study continues today, some 70 years after it began, with the second and third
generation of the FHS cohorts.
Sample Selection
Initial recruitment for the FHS began with letters being sent out to two of every
three (randomly selected) of the 10,000 families living in Framingham, MA, inviting
anyone between 30 and 59 years of age to participate (Dawber et al., 1959; Tsao &
Vasan, 2015). This group was believed to be representative of the adult U.S. population
and the study was intended to run for only 20 years and to offer the benefits of a clinical

89
exam to all. News of the study spread, mostly by word of mouth, from first few recruits
who were honored to be involved, and soon 100s of participants turned into several
1,000s (Tsao & Vasan, 2015a). Of the 6,507 contacts made, 2,336 men and 2,873 women
responded to make up the original cohort 5,209 ( Long & Fox, 2016; Tsao & Vasan, 2015
). The data from this original cohort was intended for use in the analysis for the research,
but due to concerns about the age (over 60 years) of the data set, the data from the third
generation (most recent) was chosen instead.
The community-based structure of the FHS study enabled the identification of
aggregation of the traits among family or communal groups (Tsao & Vasan, 2015a). The
detection of shared family traits led the researchers to start recruiting the second
generation participants from the children and their spouses of the original husband and
wife pairs in 1972 (Tsao & Vasan, 2015a). The off-springs and their spouses of the
second generation (grandchildren of the original cohort participants) made up the third
FHS generation enrolled in 2002 (Mahmood et al., 2014; Tsao & Vasan, 2015). These
groups provided many invaluable insight including who were susceptible, the effects of a
shared environments, and most importantly, the familial and multigenerational genetic
factors involved (Long & Fox, 2016; Mahmood et al., 2014). The first FHS offspring
(second generation) study was organized in 1971, with 5,124 participants and consisting
of the children of the original cohort participants and their spouses (Tsao & Vasan,
2015a).
The smaller OMNI1 and OMNI2, started in 1994 and 2003 respectively, focused
on increasing the racial and ethnic diversity of the participant pool beyond the mostly
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white (of European descent) participants that made up the first three (original, second
generation and third generation) cohorts (Long & Fox, 2016; Tsao & Vasan, 2015a). All
the succeeding cohorts now include state of the arts health data collection methods like
ECG, imaging, and genotyping and have contributed valuable temporal trend and
genotypic. Data on other diseases such as cancer, COPD, diabetes, epilepsy, arthritis,
Parkinson’s, and Alzheimer’s is also included (Tsao, 2015). The factors measured have
expanded from the original dozen or so to include almost twice as many with the addition
of blood tests for insulin, HbA1C, thyroid hormones, liver function tests, c-RP, and
testing for specific genes, etc. Add summary and synthesis to fully conclude the section.
Sample Size Determination
Statistical power analysis is a method used to determine the sample size required
to bestow sufficient power to the research result (Rudestam & Newton, 2014). The
statistical power reflects the probability of the Type II error (β) for the analysis, which is
the failure to reject the null hypothesis when it is in fact false. This power is equal to 1
minus probability of the Type II error (Power = 1- β), thus as the probability of error
increases, the power of the study or the significance of the results decreases. It is for this
reason that the power of a model is inversely proportional to the number of factors, and
formulas with the lower number of variables are preferred (Sperandei, 2014).
The statistical power not only depends on the level of Type II error, but on the
effect size and the sample size as well. The effect size is a measure of the treatment effect
and is usually calculated by dividing the difference of the means by the standard
deviation ((M1 – M2)/SD), and the sample size is simply the number of participants

91
(Fuller, 2009). There are many formulas (some more complicated than others) that use
the effect size, the sample size, and the probability of Type II error to calculate the
statistical power. In other cases, a reverse calculation is performed, and the appropriate
sample size is determined from the desired statistical power, the estimated effect size, and
the predetermined probability of Type II error (Pearl, Glymour, & Jewell, 2016).
Calculating the sample size for a multivariate logistic regression is challenging.
First, there is the issue of the nonlinear correlation that is represented by the odds ratio,
which describes the relationship between the independent variable and the dependent
variable. Second, there isn’t one independent but several independent variables, with nonzero interaction between them, and each having a different probability value in the
population. Choosing from among the many possible coefficients can be difficult,
however, simulation using the G*Power application has simplified the process (Faul,
Erdfelder, Lang, & Buchner, 2007). This app allows you to choose among several
different types of test, including F tests, t tests, chi-squared tests, and z test, etc., and the
input parameters include, but are not limited to, “Tails”, “Odds ratio”, “Power”, and
“R2”. I used generic values of 1.3 for the “Odds Ratio”, 0.05 for the “error”, and 0.8 for
the “Power” and a value of 962 was returned for the “Total Sample Size”. For the data set
in question, with over 5000 participants, the sample size is more than adequate for
statistically significant effect size determination.
Data Collection
Traditionally, the FHS data were collected by the biennial follow-up exams and
consisted of face-to-face survey questions and clinical exams. The information gathered

92
comprised physical and medical data, including blood pressure, blood glucose, height and
weight (Long & Fox, 2016). For the original cohort, those determined to have a history of
CVD were excluded from the study, but for subsequent cohorts, their data were included
and their information collected. Originally the researchers wanted to focus only on those
who were free of any cardiovascular complications at baseline so as not to confound the
data (D’Agostino et al., 2013; Kannel et al., 1999). But they later realized that a history
of CVD was a strong risk factor for a future CVD event, and this eventually became one
of the factors recorded for each subject in subsequent cohort (Kannel et al., 1999).
Each of the biannual exam began with a written informed consent form along
with a questionnaire on the patient’s medical and family history (see Appendix A). The
data collection included but was not limited to information on: family history, medical
history, current symptoms, medication, personal and dietary habits, weight, biometrics,
cardiac exam, x-ray, ECG, blood (Hb, cholesterol, uric acid, glucose, syphilis) and a
urinalysis (Dawber et al., 1951). A complete physical, targeted at the cardiovascular
health, as well as collection of blood and urine samples followed the written portion of
the exam. These exams were mostly conducted at the designated sites, otherwise staff
members visited home-bound participants. Included in the medical consent was
permission for the FHS group to access the diagnostic and chart records from clinics and
doctors’ offices and hospitals, medical examiners’ reports, physician’s files, and death
certificates (Friedman, Hyg, Kannel, Dawber, & McNamara, 1967).
For each case, chart data were eventually compared to the original clinical
findings on attributes associated with the development of CVD, paying attention to the
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most common CVD subtype- CHD (Tsao & Vasan, 2015a). The frequency of the exams
fostered relationships between the participants and the researchers and helped retention,
while the comprehensive nature of the follow-up exams minimized the possibility of
collection bias (Friedman et al., 1967). The dedication of the participants and the
perceived value of the ‘free’ medical exams resulted in high retention rate, contributing to
the exceptional quality of the FHS data and setting a high standard that continued with
subsequent cohorts. Of the 5209 participants in recruited between 1948 and 1952, event
data on 4,439 participants were collected over three exam cycles from 1956 to 1968
(Sorlie & Coady, 2004). That is a retention rate of 85%, which high by most standards.
Data Handling
The first step in handling any data set is the cleaning process, which entails
detecting and removing or replacing all corrupt, inaccurate, or incomplete records. The
FHS data set was assessed for missing data, incorrect data and outliers, and each variable
was evaluated to ensure that no more than 10% of the data is missing, as missing data
could the produce incorrect analysis (Field, 2013). In the case of missing or incorrect
data, the use of mean or weighted values can be generated to compensate, depending on
the nature of the variable being measured, but there was no need for this. Box or Whisker
plots with the interquartile range determination was used to detect for any outlier values
that may have required the removal of all corresponding for offending subject (Field,
2013). However, the potential outliers were tested and determined to be legitimate
measures, and no exclusion of participants data was needed.
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The data was received in the statistical analytical system (SAS) form, which was
downloaded from the NIH website following the granting of permission (password) to
access. The SAS zip files (FHSIII, OMNI2 and NOS2) were saved on my hard drive and
unzipped for use. The relevant SAS files (CHD event, lab tests, general health screen,
etc.) were opened in SPSS and working version will be created for selecting of the
appropriate variables. The files were combined into one, utilizing the unique patient
unique identification number, and assessed for errors then filtered, as described in chapter
four. All variables will be checked to ensure that the SPSS type, length and description in
SPSS matched that listed in the data dictionary provided, and data set was filtered to
remove those with a history of heart disease. Following the filter, the variables were
subjected to comprehensive descriptive and correlation analyses before the inferential
analyses were conducted (Lani, 2015).
Ethical Considerations
Permission was obtained from the Institutional Review Board (IRB #: 10-18-180031692) of Walden University to request access to the FHS data set, and since it is a
secondary analysis an exempt status requested. The data set from the FHS is distributed
minus any personal information or any unique identifiers, ensuring participants’
confidentiality. This guarantees the individuals’ privacy and compliance with the Health
Insurance Portability and Accountability act (HIPPA). The FHS data is available for
research and analysis purposes and has been used for 100s of invaluable studies over the
last several decades, with no history violation of rights.
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Operational Definition of the Variables
Dependent Variable: Disease Outcome
The FHS was the first epidemiological study of its kind and it led the way in
identifying CVD risk factors. The risk factors identified were then made the subject of
many clinical trials that revealed the efficacy of risk factor reduction in CVD prevention
strategies (Nieto, 1999a). The researchers realized that CHD was the most common CVD
event, with the most lethal consequences, so they decided to focus on the risk factors for
CHD in the risk assessment formula (Truett et al., 1967). However, in 2008, the FHS
team decided that a more global formula was also needed and developed a formula, with
a comprehensive FRS to include predictions of CVD that included cerebrovascular
disease, intermittent claudication and congestive heart failure (Kones, 2011). The more
commonly used formula however, estimates the 10-year absolute probability of
developing the risk of hard CHD, where coronary death or myocardial infraction was the
outcome (D’Agostino et al., 2013). The formula returns three categories of risk: high risk
for a 10-year risk score >20%; moderate risk for a score between below 20% but above
10%; and low risk for a score below 10% (Pedersen, 2002). This analysis used CHD as
determined by the FHS team and recorded as the dichotomous nominal ‘1’ or a CHD
event and ‘0’ for no-CHD event.
Independent Variables: The Risk Factors
The FHS is credited with uncovering the multifactorial nature of CVD and with
the recognition of interactions between the risk factors, leading to the creation of the
multivariate risk prediction formula (Kannel & Boston, 1990). The risk factors -gender,
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age, systolic blood pressure (SBP), HDL cholesterol (HDL), body mass index (BMI),
smoking behavior (SMKG) and ‘diabetes status’ (DM2)- all comprise the current
algorithm that is used as the Framingham Risk Score (FRS) for estimating a patient’s
CHD. There have been changes in the way a few of the variables are measured and
utilized in the formula, namely blood glucose, which although measured for determining
diabetic status it was not included in the FRS formula; and HDL values replacing total
cholesterol by the second cohort as technological advancement facilitated it
determination, and only systolic BP (SBP) as being a better predictor of CHD than
diastolic BP (DBP). The following section will take an in-depth look at the factors in the
FRS formula and the role they each play in predicting CHD.

The Risk Factors Measured in FHS Cohort 1, 2, and 3. (Govindaraju et al., 2008).
Cholesterol. Cholesterol is a fatty substance transported in the blood as small
bundles of proteins and fat molecules, aka lipoproteins. The two major types of
lipoproteins are high-density lipoproteins (HDL) and low-density lipoproteins (LDL) and
are named based on the ratio of lipid to protein. HDL, the larger, heavier molecule, has a
higher protein content, while LDL is smaller and lighter with more fat than protein
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(Chowdhury et al., 2014). Cholesterol is carried to the tissues as LDL, which why it is
found deposited on the arterial walls and is the major component of plaque (National
Heart Lung & Blood Institute, 2013). High levels of LDL are associated with an
increased risk of CHD, heart attack and stroke (Srikanthan et al., 2016). Cholesterol is
removed from the arteries and tissues by HDL molecules and taken to the liver for
expulsion (National Heart Lung & Blood Institute, 2013). High levels of HDL are
associated with a reduced risk of CHD, making it the “good/healthy” cholesterol.
Blood Pressure. Blood pressure is a measure of the force exerted on the walls of
the arteries as by the blood flowing through it. The pumping of the heart pumps forces
blood to move through the blood vessels delivering oxygen and nutrients to the cells and
tissues of the body. Damaged arteries, narrowed by plaque deposits, require extra force or
higher pressure to overcome the increased resistance. This persistent high blood pressure
or hypertension is overworks the heart muscles, and together with the damaged arteries, if
left untreated, leads to heart disease (Franklin & Wong, 2013). High blood pressure is
referred to as the “silent killer” as it develops slowly and can go undetected for many
years. Fortunately, the FHS discovered that systolic blood pressure (SBP) is more
strongly associated with CVD than is diastolic blood pressure (DBP), and the FRS only
includes the former (Kannel, Gordon, et al., 1971). Hypertension, now defined as an SBP
above 140 mmHg, and is associated with an increased risk of CHD (Pedersen, 2002).
Diabetic Status. Diabetes Mellitus II (DM2) or hyperglycemia describes the
condition of persistently high concentration glucose in the blood. Normally, ingested
carbohydrates are converted to glucose and transported into the cells by insulin to meet
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the cells energy need. However, when the supply of glucose supply is excessive, the cells
become unresponsive to insulin and this excess glucose remains dissolved in the blood
(Sah et al., 2016). This increased glucose causes an upsurge in the pancreas’ insulin
production (Faerch et al., 2012), and it is this elevated levels of glucose and insulin is
known to damage the walls of the arteries and increase the risk of heart disease (Faerch et
al., 2012; Laakso, 2015; Tostes & et al., 2009). For first FHS cohort, diabetic status was
made by either of three determinations: (i) the use of insulin; or (ii) two separate
incidents of a glucose level >150mg/dL; or (iii) an abnormal glucose tolerance test (Qazi
& Malik, 2013a). It was the FHS researchers who first reported the link between diabetes
and CVD (Kannel & McGee, 1979a), a link that was confirmed by many subsequent
studies (Carter et al., 2016; Cockram et al., 2001; Ray et al., 2014; Zhang et al., 2014).
Although elevated glycated hemoglobin (HbA1c) is becoming more popular in
diagnosing DM2, in many cases a FBG above 120 mg/dL is also used.
Glucose Level.
In the original FHS study, glucose level was used only for the determination of
diabetic status. Fortunately, the raw values of fasting blood glucose (FBG) have always
been recorded for all cohorts and are available for use in the current analysis. High FBG
is now recognized as being a strong risk factor for CVD as well as other diseases such as
diseases of the kidney, the eye, the brain, and the central and peripheral nervous (IsmailBeigi, Moghissi, Kosiborod, & Inzucchi, 2008; Laakso, 2015). However, the only
established glucose level threshold is that used for the diagnosis of diabetes, and glucose
levels in the diabetic range are now accepted as a risk of microvascular damage that leads
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to other disease (Sarwar et al., 2010). But the threshold for diabetes diagnosis was not
based on the risk of CHD and that threshold may not relevant to the risk of a CHD
outcome. In fact, research now shows that the link between glucose and atherosclerosis
and cardiovascular disease may extends below the diabetes threshold (Braun et al., 2013;
Desouza, Raghavan, & Fonseca, 2010; Valentino et al., 2015). Low levels, intermediate
(impaired glucose tolerance) levels, and low-normal (pre-diabetes) levels of glucose have
all been shown to be associated with a risk of developing CHD (Coutinho et al., 1999;
Desouza et al., 2010; Faerch, Vistisen, Borup, Marit, & Jørgensen, 2014; Park et al.,
2013; Valentino et al., 2015). For this reason, this study contends that FBG, a continuous
and modifiable CHD risk factor, can improve the efficacy of the CHD risk prediction.
Body Mass Index. An overweight person is one whose weight is above what is
considered normal or healthy. Body mass index or BMI is a measure of overweight and is
calculated by dividing the weight in kilograms (Kg) by the square of the height in meters
(m2). i.e. BMI = Kg/ m2 (Herman & Rothberg, 2015). For adults, a BMI below 25 is
normal, above 25 is overweight, and above 29 is obese (American Diabetes Association,
2015). A person increasing BMI is an indication of an increasing dysfunction in their
body’s ability to metabolize glucose (Srikanthan et al., 2016). The high BMI in
overweight and obese persons is usually associated other CHD risk factors such as high
blood cholesterol, high blood pressure, and hyperglycemia, making an elevated BMI
strong risk factor CHD and heart attack (Grundy et al., 2002).
Smoking. Cigarettes or tobacco smoking or exposure to secondhand smoke
subjects the body to toxic gaseous molecules that are harmful to its tissues and organs.
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These toxins cause damage the blood vessels, mainly to the lungs and heart first, which
initiates a buildup of plaque and the formation of blood clots in the arteries (Huxley et al.,
2011). Smoking is also associated with a lower level of the healthy HDL, exacerbating
the development of heart disease risks. Smoking as a CHD risk is dependent on the how
long the individual has smoked and how many packs are smoked per day (Mannan,
Stevenson, Peeters, Walls, & McNeil, 2010). Ideally, smoking should be used as a
continuous risk factor (number of cigarettes or number of packs per day, or a similar
measure), and some optimized versions of the FRS do so. However, the current FRS
formula used for purposed of CHD risk screening uses as a binary (yes/no) factor of
current smoking status and will be similarly used in this study.
Age. As the body ages so does the blood vessels and older blood vessels are less
supple and more susceptible to damage. Both the buildup of plaque in response to any
damage and the loss in flexibility makes blood flow more difficult, resulting in the need
for increase in blood pressure from the heart (Rodondi et al., 2012). Over time, these
conditions combined with an extended exposure to other harmful influences makes heart
disease more common as subjects get older. Persons in an older age group are more likely
to die from heart disease than those in a younger age group, in fact over 80% of the
people who die from CHD are over 65 years and (Mozaffarian, Benjamin, Arnett, et al.,
2015). Older people are not only more likely to develop heart disease they are also more
likely to die from it, making age a major CHD risk factor (Tsao, 2015). The age of the
participants, as recorded in years, at the original exam was used in the MLR formula.
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Gender. Being female is somehow heart protective, relative to make, and women are less
likely to develop CHD. Not only is there is a lower prevalence of the heart disease among
women but and women also tend to develop CHD at a later age than men (Franklin &
Wong, 2013). Unfortunately, there are gender specific factors such as preeclampsia
during pregnancy or menopause, that do increase women’s predisposition to CHD risk
factors such as atherosclerosis and hypertension (Hosseini, 2015). Additionally, the risk
posed by cigarette smoking is more harmful to women and furthermore women have
greater incidences of metabolic dysfunction (obesity, prediabetes, diabetes) than do men
(Huxley et al., 2011; Moore et al., 2017). Moreover, the major CVD risk factors affect
the female body differently than it does the male, for example diabetes raises the risk of
CVD for both genders, but it does so to a greater extent for women than it does for men
(Hosseini, 2015; Qazi & Malik, 2013b). Diabetic women tend to have a greater burden of
risk as well as a higher risk of developing CHD, making gender another important nonmodifiable risk factor (Amsterdam, 2011; Booth et al., 2006). All these factors combined,
makes gender or sex a major risk factor for CHD and in some instances, separate genderspecific formulas are used for screening purposes (Çevik et al., 2015). Here gender was
included as a nominal dichotomous variable along with the other risk factors in the
multivariate formula.
Data Analysis
This study sought to use statistical analysis of the FHS data set to answer the
following three research questions:
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Research Question 1:
Is the relative risk of ‘glucose level’ higher than that of ‘diabetic status’ for the
development of CHD in the FHS data set?
Null Hypothesis. There is no difference between the relative risk of ‘glucose
level’ and that of ‘diabetic status’ for the development of CHD in the FHS data set.
Alternative Hypothesis. The relative risk of ‘glucose level’ is higher than that of
‘diabetic status’ for the development CHD in the FHS data set.
Statistical Analysis. This first question compared the strength of the association
between the two predictors, FBG and DM2, and the outcome. Given the binary outcome
variable (10-year CHD event), a logistic regression is most suitable for this analysis. Here
two different univariate logistic regression formulas were generated, one for ‘diabetic
status’ (DM2) and one for ‘glucose level’ (FBG), and the odds ratio (OR) for each was
recorded. The OR is a measure of the change in odds for the outcome (CHD)
corresponding with a unit change in the predictor, and an OR > 1 implies that the
presence of predictor or exposure increases the odds or the probability of the outcome
event (Tripepi, Jager, Dekker, Wanner, & Zoccali, 2007). This ORs from each of the
formulas, which indicated the crude or unadjusted measure of association for the
outcome, was used to compare the relative strength of two independent variables and to
make a determination of which was the stronger (Field, 2013).
Logistic regression (LR) analysis generates a regression coefficient for the
predictor variable, and the OR is calculated by finding the exponential or inverse-logit
function of that regression coefficient (Sperandei, 2014). In LR, the categorical nature of
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the outcome violates the regular assumption of linearity, but the relationship between the
predictor variables and the logit of the outcome variable is assumed to be linear (Lani,
2015). The statistical significance of the OR is based on both the p-value and the 95%
confidence interval (CI). A α level of 0.05 was used and an OR with a p-value less than
0.05 was considered statistically significant. The CI reflects the range within which the
OR value can be found 95% of the times the test is run on this data set, (Giancristofaro &
Salmaso, 2003; Sullivan, n.d.) The precision with which the OR was estimated from the
width of the CI and a ranges that did not cross “1” (a pair of positive numbers of a pair of
negative numbers) was considered statistically significant (Field, 2013; Sullivan, n.d.).
Research Question 2:
Is the measure of accuracy higher for the ‘glucose level’ formula than that for
‘diabetic status’ formula in the FRS-CHD 10-year risk prediction model?
Null Hypothesis. There is no difference between the measure of accuracy for
‘glucose level’ and ‘diabetic status’ versions of the FRS-CHD 10-year risk prediction
formula.
Alternative Hypothesis. The measure of accuracy for ‘glucose level’ formula is
higher than that for ‘diabetic status’ version of the FRS-CHD 10-year risk prediction
formula.
Statistical Analysis. This second question dealt with the relative performance of
the two versions of the Multivariate Logistic regression (MLR) model. An MLR is used
to describe a data set containing several predictor variables and one dichotomous
outcome. Its ability to determine strength of association and to predict risk while

104
controlling for confounding effects makes it the analysis of choice for medical research
(Stoltzfus, 2011). MLR analysis is common with longitudinal data, which is collected on
the various risk factors believed to be associated with a disease or medical event. Here
the independent or predictor variables can be categorical, or continuous, but the outcome
must be binomial (Stoltzfus, 2011). For this research question, two MLRs were
generated, one with FBG and another with DM2, and both included the other independent
variables including- age, gender, HDL, SBP, smoking status, and BMI. The dependent
variable was the presence or absence (yes/no) of a 10-year CHD event outcome.
For assessing the performance of screening models, there are several tests that can
used, depending on whether the goal is prediction, selection, or causal modeling
(Steyerberg et al., 2010). In this study the goodness-of-fit or modeling power was
assessed using three parameters: the pseudo-R2 values, the Hosmer-Lemeshow test, and
the maximum likelihood function in the form of chi-square values. The pseudo-R2
measures the amount of variance in the dependent variable explained by the independent
variables and provides a measure of the model’s discriminatory capability (Field, 2013).
The maximum likelihood function estimates the how likely is the inclusion of the
variable (or variables) in the model, relative to not including it, to make the correct
outcome prediction (Hu, 2007). The Hosmer-Lemeshow (H-L) chi-squared test is another
goodness-of-fit test that measures the model’s calibration, giving an average of fit for the
sub-groups within the data set when divided into deciles of predicted risk values (Demler,
Paynter, & Cook, 2015; Stoltzfus, 2011). Unlike the chi-square values for the maximum
likelihood, a lower H-L chi-square (and larger p-value) was considered a superior fit, as
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the null hypothesis assumes that the model is a good fit of the data (Giancristofaro &
Salmaso, 2003).
Assumption/Rationale. As a regression analysis, the MLR does not depends on
the ordinary least square algorithms required in general linear models. A linear
relationship between the independent variable (IV) and outcome is not required, neither is
a normal distribution of the residuals (homoscedasticity), nor that the dependent variable
should be an interval or ratio scale (Lani, 2015). The assumptions for the MLR instead
include: independence of little or no multicollinearity among the variables and linearity
between the variable log odds measure for the outcome (Stoltzfus, 2011). Additionally,
the MLR should be generated from a large enough sample size, with a minimum of 10
cases for each IV, to avoid overfitting of the data (Sperandei, 2014; Stoltzfus, 2011). The
maximum number of variables in the main multivariate formula was seven (when gender,
and BMI were included), requiring a minimum of 70 cases, which was far exceeded by
the sample size of over 2,600 after filtering. Pearson correlation coefficient (for
continuous IVs) and the Chi-Square Cramer’s V values (dichotomous IVs and continuous
IVs as groupings) were used to analyze the strength of the association among the
variables. The pairs that were deemed strongly correlated were used to create interaction
terms, which were then tested for significance by including in the MLR formula.
Statistical Significance.
Determining the statistical significance of a logistic regression is relatively
straightforward, as the model results are generated with a corresponding p-value and CI
for each of the predictors in the equation. If the p-value is less than the predetermined α-

106
value of 0.05 then the term, and by extension the association between the predictor and
the outcome, is considered significant (Giancristofaro & Salmaso, 2003). The size or
strength of the association is based from the odds ratio, which is generated with a 95%
CI. If the p-value is less than 0.05 and the OR is outside of one, statistical significance is
accepted and the null hypothesis is rejected (Cook & Sheikh, 2000; Sullivan, n.d.).
Since this research question focuses on the model’s performance or how well the
model fits the data, it is important to evaluate the goodness-of-fit results. The goodnessof-fit test tells the extent to which the predicted probabilities deviate from that recorded
in the data (Demler et al., 2015). For logistic regression, pseudo-R2 can be used as a
goodness-of-fit test, that reflects the model’s predictive power, as a measure of variation
accounted for by the variable included. There is no established threshold of significance
for this measure, but when used to compare models, the greater the R2 value the better the
fit of the model (Steyerberg et al., 2010). The maximum likelihood measure does not test
the model independently, but compares the fit of models generated from the same data set
and each is reported with a corresponding p-value (Burnham & Anderson, 2004). For the
H-L test, unlike in the logistic regression test on which it is based, the alternative
hypothesis assumes a poor match between the observed and the predicted, and therefore a
χ2 < 20 and ap > 0.05 is considered statistically significant (Demler et al., 2015)..
Research Question 3:
Is the measure of accuracy for the ‘glucose level’ formula independent of ‘age’,
‘BMI’, ‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-year CHD prediction
model?
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Null Hypothesis. The measure of accuracy for ‘glucose level’ is independent of
‘age’, ‘BMI’, ‘cholesterol level’ or ‘blood pressure level’ in the 10-year CHD prediction.
Alternative Hypothesis. The measure of accuracy for ‘glucose level’ is
dependent on ‘age’, ‘BMI’, ‘cholesterol level’ or ‘blood pressure level’ in the CHD 10year CHD prediction.
Statistical Analysis. This third question evaluates extent to which the interaction
between the independent variables moderates the association between ‘glucose level’ and
the 10-year CHD outcome. The variables chosen for interaction testing were considered
factors involved metabolism and are thus connected in the cardiometabolic hypothesis of
CVD development. For the moderation analysis, the FBG model in addition to the
respective interaction items (a product of the moderator and the predictor) (Field, 2013).
Since the FBG itself was determined to have an insignificant relationship with the
outcome, the FBG-group variable was created, and this was used to generate the
interaction terms. Since the correlation coefficient between these variables were all below
0.350, there was no need for centering of the variables.
Statistical Significance. To determine the statistical significance of the
interaction term, the properties of its coefficient was evaluated (Newsom, 2016). Like
with the other ORs, a p-value that is less than α and a 95% CI that does not include “1”
indicate statistical significance for the interaction terms. The statistical significance of the
overall model, as well as the p-value and CI for each of the interaction and noninteraction variables of the model was evaluated for comparing the accuracy of the
models- FBG with interaction terms, and FBG model without interaction terms
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(Newsom, 2016). The relevant performance analyses will also be compared for the new
‘interaction’ model against that for FBG model without interaction terms to determine if
the interaction terms provide any improvement to the model.
Summary
The goal of this study was to measure the effect of fasting blood glucose (FBG)
levels on the performance of the Framingham Risk Score (FRS). The FRS was designed
from the FHS data, from the first cohort of which originating several decades ago, and
the more commonly used current version includes the major CHD risk factors; age,
gender, HDL cholesterol, systolic blood pressure, smoking behavior and diabetic status.
The 10-year FRS score is a measure of an individual’s probability of succumbing to a
CHD event over the next 10-years. Limits to the generalizability and discriminatory
power of the FRS has led to customization and optimization of the formula over the past
four decades, with goal of improving its performance and widening is applicability in a
diversity of populations.
In this study, multivariate logistic regression (MLR) model was the statistical
analysis of choice, as it was the method used to first develop the FRS model. Using the
data from the third generation (most recent) of the FHS cohort as secondary data,
univariate and multivariate regression analyses was performed to evaluate and compare
the predictive power of the ‘diabetic status’ (DM2) model with that of the FBG model.
The strength of the relationship between the respective variables and the outcome, the
predictive power of the two models, and the effect of interactions (in the FBG model)
between the independent variables were all assessed based on the p-values and the CI of

109
the odds ratio for each. The goodness-of-fit parameters were employed included the odds
ratio or OR (assessed the unadjusted strength of the association), the pseudo-R2 (how well
the variance in the outcome is accounted for by the predictive factors), the Chi-square
values (the extent to which the model predictions matches the recorded data), and the
Hosmer-Lemeshow test (the average of the fit of model for each decile of the outcome
variable). The next chapter will provide specific details of the steps involved in the
statistical analysis performed to answer the three research questions and whether the null
hypothesis was rejected or not.
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Statistical Analyses
Research Question
RQ1: Strength of
Association

Statistical Test
Univariate Logistic
Regression (ULR)

Glucose vs. Diabetes
RQ2: Model Comparison Multivariate Logistic
Regression (MLR)
Glucose model vs.
Diabetes model

RQ3: Model Comparison Multiple Logistic
Regression w/
‘Glucose’ x ‘Moderators’ Interaction
model

Assumptions
Outcome matches test
Correct labeling of outcome
Large sample size

Interpretation

Significance

Estimated from OR

p<α

Outcome matches test
Correct labeling of outcome
Only meaningful variables
No/little collinearity
Large sample size

R2DM2 > R2FBG

Hosmer-Lemeshow Test

p > α*

Same as MLR
Minimal collinearity

Coefficient of interaction term

p-value < α

ORDM2 > ORFBG?
p<α

DM2 χ2 > FBG χ2

OR from MLRG+Ms

111
Chapter 4: Results
Overview
The objective of this quantitative analysis was to assess the contribution of the
variable FBG level compared to that of DM2 diagnosis as a predictor for (CHD in the
FHS cohort dataset. The variables were compared unadjusted, adjusted and then
possible interactions tested, in the three research questions examined. The research
questions and the related null and alternative hypotheses are as follows:
RQ1: Is the relative risk for glucose level higher than that for diabetic status in
the CHD 10-year risk prediction?
H01: There is no difference between the relative risk for glucose level and that
for diabetic status’ in the CHD 10-year risk prediction.
Ha1: The relative risk for glucose level is higher than that for diabetic status in
the CHD 10-year risk prediction.
RQ2: Is the measure of accuracy for glucose level higher than that for diabetic
status in the CHD 10-year risk prediction formula?
H02: There is no difference between the measure of accuracy for glucose level
and diabetic status in the CHD 10-year risk prediction formula.
Ha2: The measure of accuracy for glucose level is higher than that for diabetic
status in the CHD 10-year risk prediction formula.
RQ3: Is the measure of accuracy for glucose level independent of age, BMI,
cholesterol level or blood pressure level in the CHD 10-year risk prediction formula?
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H03: The measure of accuracy for glucose level is independent of age, BMI,
cholesterol level or blood pressure level in the CHD 10-year risk prediction formula.
Ha3: The measure of accuracy for glucose level is dependent on age, BMI’,
cholesterol level or blood pressure level in the CHD 10-year risk prediction formula.
This chapter outlines the data collection (obtaining access to the secondary data)
process, how the data was treated and analyzed, and the results of the statistical
analyses. The data I analyzed is from the third generation of the original cohort
(GenIII), combined with data from the OMNI2 and the NOS cohorts. The reporting of
results begins with the descriptive analyses performed on the dependent variable as
well as all the independent variables included in the study. This is followed by the
results of each of the logistic regression analysis conducted to answer the specific
research questions. Finally, the chapter summary highlights the overall findings as it
relates to the objective of the study.
Data Collection
The data analysis for this study was conducted using secondary data obtained
from the FHS, via the BioLINCC division of the NHBLI. The data set from the third
cohort (FHSIII), as this was the most recent, were collected from the grandchildren of
the participants of the original cohort (FHSI) beginning in 2001. The recruitment and
response rates were described in detail in chapter three. Following IRB approval
received from Walden University (Appendix B), I was granted access to the data from
the BioLINC website according the signed agreement (Appendix C) for third party
researchers. The data was provided as large zip file that was downloaded to my laptop
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and opened to separate folders containing the data, the documentation, and the data
dictionary. The data set folders contained two folders each, one with the data in CSV
(Excel files) and the other with a SAS duplicate of all the files. The CSV files were
opened in the SPSS application, subjected to several data screening and data cleaning
steps before being used for the data analyses described below.
Preanalysis Data Cleaning
I combined several pertinent files in SPSS to create a new file that contained
only the variables of interest. This involved duplicating the main file (CHD outcome,
CHD date, etc.), deleting unwanted variables (CVD, CHF outcomes, etc.) and then
merging into one file (based on the ID numbers) that included the predictor variables
(age, sex, HDL, glucose, smoking status, BP, DM status and CHD outcome). Some of
the variables were renamed (e.g. age @ exam 1 to simply AGE) for clarity, others
required reformatted (e.g. CDH update status to 10-year update status) or used to create
new variables (age groups, HDL groups, etc.). This file was then filtered twice, first to
remove all those who had a history of CHD and then to remove those whose CHD
event happened after more than 10 years. The filtered file was saved as the working file
and used to perform the descriptive and inferential analyses.
Results of Data Analysis
Descriptive Analysis
Valid Number of Sample Size. After filtering, a total of 2,677 participants
were included (from the original 4578 sample size) in the data set, with a valid N of
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2,649 after accounting for the missing values from some (BP, FBG, HDL and DM) of
the variables (See Table 1).
Table 1
Valid Number of Variables
N
Valid

Missing

Sex of participant

2,677

0

Age (years)

2,677

0

Diastolic blood pressure

2,675

2

Fasting blood glucose (FBG)

2,652

25

HDL cholesterol

2,676

1

Diabetes Mellitus Status (DM2)

2,674

3

CHD status

2,677

0

Valid N (listwise)

2,649

Measures of central tendency (Continuous Variables). The average age of
the sample of participants was 40 years and 6 months, with the youngest being 19 and
the oldest being 82 years old. As the histogram of the age distribution shows (Figure 4),
there is a right shift, as there are fewer persons at the extreme end (elderly) than are at
the left (<25 years). Despite this skewness, the trend line of frequency distribution
indicates that the assumption of normalcy is met. Similarly, with the distribution of
FBG levels, some very high values cause right skewness, but overall the distribution is
still considered normal (Figure 4).

115

Figure 4. Histogram of AGE distribution.
The mean value of FBG was 94.43 but the median was only 92.00, confirming
the presence of very high FBG values causing the shift in the mean to the right of the
median (See Figure 5). The relatively large SE also suggests that the sample mean may
be greater than the true population mean, but still within range. As can be seen in Table
2, the other continuous variables, BMI and SysBP, were also normally distributed, with
respective means 26.7 and 116.8 (mmHg). The BMI was calculated based on weight
and height measures, and like all other measurement, were based at the initiation exam
(Exam 1) and are regarded as baseline measurements.
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Table 2
Measures of Central Tendency of CHD Risk Factors
Mean

Median Std. Dev Min

Max

.176

41.00

9.102

19

82

Systolic Blood Pressure 116.80

.278

115.00

14.403

81

192

Body mass index

26.684

.105

25.720

5.440

16

59

Fasting blood glucose

94.43

.322

92.00

16.588

64

357

HDL Cholesterol

54.87

.316

53.00

16.352

19

206

Age (years)

40.51

S.E. Mean

Figure 5. Histogram of fasting blood glucose (FBG) levels.
Distribution of CHD risk factors. In the case of the nonmodifiable risk factors,
Age and Sex, there was an equal representation of the major groups. There were 271
more females than males, but the difference accounted for only a 10% difference (See

117
Table 3). And all the participants were adults (at least 19 years old), but the two largest
groups were those between 26 and 40 (44.0%) and those between 41 and 55 (46.4%).
Those younger than 25 and those older than 56 years made up a little less than 10%
(combined) of the total sample. This distribution of age is consistent with the fact that
most of the participants that make up this sample were from the third generation of the
original FHS participants. The rest of the sample was made up from the second
generation of the OMNI sample group and the new offspring group, both used to
provide diversity.
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Table 3
Distribution of Risk Factors
Frequency

Percent

Cumulative Percent

Male

1204

45.0

45.0

Female

1473

55.0

100.0

< 25

156

5.8

5.8

26 - 40

1178

44.0

49.8

41 - 55

1241

46.4

96.2

56 - 70

90

3.4

99.6

> 70

12

.4

100.0

< 41 (Risk)

504

18.8

18.8

41-60 (Boderline)

1301

48.6

67.4

> 60 (Optimal)

872

32.6

100.0

<91 (Low)

23

.9

.9

91-120 (Normal)

1728

64.5

65.4

121-140 (Prehypertensive)

748

27.9

93.4

>140 (HyperTension)

178

6.6

100.0

Non-Smoker

2334

87.2

87.3

Smoker

341

12.7

100.0

143

5.3

5.3

81 - 100 Normal

2017

75.3

80.7

101 - 125 PreDM2

443

16.5

97.2

126 - 150 Boderline DM2

27

1.0

98.2

151 - 200 High DM2

9

.3

98.6

>200 Very High DM2

13

.5

99.1

Missing

25

.9

100.0

19

.7

.7

18 - 24.9 Normal

1117

41.7

42.4

25 - 39.9 Overweight

1443

53.9

96.3

>= 40 Morbid Obesity

98

3.7

100.0

Sex of participant

Age Groups

HDL Chol Group

Systolic Blood Pressure Group

Smoking Status

FBG Groups
<81 Hypo

BMI Groups
<18 Underweight
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Bivariate Analysis
Pearson correlation of risk factor. The correlation between the risk factors
measured as continuous variables (age, HDL, BMI, FBG and SysBP) were statistically
significant, with p values less than 0.000. The Pearson correlation values were all
positive, except for HDL, as was expected, which was negatively correlated with BMI
(-0.321), FBG (-0.200), and SysBP (-0.128). Since the strongest correlation was
between BMI and SysBP (0.384) all the correlations were determined relatively weak
or negligible.
Table 4
Pearson Correlation Between Variables
HDL

Body mass

Blood

Systolic blood

Age

cholesterol

index

glucose

pressure

1

.068

.161

.234

.323

.000

.000

.000

.000

1

-.352

-.200

-.128

.000

.000

.000

1

.341

.384

.000

.000

1

.309

Age
Pearson Correlation
p-value
HDL cholesterol
Pearson Correlation

.068

p-value

.000

Body mass index
Pearson Correlation

.161

-.352

p-value

.000

.000

Pearson Correlation

.234

-.200

.341

p-value

.000

.000

.000

Pearson Correlation

.323

-.128

.384

.309

p-value

.000

.000

.000

.000

Blood glucose

.000

Systolic Blood Pressure
1
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Association between risk factor groups across gender. When comparing the
distribution of risk factors across genders, the differences in age group and smoking
status were not statistically significant and the differences among the other variables
were. The 17% (200) excess of females (1,204 males and 1,473 females) was reflected
in all of the age groups. Similarly, despite there being more male smokers than female
smokers, the difference in male (177) smokers compared female smokers (164) was not
statistically significant (p = 0.215). Advanced age and smoking are the strongest,
modifiable risk factors for CHD, and both they were both found to be equally
distributed across the genders in this data set.
All the other risk factors demonstrated a statistically significant difference in
association across the genders, with all p-values less than or equal to 0.001. However,
for the effect size of the gender difference for diabetic status was considered weak
(Cramer’s V = 0.062), while the effect size for HDL, BP, and BMI and FBG were
moderate in effect, with HDL being the largest (Cramer’s V values of 0.431, 0.207,
0.312, 0.431, and 0.265 respectively). The effect sizes of these association did not
warrant the centering of the variables prior to the interaction study, but it did justify
investigating the interactions.
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Table 5
Chi-square Analysis of Association
Male

Female

Age
<25

67

89

26- 40

545

633

41 - 55

546

695

56 - 70

39

51

>70

7

5

Diabetic Status
Non-Diabetic

1160

1447

Diabetic

43

24

Smoking Status
Non-Smoker

1039

1295

Smoker

164

177

HDL Chol
<41 (Risk)

396

108

41 – 60 (Normal)

650

651

>60 (Optimal)

158

714

Sys Blood Press
<90 (Low)

2

21

91-120 (Normal

660

1068

121-140 (Prehypertensive)

446

302

>40 (Hypertension)

96

82

χ2

p-value

Cramer’s V

2.494

0.646

0.031

10.226

0.001

0.062

1.539

0.215

0.024

497.074

0.000

0.431

114.982

0.000

0.207
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Male

Female

BMI
<18 (Underweight)

2

17

18 – 24.9 (Normal)

315

802

25 – 39.9 (Overweight)

855

588

>= 40 (Morbid Obesity)

32

66

Blood Glucose
< Hypoglycemic

15

128

81- 100 (Normal)

842

1175

101 – 125 (PreDM2)

306

137

126 – 150 (Borderline DM2)

19

8

151 – 200 (High DM2)

5

4

> 200 (Very High DM2)

6

7

χ2

p-value

Cramer’s V

260.973

0.000

0.312

188.646

0.000

0.265

Distribution of Risk Factors Across Diabetic Status
The other set of bivariate analyses conducted, were the distribution of the risk
factors across the diabetic status groups (DM2 and Non-DM2). The chi-square analyses
(Table 6) indicated that there was a statistically significant difference between the two
groups for all the risk factors, with the exception of Smoking status (p = 0.201). In the
case of Age, HDL, SysBP, and BMI, even though the differences were statistically
significant, the value of the Cramer’s V were all below 0.200, with the largest effect
seen across the age groups (Cramer’s V=0.198). The percent of diabetics increased with
age, with an average of 0.6% for those younger than 40, increasing to 3.7% between the
ages 40 to 55, to 12.5% for those over 56, and to 57% for those over 70 years (See
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Table 6). Similar trends occur in the risk factors that are also negatively predictive,
such as SysBP and BMI, with the percentage of diabetics increasing as the value of the
risk factor increases, e.g. from Normal BMI to Overweight BMI or from Normal SysBP
to Hypertensive SysBP. The converse happens with HDL, which is the only factor that
is positively predictive (of a reduced risk) of CHD. As the HDL value goes up from one
group to the next, the percentage diabetics in the group goes down.
Table 6
Association of Risk Factor Groups Across Diabetic Status
Diabetic

Non-Diabetic

Age
<25

1

155

26- 40

7

1170

41 - 55

45

1195

56 - 70

10

80

>70

4

7

Smoking Status
Non-Smoker

55

2276

Smoker

12

329

HDL Chol
<41 (Risk)

30

474

41 – 60 (Normal)

25

1274

>60 (Optimal)

12

859

Sys Blood Press
<90 (Low)

0

23

χ2

p-value

Cramer’s V

105.124

0.000

0.198

1.636

0.201

0.025

30.842

0.000

0.107

51.338

0.000

0.139
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Diabetic

Non-Diabetic

91-120 (Normal

19

1708

121-140 (PreHyperT)

33

713

>140 (Hpertension)

15

163

BMI
<18 (Underweight)

0

19

18 – 24.9 (Normal)

8

1107

25 – 39.9 (Overweight)

43

1399

>= 40 (Morbid Obesity)

16

82

Blood Glucose
< Hypoglycemic

1

141

81- 100 (Normal)

2

2015

101 – 125 (PreDiabetic)

14

429

126 – 150 (Borderline Diabetic)

27

0

151 – 200 (High Diabetic

9

0

> 200 (Very High Diabetic)

13

0

χ2

p-value

Cramer’s V

93.053

0.000

0.187

1957.410

0.000

0.856

Expectedly, the association between fasting blood glucose (FBG) group and
DM2 was statistically significant with a very large effect size (Cramer’s V=0.856). As
can be seen from the Table 6, all those with very high blood glucose levels (above 126
mg/dL) belonged to the diabetic group. But surprisingly, all of the very high glucose
levels were with the younger diabetics, while many the older diabetics have blood
glucose levels closer to that of the Non-Diabetic (See Figure 6). Also, of note is the
association between those who those who had a CHD event and those who didn’t,
relative to increasing age and blood glucose level. Most of the CHD events occurred
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with those whose blood glucose levels were within the normal range. According to
Figure 6, the majority of diabetics were 40 years and older, but as can be seen in Figure
7, those for whom a CHD event was recorded, the ages were both above and below 40
years, but mostly in the normal FBG region. These findings would have an impact on
the inferential analysis and is discussed further in chapter 5.

126

Non-Diabetic
Diabetic

Figure 6. Scatterplot of fasting blood glucose (FBG) vs. AGE by diabetic status (DM2).

Figure 7. Scatterplot of fasting blood glucose (FBG) vs AGE by CHD status.
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Research Question 1
Research Question 1: Is the relative risk of ‘glucose level’ higher than that of
‘diabetic status’ for the development of CHD in the FHS data set?
Null Hypothesis. The relative risk of ‘glucose level’ is less than that of ‘diabetic
status’ for the development of CHD in the FHS data set.
Alternative Hypothesis. The relative risk of ‘glucose level’ is higher than that of
‘diabetic status’ for the development CHD in the FHS data set.
Two univariate binary logistic regression analyses were conducted to answer
this first research question. The dichotomous outcome variable was the occurrence of a
CHD event over the 10-year period. In this unadjusted model, Diabetic Status (DM2)
was predictive of CHD as the model was statistically significant, with the χ2 = 24.652, p
= .000 and the pseudo-R2 = 0.043 (See Table 7). In a similar unadjusted model, fasting
blood glucose (FBG) was also statistically significant, with the χ2 = 14.649, p = .000
and the pseudo-R2 = 0.025. The larger pseudo-R2 of the DM2 model would imply that
it is a superior representation of the variance in the CHD outcome than the FBG model.
Table 7
Comparison of the Unadjusted Models of the Odds for CHD
χ2

Pseudo-

R2

p-value

DM2 Model

24.652

0.043

0.000

FBG Model

14.649

0.025

0.000

With respect to predicting CHD, the odds ratio (OR) for glucose level was
1.015, 95% CI [1.009, 1.022], suggesting that for each unit level increase in FBG the
likelihood of CHD goes up by 1.5%. The OR for DM2 was 8.483, 95% CI [4229,
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17.015], implying that on average, a diagnosis of diabetes increases the likelihood of
CHD by 848%. According to the results from the two models, in the absence of
adjusting for any other risk factor, DM2 status is shown to have a higher OR and is
therefore a better predictor of CHD. The relative risk of an increasing FBG level, for
one each unit change, is lower than that for change in DM2 Status, from non-diabetic to
diabetic. The results of the analysis indicate that the null hypothesis cannot be rejected
and that the relative predictive value of FBG is less (based on OR measures) than that
of DM2 for the probability of CHD, in this FHS data set.
Table 8
Two Models of Odds of CHD Relative to Diabetic Status or Fasting Blood Glucose
95% C.I.
Lower Upper

B

S.E.

Wald

df

Sig.

Exp(B)

DM2 Model

2.138

.355

36.249

1

.000

8.483

4.229

17.015

FBG Model

.015

.003

21.060

1

.000

1.015

1.009

1.022

Research Question 2
Research Question 2: Is the measure of accuracy higher for the ‘glucose level’
formula than that for ‘diabetic status’ formula in the FRS-CHD 10-year risk prediction
model?
Null Hypothesis. There is no difference between the measure of accuracy for
‘glucose level’ and ‘diabetic status’ versions of the FRS-CHD 10-year risk prediction
formula.
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Alternative Hypothesis. The measure of accuracy for ‘glucose level’ formula is
higher than that for ‘diabetic status’ version of the FRS-CHD 10-year risk prediction
formula.
For answering this second research question, a multivariate logistic regression
was used. The variables SEX, AGE, HDL, SysBP, Smoking Status, and BMI were
entered as the cofactors, but SEX proved to be a statistically insignificant predictor and
was eliminated from subsequent formulations. The adjusted DM2 model (Table 9), was
statistically significant, with χ2 = 100.242, p = .000 and a pseudo-R2 = .171, as was the
adjusted FBG model (Table 10), with χ2 = 92.098, p = .000, and the pseudo-R2 = .163.
The adjusted OR for DM2 (Table 9), dropped to 2.295 (from 8.483), 95% CI [1.035,
5.087] but it remained statistically significant (p = .041). However, in the case of FBG
(Table 10), the OR decreased to 1.008 (from 1.015) and was no longer a statistically
significant predictor, as p = .079.
Table 9
Odds of Diabetic Status for CHD Adjusted for Age, Smoking Status, HDL, and SysBP

Sig.

Exp(B)

95% C.I.
Lower Upper

1

.000

1.093

1.062

1.125

9.351

1

.002

2.512

1.392

4.533

.009

8.506

1

.004

.974

.957

.991

.021

.008

7.395

1

.007

1.022

1.006

1.037

.831

.406

4.182

1

.041

2.295

1.035

5.087

-9.029

1.088

68.808

1

.000

.000

B

S.E.

Wald

Age

.089

.015

36.985

Smoking Status

.921

.301

HDL cholesterol

-.026

Systolic blood
DM2
Constant

df
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Table 10
Odds of FBG for CHD adjusted for Age, Smoking Status, HDL, and SysBP

Sig.

Exp(B)

95% C.I.
Lower Upper

1

.000

1.098

1.067 1.129

8.279

1

.004

2.422

1.326 4.423

.009

8.973

1

.003

.972

.018

.008

5.119

1

.024

1.018

1.002 1.035

.008

.004

3.077

1

.079

1.008

.999 1.017

-9.504

1.154

67.788

1

.000

.000

B

S.E.

Wald

Age

.093

.015

41.080

Smoking Status

.884

.307

HDL cholesterol

-.028

Systolic blood
FBG
Constant

df

.955

.990

To evaluate and compare the performance of the two models relative to each
other, various performance parameters were used. In the case of the predictive power
(the Log Likelihood and the Wald statistics), and for the discriminating power (pseudo
R-squared) the values for the DM2 model were greater than these of FBG model (See
Table 11) suggesting a superior DM2 performance. For the goodness-of-fit measure, as
determined by the Hosmer-Lemeshow values, the FBG model had the lower chi-square
and the higher p-value indicating the FBG superiority over the DM2. These seemingly
contradiction in performance measures and the lack of statistical significance of the
actual FBG variable in its model, were considered evidence that the FBG model was
not an improvement to the DM2 model. Consequently, the null hypothesis was rejected
as there was no significant difference between the measure of accuracy for ‘glucose
level’ and ‘diabetic status’ versions of the FRS-CHD 10-year risk prediction formula.
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Table 11
Comparison of Model’s Performance
DM2 Model
χ2

FBG Model

p-value

χ2

p-value

Overall Model
Log Likelihood

547.800

.000

532.995

0.000

Wald

891.077

.000

871.000

0.000

8.115

.422

6.524

0.589

Goodness-of-fit
Hosmer-Lemeshow

Coefficient of Determination
Pseudo-R-square
Cox & Snell

.037

.034

Nagelkerke

.171

.163

Research Question 3:
Is the measure of accuracy for the ‘glucose level’ formula independent of
‘BMI’, ‘HDL’ or ‘SysBP’ in the CHD 10-year CHD prediction model?
Null Hypothesis. The measure of accuracy for ‘glucose level’ is independent of
‘BMI’, ‘HDL’ or ‘SysBP’ in the 10-year CHD prediction.
Alternative Hypothesis. The measure of accuracy for ‘glucose level’ is
dependent on ‘BMI’, ‘HDL’ or ‘SysBP in the CHD 10-year CHD prediction.
In answering this third research question, instead of using the fasting blood
glucose level as a continuous variable it was used as an ordinal variable. The sample
was divided into blood glucose level group (FBG group) variable, which was first run
in an unadjusted logistic regression model and determined to be statistically significant.
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When the FBG group variable was entered in the model, the model was also
statistically significant, as χ2 = 100.781, p = 0.000 and the pseudo R-square = 0.172
(Table 12). All the variables, including the FBG groups were shown to be statistically
predictive on a CHD event, with the FBG being the strongest predictor (0R = 1.360, p =
0.01, 95% CI [1.076, 1.720].
The introduction of interaction the terms, FBGxHDL, FBGxBMI, and
FBGxSysBP (created from the metabolically linked factors), did produce a statistically
significant overall model, with χ2 = 102.407, p = 0.000 and the pseudo R-square =
0.175 (Table 13). However, the only variables that remained statistically significant in
this new ‘interaction’ model were Age, and Smoking status. All the other variables,
including the interaction variables along with HDL and SysBP, were no longer
statistically significant in this model.
Table 12
Odds of FBG Groups for CHD Adjusted for Age, Smoking Status, HDL, and SysBP
95% C.I.
B

S.E.

Wald

df

Sig.

Exp(B)

Lower

Upper

Age (years)

.085

.014

35.940

1

.000

1.088

1.059

1.119

Smoking Status

.951

.300

10.016

1

.002

2.588

1.436

4.664

HDL cholesterol

-.025

.009

8.020

1

.005

.975

.958

.992

Sys blood pressure

.021

.008

7.025

1

.008

1.021

1.005

1.037

FBG Groups

.308

.120

6.610

1

.010

1.360

1.076

1.720

-9.514

1.083

77.211

1

.000

.000

Constant
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Table 13
Odds FBG Groups and Interaction Variables for CHD Adjusted for Age, Smoking
Status, HDL, BMI, and SysBP
95% C.I.
B

S.E.

Wald

df

Sig.

Exp(B)

Lower

Upper

Age (years)

.085

.014

35.802

1

.000

1.089

1.059

1.119

Smoking Status

.955

.301

10.074

1

.002

2.600

1.441

4.689

HDL cholesterol

-.036

.023

2.479

1

.115

.964

.921

1.009

Sys blood pressure

-.002

.020

.009

1

.925

.998

.959

1.039

FBG Groups

-.831

1.060

.614

1

.433

.436

.055

3.481

FBG_SysBP

.009

.007

1.494

1

.222

1.009

.995

1.023

FBG_HDL

.004

.008

.199

1

.655

1.004

.988

1.020

FBG_BMI

-.004

.008

.326

1

.568

.996

.981

1.011

Constant

-6.157

2.921

4.441

1

.035

.002

The comparison of the measures of performance statistics of the two FBG
Group model (with and without the interaction variables) demonstrated very little
difference. As shown in Table 14, the Log Likelihood value did go down from 547.368
to 545.376 with the addition of the interaction terms (representing a decrease in
performance), the Hosmer-Lemeshow value also went up from 9.319 to 10.881
(representing a slight increase in performance). Collectively, the very small changes in
these values and the contradiction from one performance maker to another renders the
results insignificant. Together with the results of the logistic regression model, it can be
concluded that there is no significant interaction between FBG levels (when taken as
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groups) and the metabolic terms of HDL, BMI and SysBP. The null hypothesis cannot
be rejected, and it is assumed that the measure of accuracy of the prediction of the
CHD, in the FRS-CHD 10-year risk prediction formula, by FBG level groups is not
influenced the interaction terms.
Table 14
Comparing the Performance of the FBG Group Models
Non-Interaction Model
χ2

p-value

Interaction Model
χ2

p-value

Overall Model
Log Likelihood

547.368

0.000

545.376

0.000

Wald

891.474

0.000

891.276

0.000

9.319

0.316

10.881

0.209

Goodness-of-fit
Hosmer-Lemeshow

Coefficient of Determination
Pseudo R-square
Cox & Snell

0.037

0.038

Nagelkerke

0.172

0.175

Summary
For this research, the outcome variable was the binary measure of the presence
or absence of a CHD event within a 10-year period. The dichotomous nature of the
outcome warranted the use of a binary logistic regression analysis to answer the
research question. For the first question, where the relative risk of a diagnosis of
Diabetes was compared with the relative risk of a measure of Fasting Blood glucose
level, a univariate binary logistic regression test was used. The results indicated that
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both variables were statistically significant predictors, but the OR for Diabetes was
8.483 and that for glucose was 1.015. This suggests that the odds of a CHD event for a
Diabetic is approximately 8.5 times that of the odds for a non-diabetic, while the odds
of a CHD event go up by 0.015 for each unit increase in blood glucose level. While the
glucose would appear to give a more precise measure of risk, the results of the χ2-value
(24.652 vs 14.649) and the pseudo R-square (0.043 vs 0.025) would indicate that a
diagnosis of diabetes (in the absence of other risk factors) is a superior predictor.
For the second question, the other risk factors (Age, Sex, SysBP, HDL and
Smoking Status) were included in the model and each of the variables (glucose/FBG
and diabetes/DM2) tested separately. Here both models were statistically significant,
but the OR for diabetes dropped considerably (OR = 2.295, 95% CI [1.035, 5.087] with
adjustment, and glucose level was rendered statistically insignificant in the formula.
The performance measures also confirmed the superiority of the Diabetes model and
the null hypothesis was not rejected as ‘Diabetic’ FRS-CHD 10-year risk prediction
formula as there was no difference between the measure of accuracy for ‘glucose level’
and ‘diabetic status’ versions of the FRS-CHD 10-year risk prediction formula.
The third research question investigate the impact of any possible interaction
between glucose and the metabolic risk factors (HDL, BMI and SysBP). For this
analysis, the glucose level was transformed into an ordinal variable of groups of
glucose levels. This variable was statistically significant predictive of CHD, with a
OR=1.36, p = 0.010 and 95% CI [1.076, 1.720]. The addition of the interaction terms
did not have any significant effect on the performance, but with the exception of Age
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and Smoking Status, all the other risk factors, along with the interaction term, were not
statistically significant for the outcome (p-values > 0.05). Based on these results the
null hypothesis was not rejected, and the interaction terms were considered to not
influence the relationship between glucose (when used as FBG levels group) and the
CHD event outcome in the FRS-CHD 10-year risk prediction formula.
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Chapter 5: Discussion, Recommendations
Introduction
Purpose of the Study
CVDs continue to be the leading cause of death in developed and developing
countries around the world . Despite the efforts in the field of medicine and public
health, these diseases continue to threaten the lives of many, and causing serious
debilitation in others, while costing several billions of dollars in health care cost
annually . Screening for CVDs has proven to be an effective means of curbing the
spread and slowing the continued growth among the many affected communities
around the world. Identifying those at risk and exposing them to health care
intervention methods has reduced the incidence as well as the devastating effect of all
the major CVDs.
The FRS is still the most common screening tool used by health care providers
to identify those at risk and allocate resources to help prevent CVD or minimize its
effects on affected individuals . The risk factors included in the FRS have proven to be
very strong predictors and their combination in the multivariate FRS makes this model
most effective. The FRS was developed over 50 years ago and its usefulness
effectiveness notwithstanding, it has undergone optimization and customization that has
made it more specific the various people groups for whom it is used. The optimization
methods have focused on either the inclusion of additional risk factors or altering the
measuring of current risk factors based on novel information from research in the fields
of biochemistry and cardiology .
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This present study deals with the optimization of the FRS formula based on the
use of FBG levels as a risk factor in the place of a diagnosis of DM2. Other derivations
of the FRS that were developed in for other countries, with different populations, have
seen an increase in the sensitivity of the screening formula when similar changes were
made (see citation). The objective of this study was to carry out this substitution and
compare the models using various performance evaluation methods. Additionally, the
interaction between glucose and the metabolically significant risk factors were assessed
for the FBG model. Pairs of the univariate-, multivariate-, and the interaction-models
were all generated for the both FBG and the DM2, and the respective odds ratios, the
pseudo-R2 values, and the model-fit parameters (Log Likelihood, Wald, and HosmerLemeshow statistics) were compared for each pair.
The data set used for this study was a combination of the Gen III (third
generation of the Framingham cohort), together with the OMNI II and the NOS cohort.
This is prospective data, collected based on a series of exams over many years,
beginning in 2001 and continuing today . Before beginning the analysis, the data was
streamlined to remove those with a history of heart disease, leaving only those whose
heart disease developed within 10-years period following the original exam when the
baseline data was collected. The risk factors glucose level and DM2 diagnosis along
with smoking status (dichotomous), HDL-cholesterol (continuous), systolic blood
pressure (continuous), gender (nominal) and age (continuous) were included. The
outcome variable was the dichotomous measure of coronary heart disease (CHD =1, no
CHD = 0) and a series of logistic regression analyses was used to carry out the
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inferential statistics to answer the research questions. Before conducting the inferential
statistics, descriptive statistics on the predictor variables was carried out, the results of
which are presented in Chapter 4 of this dissertation.
Results and Findings
RQ1: Is the relative risk for glucose level higher than that for diabetic status in
the CHD 10-year risk prediction?
H01: There is no difference between the relative risk for glucose level and that
for diabetic status in the CHD 10-year risk prediction.
Ha1: The relative risk for glucose level is higher than that for diabetic status in
the CHD 10-year risk prediction.
RQ2: Is the measure of accuracy for glucose level higher than that for diabetic
status in the CHD 10-year risk prediction formula?
H02: There is no difference between the measure of accuracy for glucose level
and diabetic status in the CHD 10-year risk prediction formula.
Ha2: The measure of accuracy for glucose level is higher than that for
diabetic status in the CHD 10-year risk prediction formula.
RQ3: Is the measure of accuracy for glucose level independent of age, BMI,
cholesterol level, or blood pressure level in the CHD 10-year risk prediction formula?
H03: The measure of accuracy for glucose level is independent of age, BMI,
cholesterol level, or blood pressure level in the CHD 10-year risk prediction
formula.
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Ha3: The measure of accuracy for glucose level is dependent on age,

BMI,

cholesterol level, or blood pressure level in the CHD 10-year risk prediction
formula?
Descriptive Statistics: How This Data Set Compares with Others
Comparing Nonmodifiable Risk Factors. The descriptive analysis conducted
on this data set revealed that the distribution of the gender reflects that of most other
data sets used for this type of study, as well as that of the distribution in the general
population (Center for Health Statistics, 2017; D’Agostino, Grundy, Sullivan, &
Wilson, 2001b; Jahangiry et al., 2017). In the current study, there was almost an equal
balance, with slightly more female (55%) than males, similar to the distribution in the
original FHS cohort, and in the subsequent (FHSII) cohort ( Lloyd-Jones et al., 2002;
Tsao & Vasan, 2015b). This distribution is also reflective of the distribution of the
sexes in the general population according to the U. S. Census Bureau (U. S. Department
of Commerce, n.d.).
Unlike the distribution of the genders, the racial distribution in this data set does
not reflect that of the general population but is considered like the original FHS cohort
(mostly White), given that most of the subjects were descendants of the original FHS
participants. This current data set is made up of three groups, the FHS III, the OMNI II,
and the NOS cohorts. The FHS III data accounts for 4,578 adults, who are the
grandchildren of the FHS I, along with an additional 101 of their non-FHS parents who
had not been included in any of the previous FHS cohorts (Splanksy, 2007). The OMNI
II are the children of the original OMNI cohort, introduced to include a more racially
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and ethnically diverse sample set, but they numbered only 405 (Tsao & Vasan, 2015a).
The NOS cohort also added to increase genetic diversity, was made up of the spouses
of the OMNI2 and consisted of only 101 subjects (Govindaraju et al., 2008).
Unfortunately, the ethnically diverse participants made up no more 10% of the total
sample size, in its original iteration. However, that percentage was reduced with each
subsequent generation, and race data was only collected for the OMIN2 participants, so
race was not included in any of these analyses.
The age values followed a normal distribution of adults (over 19 years), with an
average of the sample being slightly above 40 years, and 93.8% of the subject between
26 and 55 years old. In the original cohort, the age range (30 to 62) was narrower that
the current 20 to 92 and this could have impacted the results of the data analysis. Age is
not only a major CHD risk factor; it influences the prevalence of other risk factors as
well and thus the overall reliability of the model. Other risk model optimization studies
used data sets with older subjects and shorter age ranges, e.g. 45 to 64 (Conroy et al.,
2003), or 35 to 74 (Hippisley-Cox et al., 2007), or 30 to 74 (D’Agostino et al., 2001b).
A 10-year CHD prediction formula is less accurate for younger adults than it is for
older adults and this is one of the reasons why formula optimization is preferred with a
age distribution with smaller standard deviation (Booth et al., 2006).
Comparing Modifiable Risk Factors. The results of the prevalence evaluation
of the various risk factors among the participants in this data set revealed that some of
the prevalences were similar to the national prevalence but most were lower. For
example, the prevalence of lower HDL (CHD protectant) values was 18.8%, like the
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national average of 17.1% (Zwald, 2017), but the prevalence of hypertension (>140 m)
was 6.6%, compared to a 29% national average (Paulose-Ram, 2017). In this data set,
only 1.3% of the subject were reported as diabetic as baseline, which is much lower
than the national average of 9.4% (or even 7.4% for Whites) ( Benjamin et al., 2017).
And while it is not known how many patients developed DM2 during the 10-year
period, those who were classified as prediabetic made up 16.5%, almost half of what is
the average percentage nationally- 33.9% ( Benjamin et al., 2017). The prevalence of
overweight/obesity is also a lot less 57.6% compared to the 65.7% reported by the CDC
at the time of the initial exam (Health E Stats, 2003-4). Based on these analyses, the
current data set was made up of subjects with lower prevalence of the major risk
factors.
The descriptive analyses revealed that the people making up had a lower risk of
heart disease than the general population average and this was reflected in the CHD
outcome. After 10 years, only 2.6% had a CHD event, 4.7% CVD in general, which is
much less than in previous decades, 18.09% for men and 10.08% women for the
(D’Agostino et al., 2008), or the 15.9% men and 6.9% women for CVD for the two
previous FHS cohorts (Ford, 2014). The rate of CHD across the U.S. population has
gone from 10.3% (2001-2), down to 8.0% (2011-12) (Yoon, 2016), and currently is at a
national average of 3.9%, but ranges from WV’s 7.4% to HI’s 2.5% (CDC BRFSS,
2017). This low CHD prevalence in this data set countered the effectiveness of the
logistic regression modelling and evaluation, which works best with not so rare
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outcomes (Giancristofaro & Salmaso, 2003; Stoltzfus, 2011) and made the formula
development more challenging.
Bivariate Analysis: Gender Differences
Historically, the distribution of heart disease and its risk factors have always
differed across the genders (Amsterdam, 2011; Hosseini, 2015; Tunstall-Pedoe,
Woodward, Tavendale, Brook, & Mccluskey, n.d.). In the present study also, there
were more almost twice as many male diabetics (n=43) as female diabetics (n=23)
contrasted with the more than four times as many women (n=714) than men (n=158)
with optimal HDL measures. These findings were also congruent with others, including
that the fact that the overweight/obese men (887 or 73.7%) outnumbered the
overweight/obese women (654 or 44.4%). The association between gender and the
various groups of systolic blood pressure was also significant, (p = .000) with 45% of
men being hypertensive compared to 22% of the women. These findings are consistent
with previous research where men had higher prevalence of CVD risk factors
(D’Agostino et al., 2013, 2008; Fawwad et al., 2016). A related study that used
electronic health records (EHR) to compare the performance of three CVD risk score
functions (FRS, ASCVD and QRISK), found that 82% of the men were overweight or
obese compared to 63% of the women; 14% of men were diabetic compared with 9% of
women; and ultimately 8% of the men and 4% of the women had a CVD event during
the 10-year follow-up (Pike et al., 2016). These gender differences in the current study
were ultimately reflected in the CHD rate outcome as 3.25% of men and 1.31% of
women had a 10-year CHD event. Interestingly in this data set, when the covariates
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were adjusted for in the formula, gender was not a statistically significant predictor.
This lack of effectiveness of gender in the CHD outcome has been reported in previous
research (Jahangiry et al., 2017; Kozakova et al., 2017).
Bivariate Analysis: Diabetics versus Nondiabetics
The bivariate analysis of this data set confirmed the association between DM2
and the other cardiometabolic risk factors. Increasing BMI, Sys BP, and age, and
decreasing HDL were all associated with an increased probability of a DM2 diagnosis
(see Table 6). The older the subjects the higher the percentage of diabetes, going from
3.76% of those 41 - 55, to 12.5% for 56 - 70, and to 57.2% of those over 70 years old.
Similarly, only 1.1% of the nonhypertensive (Sys BP < 120) were diabetic, but 9.2% of
the hypertensive were diabetic; only 0.7% of the normal/underweight (BMI < 25) were
diabetic but 3.98% of the overweight or obese were. Only 1.3% of those with optimal
HDL levels were diabetic, but of those with low (not-optimal) HDL, 3.15% were
diabetic. These results are similar to those found in other DM2-CVD risk factor
correlation studies (Bragg et al., 2014; Haregu et al., 2016; Qazi & Malik, 2013a;
Selvin et al., 2010). The Chi-square analysis of all these association, proved they were
all statistically significant (p = .000), and based on the Cramer’s V, relatively strong,
measuring 0.107, 0.139 and 0.187 for HDL, SBP and BMI respectively. Despite these
values, however, in the multivariate formula, BMI was not predictive, and the
interaction variables for each of HDL and SBP were not statistically significant.
Smoking is traditionally the strongest CVD risk factor (CDC, 2014; Mannan et
al., 2010), yet it had no significant association with the second strongest risk factor-
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DM2 (p = 0.201). In this analysis, smokers were no more likely to be diagnosed as
diabetic than nonsmokers. This is probably an indication that though both smoking and
DM2 increases the risk of developing CVD, the mechanism by which these two factors
cause damage to the cardiovascular system are different. Smoking introduces toxins
and external sources of oxidative stress that ultimately damages the endothelial and this
precipitates atherosclerosis (CDC, 2014; Huxley et al., 2011). On the other hand, as a
disorder of metabolism, DM2-driven CVD is mediated by the internally produced
biochemicals, namely excessive insulin, that eventually generates ROS and the
associated tissue damage then leads to atherosclerosis and (Faerch et al., 2012; Kumar
et al., 2019; Laakso, 2015). These differences may be a possible explanation for
absence of association between the variables at baseline.
The etiology of CVD as a cardiometabolic disease that has been postulated in
many prospective epidemiological studies, though not clearly defined, is increasing
being supported by the clinical and genetic research (Holmes, Pulit, & Lindgren, 2017;
Nichols et al., 2012; Wilson & Meigs, 2008). One such study is the comprehensive
meta review of over 100,00 cases that used gene analysis to research the causal role of
central/general obesity in several CVD outcomes (Dale et al., 2017. The results suggest
that patients with a genetic disposition to metabolic disorder, of which central or
abdominal obesity is symptomatic, are more susceptible to both DM2 and CVD (Dale
et al., 2017). Another genetic study of over 26,000 Finnish subjects verified the causal
role of metabolic disruption and rising insulin as the source of heart damage and that
hyperinsulinemia was absent in the obese patients who did not develop CVD (Tikkanen
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et al., 2016). Another study, conducted with 1.3 million obese or overweight (BMI >
25), nondiabetic adults on the distribution of four metabolic risk factors -elevated blood
pressure, low HDL, elevated triglycerides and prediabetes- found the number and
prevalence of the CVD increased significantly with each age group indicating a
progression of the risk factors culminating in CVD (Assmann et al., 2008). This may
also explain, the correlation between BMI in a univariate model, but no statistical
significance in the multivariate model, when adjustments are made for other more
strongly predictive risk factors.
Answer to Research Questions
RQ1: Is the relative risk for glucose level higher than that for diabetic status in
the CHD 10-year risk prediction?
H01: There is no difference between the relative risk for glucose level and that
for diabetic status in the CHD 10-year risk prediction.
Ha1: The relative risk for glucose level is higher than that for diabetic status in
the CHD 10-year risk prediction.
Comparison of Unadjusted Odds Ratio. The results of the univariate analyses
do indicate that a DM2 diagnosis is stronger predictor of CHD risk than is a measure of
fasting glucose level. However, it is difficult to compare these results, as one variable is
dichotomous, and the other is continuous. The odds ratio indicate that a diabetic person
has an almost 850% (OR = 8.483) increased risk of CHD compared to a non-diabetic.
On the other hand, every unit increase in FBG confers an increased risk of 1.5% (OR =
1.015) of CHD, but it also means that a 10 unit increase in FBG corresponds to a 16%
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(OR = 1.161), and a 20-unit FBG increase confers a 35% (OR = 1.347) increased CHD
risk. Despite the large discrepancy in the odds for DM2 and FBG, they were both
predictive, but the difference in odds is mainly due to the way the variables are
measured as both are statistically significant (p-value < 0.001).
This minimal effect in the predictive value of FBG may be further explained by
a number of reasons, including (a) the formula used for evaluating; (b) the cohort used
to generate the formula; and (c) the method of comparison. Firstly, previous studies that
have evaluated the performance of glucose included models that were based on
different (optimized) variations of the FRS than the one used in this study (Collins &
Altman, 2009; Rücker et al., 2016), or other studies used hazard ratio (HR) measures
instead of OR for comparison of the variables (Demler et al., 2015; Kadowaki et al.,
2008; Sarwar et al., 2010), or still others compared classification categories for CHD
risk outcomes and not the goodness of fit parameters (Conroy et al., 2003; Garg et al.,
2017). Secondly, the Framingham cohort is known to be made up of predominantly
White subjects and as have been confirmed by many studies race dose play a role risk
of heart disease (see Nichols et al., 2012; Pike et al., 2016; Sarwar et al., 2010; Singhal,
Tien, & Hsia, 2016). Two such study in particular found that glucose level was a strong
predictor of CVD risk than blood pressure and cholesterol values, for African
Americans (Carter et al., 2016). These factors may have impacted the performance of
the model in this study and thus render the model optimization futile.
Other explanations for the apparent underperformance of the glucose level as a
CHD risk predictor may lie in the unique nature of the relationship between the
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variables. The coefficient and the corresponding odds ratio for each independent
variable approximates the relationship. One of the assumptions of the logistic
regression is that the predictor has a linear relationship with the log of the outcome, else
the strength and significance of the relationship is underestimated (Lani, 2015;
Sperandei, 2014). For example, a few studies have reported that the (log odds)
relationship between glucose level and heart disease risk follows a J-shaped curve,
representing that the glucose level associated with a reduced risk is only a narrow
range, and an increased CVD risk for levels below and above that range (MongrawChaffin et al., 2019; Park et al., 2013; Selvin et al., 2010). In the present study, when
the FBG was turned into a categorical variable (FBG groups) the odds ratio varied
considerably among the groups, but the relationship was not linear. Other studies have
reported that the strength of the relationship between glucose and CHD decrease with
the age of the subjects, as other CHD risk factors become more prominent (Booth et al.,
2006; Conroy et al., 2003). This combined with the fact that CHD prevalence in the
population increases with age, are the main reasons why the hazard ratio is the
preferred method of risk evaluation. With the current study, the only age range within
which glucose remained statistically significant in the model was between 56 and 70
years. Using ORs as was done in here, may complicate and even preclude the
relationship necessary for formula optimization.
RQ2: Is the measure of accuracy for ‘glucose level’ higher than that for ‘diabetic
status’ in the CHD 10-year risk prediction formula?
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H02: There is no difference between the measure of accuracy for ‘glucose level’
and ‘diabetic status’ in the CHD 10-year risk prediction formula.
HA2: The measure of accuracy for ‘glucose level’ is higher than that for
‘diabetic status’ in the CHD 10-year risk prediction formula.
Comparison of Adjusted Odds Ratios
Although both factors (glucose level and diabetic status) were significant in
their respective univariate models, only DM2 remained statistically significant after
adjusting for the other cofactors. In comparing the two models, the various parameters
indicated that the both models performed similarly, with the glucose model being
slightly weaker model than that for DM2 model. Looking at the chi-square (measure of
the association between the observed and the expected probabilities) values for the
multivariate models, shows that the DM2 model is slightly superior fit to the overall
data (χ2: 547.800DM2 vs 532.995FBG); and similarly the pseudo R-square values
indicating that the DM2 model has marginally better predictive power (0.171 DM2 vs
0.163 FBG). Based on these two parameters, there is no advantage gained by using blood
glucose level instead of diabetic status in the FRS model when screening for CHD risk
in asymptomatic clients.
The Hosmer-Lemeshow (H-L) test tells a similar story about the similarity of
the models, with one interesting caveat. It should be noted that with the H-L test, which
gives an average of the chi-square for deciles of the outcome probability, unlike the
Omnibus test, a lower chi-square and higher p-values are preferred (Giancristofaro &
Salmaso, 2003). In the H-L analysis of the two models, the FBG model was slightly

150
superior to the diabetic status model, as indicated by the lower chi-square values (H-L:
6.524 FBG vs 8.115 DM2) and the higher p-values (0.589 FBG vs 0.422 DM2). This points to
the superiority of the glucose model as a better fit (predicted versus observed) for the
data when divided into sections (Moons et al., 2012.; Peng, Lee, & Ingersoll, 2002).
The H-L results lend further support to the recommendation that model performance
evaluation is best estimated only after dividing the data into various strata.
RQ3: Is the measure of accuracy for ‘glucose level’ independent of ‘age’, ‘BMI’,
‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-year risk prediction
formula?
H03: The measure of accuracy for ‘glucose level’ is independent of ‘age’,
‘BMI’, ‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-year risk prediction
formula.
HA3: The measure of accuracy for ‘glucose level’ is dependent on ‘age’, ‘BMI’,
‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-year risk prediction formula.
Assessing the Interaction Variables
Testing the interaction variables in the given formula proved futile, as the FBG
variable itself was not statistically significant in the multivariate model. Consequently,
different interaction terms were created with the ‘FBG-groups’ variable, which was
statistically significant, but again the interaction variables were not statistically
significant. Though only the age and smoking status variables remained significant in
this new interaction-included model, the addition of the interaction terms had very little
effect on the model’s performance. This is probably because, even in its most effective
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version, the model only accounted for 17.2% of the variability in the outcome, and the
low prevalence of the disease conferred an already high accuracy (~97.4%) to the null
(no variable) model leaving very little room for improvement. The area under curve
(AUC) values, which assesses the classification power of the models, were 0.816 for
DM2 and 0.813 for glucose; with the DM2 model have a slightly higher specificity and
sensitivity, at the 20%-CHD risk cut off point, 14.3% vs 11.7% and 1.0% vs. 0.9%
respectively. The UC values are similar to those found in previous studies, higher than
some, 0.69 – 0.71 (Pike et al., 2016), 0.809-0.834 (Pandya, Weinstein, & Gaziano,
2011) and lower than others, 0.811 -0.819 (Günaydın et al., 2016). However, based on
the confidence intervals for the present AUC values (overlapping CIs), the differences
between the two models were not considered significant.
Limitations of the Findings
This study presented insight into the performance of the FRS formula, but there
are some specific limitations to the generalizability of the findings. Firstly, the main
limitation of these findings relates to the uniqueness of all the FHS cohorts, which is
specific to a particular population, namely White American of European descent,
connected to the Framingham, MA region. As other studies have proven, FRS findings
are sometimes not applicable to the other population that include other ethnicities, and
require recalibration prior to application (Elosua, 2014; Hemann et al., 2007; Rücker et
al., 2016). Furthermore, this FRS III cohort is the most recent version and was chosen
for that reason, but it should be noted that there were differences between this and the
FRS I from which the formula was initially developed. Most importantly, the diabetes

152
diagnosis has changed since the 1950s, and was mentioned before, many more diabetes
were previously diagnosed and receiving treatment than was the case with the
participants of the FRS I.
Another important limitation relates to the FRS formula used here was restricted
to very specific risk factors, namely Age, Sex, Sys BP, HDL, DM2 and FBG and did
not include others. This model did not account for factors, such as family history of
heart disease, presence of other diseases (chronic kidney or liver disease or
inflammatory disease), level of physical activity, etc., all of which have been proven to
impact CHD risk levels (Kones, 2011; Ray et al., 2014; Sarwar et al., 2010; Tsao, 2015;
Tsao & Vasan, 2015b; Wilson et al., 1998; Woodward et al., 2007). The presence of
these attenuating factors for some participants, but not included in the analysis, may
have weakened the measure of the association between the outcome and the risk factors
being assessed.
A most important issue in this model is that it did not include relevant
information on patient medication, especially glucose lowering medications for the
diabetics, including sulfonylureas, biguanides, alpha glucosides inhibitors or exogenous
insulin. Like with other medications, this was not included for the sake parsimony of
the model, but it should be noted that doing so limits the model’s accuracy. In this
study, almost 25% of the diabetics had FBG levels below the threshold (see Table 6),
which could be the results of medication, or lifestyle, or both. The lowered FBG for
these diabetics would have a major effect on the relationship between the measured

153
FBG levels and the CHD outcome, thereby reducing the predictive power of
dysglycemia on a CHD event, reducing the reliability of the results.
There are several other limitations related to all disease risk score studies in
general that are also worth mentioning. Any disease risk score, based on cross-sectional
data, can only be considered as risk estimation and cannot be used for causality
determination (Dahlöf, 2010; Nieto, 1999b). Also, all risk formula should be carefully
validated by applying and testing them to a data set other than the one used to develop
it. Relying of statistical significance or internal calibration is not enough, for this type
of one-time measurement of risk factors that are known to fluctuate and interact with
each other in unpredictable ways (Collins & Altman, 2009). Finally, an issue that is
common to risk estimation studies, is the imprecision and low sensitivity of the
formulas generated. These models tend to have very low sensitivity and specificity
values and should only be used for general classification of asymptomatic patients. This
is advised to reduce the reported cases of underestimation of high-risk patients going
undetected and therefore untreated (Collins & Altman, 2012; Rücker et al., 2016;
Steyerberg et al., 2010; Tsao & Vasan, 2015b). The CVD risk prediction models have
been very effective in predicting risk probability and stratifying individuals into risk
groups, but because of their many limitations then cannot be used in place of a
thorough medical examination.
Recommendations for Future Research
The unexpected findings in this study point to the need for additional research
before it can be utilized for making clinical and resource allocation decisions related to
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heart health. The next step in this type of study would be to conduct similar
performance estimation with a cohort from a different, more diverse population. For
example, the results may be different in African Americans populations, given that
glucose level have be shown to have on the strong predictive association with CVD risk
and that there is a higher the prevalence of CHD as well (Carter et al., 2016; Clark et
al., 2015; Marshall, 2005). The prevalence of the different types of CVD as well as the
prevalence of the risk factors vary among the different population types and these
prevalence difference have been shown to impact the performance of the risk models
(Al-Nooh, Abdulabbas Abdulla Alajmi, & Wood, 2014; Nichols et al., 2012; Yosaputra
et al., 2010).
Another area of future research is the model evaluation generated with different
stratifications of the same data set. There are several ways that the data could be
stratified, including by gender, age groups, diabetic status, smoking status, etc. Other
risk assessment models have been known to have variation in their performance for
different strata of the same population (Mendis, 2010; Steyerberg et al., 2010). In this
data set, as in others reported, the prevalence of CHD is twice as high as it is for
women, consequently some forms of the risk models are sex-specific (Amsterdam,
2011; Jahangiry et al., 2017; Wilson et al., 1998). Separating the data set into different
groups or sections could potentially reveal any nuances in the performance of the
models across the groups that may be affecting overall performance.
Another important recommendation for future research is the use of other
measures of metabolic dysfunction that may prove to be more effective risk factors,
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namely glycated hemoglobin. A supplementary analysis of this data set was conducted,
replacing glucose with insulin or HbA1C values. Insulin levels were not statistically
significant but HbA1C was found to be a statistically significant predictor, even having
a stronger predictive relationship (with an OR = 1.378, p =0.039), than all the other risk
factors, except for smoking. A previous study found HbA1C to be a stronger predictor
of CHD risk than total cholesterol or total cholesterol/HDL ratio, with OR of 1.23,
1.047 and 1.073 respectively (Faeh et al., 2013). Several other studies also determined
that HbA1C has a greater association with CVD risks than does glucose (Ahn, 2017;
Carson et al., 2015; Sarwar et al., 2010; Selvin et al., 2010). Others have suggested that
HBA1C levels could replace glucose in screening for both DM2 and CVD (Danesh,
2014), or it could even be used a single parameter in determining CVD risk for nondiabetics (Garg et al., 2014). All these studies point to a strong rationalization to
including HbA1C in risk models, or at least testing the merit of its inclusion.
The final recommendation as it relates to CVD risk estimation is the use of a
different type of regression modeling to represent the prospective data. The models that
have been traditionally used are based on Logistic Regression and the Cox Proportional
Hazard, both of which are parametric analyses and therefore rely on various
assumptions about the underlying data. The Logistic regression assumes that there is a
linear relationship between the variable and the log odds of the outcome (Lani, 2015),
and the Cox Hazard assumes that the ratio of the hazard of the succumbing to the
disease constant over time (D’Agostino et al., 1990). Both of these assumptions may
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not be true in the case of CVD and its many risk factors, making models based on them
unreliable.
Non-parametric modeling are free of assumptions and are able to account for
the structure in the data and generate more accurate representation of the data (Austin,
Tu, & Alter, 2003). Methods such as decision/classification tree analysis; structural
equation model (SEM); non-parametric path analysis; as well as data mining and big
data analysis techniques are transforming medical disease modeling (Dunson, Xing, &
Associate, 2012)(Kennedy, Wiitala, Hayward, & Sussman, n.d.) (Dunson et al., 2012).
These novel techniques are outperforming older modeling approaches with increased
accuracy and improved reliability as well as providing causal inferences from
prospective data. These types of models allowing improved patient classification and
clinical treatment decision making (Vistisen et al., 2016). The combination of large
quantities of patient data, both epidemiological and HER, and the sophisticated
computer application tools may make traditional modeling obsolete.
General Conclusion
This study was the first of its kind to assess the performance of the Framingham
Risk Score model on the third generation of FHS cohort (FHS III). The present analysis
confirmed that both glucose and diabetic status had a significant association with the
outcome of a CHD event. The findings, however, indicate that there was no statistically
significant difference and no improvement in performance of the FRS model when
DM2 replaces FBG levels. The study did also corroborate the predictive value of the
major risk factors including smoking, diabetic status, age, HDL and systolic blood

157
pressure. Specific to this data set, factors of gender and BMI were not statistically
significant to the outcome, however, it should be noted that this data set, like all other
FHS cohorts, is made up of unique population of relatively heart-healthy participants.
As such further research into the accuracy and reliability of the results, along with
responsible validation studies, are needed before generalizable application of these
findings is to be considered.
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